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Studies implicating the presence of nAChRs on human PBL. 292a
SUMMARY
Nicotinic acetycholine receptor (nAChR) was purified from 
Torpedo electric organ and fetal calf muscle and used to raise 
polyclonal and monoclonal antibodies, with a view to their use 
as probes for nAChRs on lymphocytes.
Rabbits immunised with fetal calf nAChR developed symptoms 
typical of Experimental Autoimmune Myasthenia Gravis (EAMG) and 
yielded polyclonal antisera (FI and F2) which were characterised 
in terms of their specificities towards nAChRs from different 
sources.
Enzyme-linked immunosorbent assays (ELISAs) were developed to 
screen for and assay monoclonal antibodies raised against both 
Torpedo and fetal calf nAChR. Five stable hybridoma lines were 
established, following immunisation of mice with Torpedo nAChR; 
the corresponding monoclonal antibodies (Bil, C7, Cil, E8 and 
Ell) were of IgG subclass and showed single site, high-affinity 
binding to Torpedo nAChR. They all interacted with fetal calf 
and human muscle nAChR while monoclonal antibodies Bll, Cll and 
E8 also recognised nAChR expressed on cultured rat myotubes.
The specificities of monoclonal antibodies towards nAChR 
subunits were also determined. Immunisation of mice with fetal 
calf nAChR yielded anti-nAChR secreting hybridomas but no stable 
cell lines were established.
The polyclonal antiserum F2 and monoclonal antibodies, Bll, C7 
and Ell, showed specific interreactions with human peripheral
blood lymphocytes (PBLs), as assessed by ELISA and Solid Phase 
rad ioimmunoassay.
The presence of AChRs on lymphocytes was also sought by using 
radiolabelled ligands. c125i ]-D6-bungarotoxin, used
as a probe for nAChR, was found to bind specifically to mouse 
thymocytes in only one of many attempts; no specific sites were 
detected on human PBLs. [3H]-QNB, a probe for muscarinic AChRs, 
was found to bind specifically to mouse thymocytes and to human 
PBLs and binding characterisitcs were determined. C3H]- 
Nicotine apparently bound to mouse thymocytes and to human PBLs. 
Binding to human PBLs was consistent but anomalous in its 
response to classical nicotine ligands. Further studies showed 
that C3H](-)-nicotine did not bind to isolated PBL membranes and 
lysis experiments finally confirmed that the 'binding' of [*H] 
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1I N T R O D U C T I O N
1. General Introduction
It is now well established that neuromuscular transmission at 
the motor endplate of vertebrate muscle is mediated through the 
interaction of the neurotransmitter acetylcholine (ACh) with the 
nicotinic acetylcholine receptor (nAChR). This receptor has 
been the subject of intensive research activity over the past 10 
years. The receptor protein has been particularly well 
characterised to the point where the genes coding for its 
constituent peptides have been sequenced.
This progress can be attributed largely to the availability of a 
rich source of nAChR from the electric organs of electric fish, 
which has provided a stepping stone for the study of nAChRs of 
vertebrate muscle. The involvement of the nAChR as the 
autoantigen in the autoimmune disease, myasthenia gravis (MG) 
has provided further impetus to the study of this receptor. 
However, in contrast to the wealth of information about the 
purified nAChR, there has been relatively little progress in the 
understanding of the initiation of the autoimmune response in 
the disease.
Antibodies raised against the nAChR, in particular monoclonal 
antibodies (Mabs), have been invaluable in dissecting and 
analysing important structural and functional features of the 
receptor. They are now finding a use in the identification and
2purification of nAChRs from the central nervous system (CNS) and 
have helped to demonstrate the presence of multiple types of 
nAChR which differ from muscle AChR in structure and 
pharmacology. There have also been suggestions that nicotinic 
receptors occur on cells of the immune system and the generation 
of antibody probes for such receptors form the basis of this 
thesis. It is therefore appropriate to review the current 
status of the nAChR, its involvement in MG and the production 
and use of Mab probes in the study of the AChR.
2. The nAChR
2.1 Neuromuscular transmission
The role of neuromuscular transmission is to transfer the 
propagated nerve impulse from the motor nerve ending to the 
muscle fibre, resulting ultimately in muscle contraction. It is 
the function of the AChR to translate a chemical signal into an 
electrical response. In the majority of vertebrate muscles, 
each muscle fibre is innervated by one nerve, and the area of 
contact between the two is termed the neuromuscular junction 
(NMJ). Figure 1 (page 3 ) gives a schematic representation of 
the NMJ.
L  3
Neuromuscular transmission is initiated when an action potential
2+
invades the nerve terminal. The resultant inward flow of Ca
/J
ions, through voltage dependent Ca^ channels^triggers the 
release of ACh, which diffuses across the synaptic cleft. The
3Figure 1 Schematic organisation of the neuromuscular junction
nerve impulse 
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4binding of ACh to the nAChR in the post-synaptic membrane 
results in a conformational change which triggers the transient 
opening (1-2msec) of a cation-selective ion channel. This 
mechanism is thought to occur by allosteric transitions (see 
Introduction, page 6 ). The channel allows Na"*~ and K^icns to 
flow down their respective electrochemical gradients. More Na 
move in than K + ions move out, resulting in a net influx of 
positive charge. This local depolarisation produces a miniature 
end-plate potential or MEPP. MEPPs reflect the random release 
of one quanta of transmitter or the entire content of one 
vesicle.
If the nerve impulse is strong enough many quanta (100-200) are 
released and the hEPPs summate to produce an end plate potential 
(EPP) significantly shifting the membrane potential at and 
around the synapse. As the membrane potential approaches the 
threshold value ( -15mV), an action potential is generated and 
spreads over the entire muscle causing the muscle to contract. 
The action of ACh is terminated by its dissociation from the 
AChR, and enzymic hydrolysis by acetylcholinesterase (AChE). 
Membrane potentials are re-established by membrane-bound Na+ / 
ATPases.
2.2 Pharmacology
Cholinergic receptors, that is receptors which interact 
specifically with ACh, were divided at an early date by Dale 
(1914) into two different types, the nAChR and muscarinic AChR
5(mAChR). Nicotine is ineffective at the mAChR and conversely 
muscarine has no effect at a nicotinic synapse. The response of 
mAChR to muscarine is slow in onset and prolonged ('v/ 100ms) and 
can be blocked by atropine. In contrast, the agonistic activity 
of nicotine at the nAChR is characterised by a fast response 
(l-2ms) and its effects can be blocked by d-tubocurarine. nAChR 
and mAChR are widely distributed throughout the nervous system. 
In general, muscarinic synapses are found in smooth and cardiac 
muscle and brain, whereas nAChR are located at autonomic ganglia 
and at skeletal NMJs.
In general, cholinergic ligands which act at the nAChR can be 
broadly classified into two categories
Agonists - which bind at the agonist binding site 
and activate the receptor.
Antagonists - agents which prevent the action of agonists.
2.2.1 Agonists
These include nicotine, ACh and carbamylcholine. The nAChR is 
stereoselective with respect to nicotine, the naturaly occurring 
isomer (-) - nicotine being more potent than (+) - nicotine.
Prolonged exposure of AChR to agonists promotes desensitisation, 
or the conversion of the receptor into an inactive state where 
the ion channel is closed. This has led to complications in the 
classification of nicotinic agonists as, under these conditions,
6they have antagonistic characteristics. Furthermore, drugs can 
vary in their effectiveness in promoting desensitised blockade.
Changeux in 1981 proposed a model which describes receptor 
function in terms of allosteric transitions between various 
states induced by cholinergic ligands. This model is shown 
below and illustrates the process of desensitisation.
The binding of agonist, to the receptor in its resting (R) state 
triggers the opening of the ion channel (active A state). 
Prolonged exposure of AChR to agonists provokes a two step 
desensitation process to the I (intermediate or rapidly 
desensitised state,^100ms) and to the D (slowly desensitised 
state, /%/ sec-min). All the states are discrete and 
interconvertible with some of the states being present before 
ligand binding. The affinity of the receptor for agonist 
increases from state R to D via the states A and I. The forward 
rate of desensitisation is dependent upon the agonist and its 
concentration whereas the rate of recovery from desensitisation 
is independent of the agonist.
2.2.2 Antagonists
Nicotinic antagonists can be subdivided into two major classes:-
a) Competitive inhibitors - which simply compete for the 
agonist binding site. At the vertebrate M U  these agents 
include d-tubocurarine, di-hydro-p-erythroidine (DHpE) and 
the od-neurotoxins, the most potent of which is
oC “Bungarotoxin (<X -BGT).
b) Non-competitive inhibitors which prevent activation of 
the nAChR by binding to sites distinct from the ACh 
binding site include local anaesthetics, the hallucinogen 
phenyclidine, non-ionic detergents and the toxin 
histrionicotoxin isolated from the Columbian tree frog 
Denrobates histrionicus. There are different affinity 
sites for non-competitive inhibitors and they inhibit
8receptor function by one of the following mechanisms 
stabilisation of the resting state, blocking the open 
ion channel or promoting desensitisation via allosteric 
in terac tions.
Finally, nicotinic receptors at the MiJ and at autonomic ganglia 
differ in their sensitivities to drugs and have been subdivided 
on the basis of their sensitivities to hexamethonium and 
decamethonium. Ganglionic receptors are sensitive to 
hexamethonium and are referred to as C6 receptors whereas 
receptors at the NMJ are sensitive to decamethonium and are 
referred to as CIO receptors. Other drugs have also been used 
to differentiate between the two groups, eg:
1,1-dimethyl-4-phenyl-piperazinium (DMPP) is a specific agonist 
for C6 receptors whilst OC-BGT is only antagonistic at CIO 
receptors (see also Introduction, page 32).
Decamethonium which was originally used in the early 
classification of CIO receptors acts as a depolarising agent at 
the NMJ first stimulating the receptor (thereby acting as an 
agonist) but then causing desensitisation.
Major advances in the biochemical isolation of the nAChR lagged 
behind the pharmalogical characterisation of the receptor and 
only became feasible following the identification, by Lee and 
co-workers, of certain elapid snake neurotoxins ((* -neurotoxins) 
as very specific, high-affinity probes for the ACh binding site 
(reviewed by Lee, 1979).
92.3 The p6 --neurotoxins
The Od-neurotoxins are small basic polypeptides with (Mr^ v/ B000) 
and have been classified into two groups on the basis of their 
behaviour at the NMJ.
Type 1 - exert a reversible neuromuscular block and have
an important application in affinity purification of AChR 
(eg: the o£-toxin from Naia naia siamensis venom). Neuro­
toxins of this class have 60-62 amino acid residues.
Type 11 - neurotoxins have 71-74 amino acids and bind 
almost irreversibly to the AChR. These toxins, particularly 
06 HBGT from the krait Bunaarus multicinctus. can be radio­
label led to high specific activity and have been used 
extensively to detect and quantitate AChR in biochemical 
analyses. The nAChR content of a tissue source is usually 
quantified in terms of moles of 0C-BGT binding sites per 
gram of protein.
Biochemical studies of the nAChR benefited further from the 
recognition that the electric organs of electric eels 
(E1ectroohorus electricus) and electric fish (Torpedo genus) are 
extremely rich sources of AChR. The electric organ is 
phylogenetically evolved from striated muscle and the nAChR from 
these sources is generally assumed to have all the important 
features of vertebrate muscle nAChR. However, nAChRs can be 
obtained in 1000-fold larger quantities from electric organ 
tissue (~100mg/kg) than from innervated muscle (<0.5mg/kg) and 
accordingly the receptor from electric fish has been extensively
10
used for biochemical characterisation (for reviews see An ho It et 
al., 1984, Stroud and Finer— Moore , 1985, Hueho, 1986, McCarthy 
et al., 1986). Extensive reviews exist and only a concise 
account of the present understanding of the nAChR will be given 
here.
2.4 Purification of nAChR
Purification of nAChR relies on the extraction of the receptor 
protein from its membrane environment using detergent (eg:
Triton X-100, deoxycholate). Specific isolation of the receptor 
has relied on affinity chromatography using Type loC-neurotoxins 
(Introduction, page 9 )> agonists, antagonists and AChR-specif ic 
Mabs (Introduction, page 22 ) • In some cases further 
purification has been carried out by using immobilised lectins 
(see Anhoit et al., 1984 for review).
In the isolation of nAChR from vertebrate muscle, advantage has 
been taken of denervation (see Introduction, page14 ) which 
results in a large increase in AChR (reviewed by Dolly, 1979), 
making it a richer source of receptor.
Purification procedures employ extensive use of anti-proteolytic 
agents because of the susceptibility of the receptor protein to 
proteolysis during purification (Lindstrom et al., 1980; Schorr 
et al., 1981; Einarson et al., 1982). The problems of receptor 
density and proteolysis become particularly important in the 
purification of AChR from other sources such as the central 
nervous system (CNS) and lymphocytes.
11
2.5 Characterisation of nAChR
The nAChR from Torpedo electric organ and vertebrate muscle is a 
glycoprotein composed of 4 different polypeptide chains 
assembled into a heterologous transmembrane pentamer (OC2,p, &  , 
£). From sodium dodecylsulphate/polyacrylamide gel 
electrophoresis (SDS/PAGE) the fish receptor subunits have 
respective Mr values of 40K, 50K, 60K and 65K. Although 
controversy initially surrounded the subunit pattern of 
vertebrate muscle nAChR (reviewed by Conti-Tronconi and Raftery, 
1982) evidence from gene cloning (see Introduction, page17 ) 
confirmed the same subunit structure. However, the subunit Mr 
values of muscle nAChR are slightly different from those of 
their fish counterpart (for review of vertebrate muscle nAChR 
see Dolly and Barnard, 1984).
The AChR is a phosphoprotein (Vandlen et al., 1979) with the 
phosphate groups located on the cytoplasmic face of the receptor 
(Huganir et al., 1984, see also Table 1 pagel2 ). The 
functional significance of phosphorylation is unknown although 
it may be involved in receptor desensitisation (see 
Introduction, page 5 )• The degree of phosphorylation of AChR 
changes during ontogenic development, adult receptor being more 
phosphorylated than its immature counterpart (Saitoh and 
Changeux, 1981). The interconversion is thought to occur by 
phosphorylation-dephosphorylation reactions catalysed by protein 
kinases and protein phosphatases (see An ho It et al., 1984). 
Pizzaghella et al., (1983a) have also demonstrated the presence
12




Subunit composition : 06 p &  <5
Mr values polypeptide chains (by SDS PAGE): 
(40,000), (50,000), (60,000), (65,000)
Mr values polypeptide chains 
(from CDNA sequences)
(50,200), (53,700), (56,300), (57,600)
Physical Properties




Diameter of receptor 8.5nm




Glucosamine, mannose, glucose, galactose 
1 mole sialic acid per mole receptor
Phosphorylation state
Contains 9 phosphoserines 










Raftery et al., 
1972
Cartaud et al., 
1978




Vandlen et al., 
1979
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of the phosphorylated protein, phosvitin, by Mab binding.
Methylation of the nAChR has also been reported however its 
physiological role is not yet established (see Hueho, 1986).
Several non-receptor proteins, mainly of 43K, are associated 
with the AChR and these may play a role in receptor stability 
and synapse formation (see An hoi t et al, 1984 for review). Che 
43K protein can be chemically cross-linked to the p -subunit of 
nAChR (Burden et al., 1983) and is co-extensively distributed 
with the receptor (Sealock et al., 1984).
The nAChR from Torpedo exists in monomeric and dimeric forms 
with sedimentation coefficients of 9S and 13S (Reynolds and 
Karlin, 1978). Monomers are linked covalently by disulphide 
bridge(s) between the (5 units to form a dimer (Sobel et al., 
1977; (see also Figure 3, page 24); the disulphide linkage may 
be extracellular (Dunn et al.,1986), with the dimeric form of 
the receptor representing the functional unit in vivo (Schindler 
et al., 1984). The dimeric form of nAChR has only been observed 
in Torpedo species. Table 1 (page]2 ) gives a summary of the 
properties of purified Torpedo nAChR.
V/ertebrate nAChRs have a sedimentation coefficient of 9S, with a 
smaller oc -BGT binding species of 4-5S sometimes also observed 
(Lo et al., 1981; Sumikawa et al., 1982a). However, the 
characterisation of vertebrate nAChR is complicated by the 
presence of two distinct forms of receptor, junctional (J) and 
extrajunctional (EJ).
Fetal and neonatal muscle fibres express nAChR over their entire 
surface (Bevan and Steinbach, 1977). Innervation results in 
clustering of nAChR below the nerve terminal and decrease of 
receptors at extrajunctional sites. At the adult synapse 
therefore J receptors are highly concentrated in the 
post-synaptic muscle membrane (Fambrough, 1979; see also Figure 
1, page 3 ). In contrast, receptors localised at sites outside 
the synapse, EJ receptors, are barely detectable in normal adult 
innervated muscle.
Denervation of muscle causes the proliferation of EJ receptors 
which became diffusely distributed over the muscle fibre 
surface. Hence, denervated muscle becomes a richer source of 
nAChR (see Harrison and Behan, 1986 for comparison of the
125C I3-06-BGT binding capacity of innervated and den. ervated 
muscle sources). EJ receptors differ, in several respects from 
J receptors (summarised in Table 2, page 16 ). The receptor 
types are indistinguishable by gel filtration and sucrose 
density gradient centrifugation (Brockes and Hall, 1975 ; 
Froehner et al., 1977; Nathansan and Hall, 1979) indicating 
that the differences are subtle. Different antigenic properties 
of J and EJ receptors have been reported (Weinberg and
Hall, 1979). Post-translational modifications such as 
phosphorylation (Saitoh and Changeux, 1981; see also 
Introduction, page 12 ) may also contribute to the biochemical 
differences observed.
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The mechanism underlying the difference in channel properties of 
the J and EJ receptors has recently been studied. Calf muscle 
AChR has been shown to contain an £  subunit which shows 
extensive homology with the &  subunit (Takai et al., 1985).
The channel properties of expressed receptor are defined by the 
presence of either the £  subunit (adult channel characteri­
stics) or ^  subunit (embryonic channel characteristics) (Sakmann 
et al., 1985). Indeed results suggest that bovine embryonic 
nAChRs have an 0C2, p subunit composition whereas adult
AChRs have an 06 2, p , ^  , £. subunit structure (Schuetze, 1986). 
These studies were made possible by the availability of cDNA 
probes from cloning.
2.6 Cloning the nAChR
The cDNAs coding for the OC -chain in Torpedo marmorata. for the 
four subunits in Torpedo califomica and calf skeletal muscle 
and the oC and ^ chains of human skeletal muscle, have all been 
cloned and sequenced (see Table 3, page'll* for references ).
By use of a calf ^ -subunit cDNA probe, a fifth type of nAChR 
subunit (£) has been cloned and sequenced from fetal calf 
muscle, (see Introduction, page*!? ).
Valuable information has been obtained from the cDNA sequences 
of the four subunits which have shown the subunits to be highly 
homologous (from 10-607. with an average of 40%) (Noda et al., 
1983b) confirming data from amino-acid sequences (Raftery et 
al., 1980) and Mab studies (see Introduction, page 21 ). This 
supports the suggestion that the subunits have descended from a
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Table 2 Biochemical and Biophysical Difference between 
Junctional and Extraiunctianal Receptors
Property






Mean channel J receptors











Differences in J receptors
Characteristic Details Reference
mobility






- Kd 4.5 x
10'* M
- Kd 5.5 x
10 M
glycosylation glycosylated than EJ 
receptors
a) from rat diaphragm muscle
c) from human fetal and adult skeletal muscle
AnhoIt et al., 































Calf skeletal muscle 
Calf skeletal muscle 
Calf skeletal muscle 
Calf skeletal muscle 
Calf skeletal muscle 
Human skeletal muscle 
Human skeletal muscle
REFERENCE
Ballivet et al.,1982 
Claudio et al.,1983
Sumikawa et al., 
1982b 
Devil lers-Thiery et 
al., 1983.
Noda et al., 1982
Noda et al., 1983a
Noda et al., 1983c
Tanabe et al., 1984
Takai et al., 1984
Kubo et al., 1985
Takai et al., 1985
Noda et al., 1983c
Shibahara et al., 
1985
Gene isolation depended upon a number of factors : the high
abundance of mRNA from Torpedo coding for the subunits (Mendez 
et al., 1980), amino terminal protein sequence data 
(Devillers-Thiery et al., 1979; Raftery et al., 1980), 
subunit-specific antibodies to each of the four chains (Claudio 
and Raftery, 1977; Lindstrom et al., 1978), and the ability of 
the Xenopus oocyte to translate, process and assemble functional 
AChR when injected with electric organ mRNA (Sumikawa et al., 
1981; Mishina et al., 1984; Sakmann et al., 1985).
The availability of cDNAs from Torpedo enabled the detection of 
homologous sequences in libraries of cDNA clones derived from 
RNA from vertebrate muscle using hybridisation techniques.
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four-fold duplication of a single ancestral gene (Canti-Tronconi 
et al., 1985).
Analysis of the primary structures revealed 4 hydrophobic 
domains homologous in all polypeptide chains (c*2 $S ) of
the nAChR and a fifth domain with alternating polar and 
hydrophobic amino acids. This latter domain is postulated to 
form an amphipathic helix with a hydrophilic core contributing 
to the ion channel formed in total by the homologous amphipathic 
helices (amino acid residues 425-451), from all 5 polypeptide 
chains. These features are the basis of the model proposed by 
Finer— Moore and Stroud (1984). Alternative structures have been 
proposed as a result of monoclonal antibody studies and are 
discussed later (Section 3).
2.7 Functional domains of the nAChR
Injection into Xenopus oocytes of mRNAs coding for the oC> ^  >
$ subunits has confirmed that all five subunits contribute 
to the ion channel (Mishina et al., 1984). The p subunit may 
have a channel-gating function (Blatt et al., 1986). Injection 
of mRNA corresponding to cDNA specifically altered at 
predetermined sites, into ooctyes has demonstrated that the 
residues 06192 and c>Cl93 are important at the agonist binding 
site and that the N-glycosylation site at asparagine residue OC- 
141 is important for the assembly and function of the receptor 
(Mishina et al., 1985). However, the effects of amino acid 
substitution or deletion may be deleterious to the tertiary
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structure of the receptor and hence the findings must be treated 
cautiously. These findings have, however, been substantiated by 
determining the reaction site of the affinity labels 
4-(N-maleimido)-benzyltrimethyl ammonium (MBTA) (Karlin, 1969) 
and bromoacetylcholine (BAC) (see McCarthy et al., 1986) which 
bind covalently to the ACh binding site on the DC—subunits after 
reduction of di-sulphide bonds. Uhder mild conditions of 
reduction, only one DC —subunit is labelled per monomer (Weill 
et al., 1974; Damle et al., 1978; Damle and Karlin, 1978) but 
under harsher conditions both sites can be labelled (Wolosin et 
al, 1980; Walker et al., 1984) suggesting non-equivalent ACh 
binding sites (see Ratnam et al., 1986c).
The cysteine (cys) residues oc192 and 06193 are the target of 
MBTA (Kao et al., 1984; Kao and Karlin, 1986), and are 
disulphide cross-linked to each other. These residues are 
unique to the OC-subunit in terms of sequence homology (Numa et 
al., 1983). The cys residues 0C128 and*142 are also disulphide 
cross-linked (Kao et al., 1984, Kao and Karlin , 1986). The 
presence of a double di-sulphide bond is unique to the oC
-subunit.
Synthetic peptides and antibodies specific to regions of the 
oc-subunit of T.califomica have implicated the amino acid 
residues 125-147, 173-204 and 185-196 (Wilson et al., 1985; 
Mulac-Jericevic and Atassi, 1986; Neumann et al., 1986) as the 
location of the OC -BGT binding site on the oc-subunit. 
Proteolysis studies of the OC-subunit indicate that the
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N-glycosylatian site at asparagine residue OC 141 is near to but 
not part of the agonist binding site (UJilsan et al., 1985; Oblas 
et al., 1986).
Despite the considerable homology between vertebrate muscle and 
electric fish nAChRs, evidence suggests that the ACh binding 
site of human muscle nAChR is structurally dissimilar from that 
of Torpedo electric organ, having a higher affinity for the 
affinity label BAC and an adjacent disulphide bond that is more 
readily accessible to reducing agents (Momoi and Lemon, 1986).
2.8 Shape of the nAChR
Estimates of the dimensions of the nAChR in the membrane have 
been obtained from X-ray scattering data and immuno-electron 
microscopy studies (reviewed by Hueho, 1986). The five 
membrane-spanning subunits appear to lie at pentagonally 
symmetrical positions arranged in a cylindrical rosette to form 
a central pore through which ions flow (Brisson and Unwin, 1985, 
Kubalek et al., 1987, see also Figure 3, page24)« The overall
length of the receptor from T. marmorata has been estimated to
o o o
be 110A, extending 15A into the cytoplasm and 55A
extracellularly.
In summary, many techniques have proved useful in the study of 
nAChRs from fish and vertebrate muscle sources. Another 
technique, the production and use of anti-(nAChR) specific Mabs 
have also greatly advanced the characterisation of the nAChR.
21
3. The production and use of polvclanal and monoclonal 
antibodies in the study of nAChRs.
Many groups of workers have raised nAChR-specific Mabs (see 
Table 4, page22). Mabs have several advantages over polyclonal 
antisera, but both have proved useful in the study of the nAChR. 
Mabs are available in relatively endless supply and are 
monospecific although limitations follow from their advantages. 
For example, a Mab may be so specific that it does not bind to 
the part of the antigen of interest. Alternatively, the 
affinity of binding might be undesirable. For instance, high 
affinity Mabs are not suitable for immunoaffinity 
chromoatography because it is difficult to recover the bound 
antigen. The Mab produced may show undesired cross-reactivity 
with an irrelevant epitope or may not cross-react with a related 
antigen. These limitations, however, have been overcame by 
developing libraries of Mabs.
Before discussing the usefulness of Mabs as probes of the nAChR 
it is relevant here to summarise briefly Mab production and 
characterisation.
Mab production is based on the clonal selection hypothesis of 
Burnet (1959) which states that each B-lymphocyte may produce 
only one specific immunoglobulin which is genetically 
predetermined. Present day methods of Mab production have been 
modified from those originally described by Kohler and Milstein 
(1975) and are well documented in a review by Campbell (1984). 
The major practical steps involved in making Mabs are outlined
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in Figure 2 (page23)- For the production of Mabs several 
myeloma fusion partners are available (see Samoilovich et al., 
1987). A common fusion partner used in the production of 
mouse/mouse hybridomas is the HAT sensitive non-immunoglobulin 
secreting cell line P3-X63-AgB.653 (X63, Kearney et al., 1979).
Table 4s Monoclonal antibodies to the nAChR
a





Gomez et al., 1979 





Torpedo califomica : 




E1ectrophorus electricus : 
Bovine fetal calf




Froehner et al., 1983
James et al., 1980 
Watters and Maelicke, 1982 
Whiting et al., 1985
Dwyer et al., 1981
Tzartos et al., 1981
Tzartos aid Lindstrom,
1981
6a r a bed i an and Morel, 1983 
Tzartos et al., 1983 
Whiting et al., 1986c
Mehraban et al., 1984
a unless other wise stated native AChR was used as immunogen 
for Mab production
b only the initial reference quoting the production of the 
relevant Mab is cited
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Figure 2 The principal steps in making monoclonal antibodies
7 \
Spleen cells from 
an immunised mouse 
(die in culture)
Myeloma line: X63



























The main immunogenic regions (MIR) are found on the extracellular 
surfaces of the <X subunits and are on opposite sides of the receptor. 
The ACh binding site projects well within the molecular boundary of 
the structure and lies at the synaptic end of the subunit in agreement 
with the study of Kistler et al., 1982. (Taken from Kubalek et al., 
1987).
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The most critical and time-consuming stage in the production of 
Mabs is the screening of hybridomas, and the type of screening 
procedure used will dictate the types of Mabs ultimately 
produced. The methods which have been used include 
radioimmunoassay (RIA; Lindstrom et al., 1981), enzyme 
1 inked-immunosorbent assay, (ELISA; Dwyer et al., 1983) and a 
passive haemagglutinatian assay (Gomez et al., 1979).
□nee obtained, the Mab must be characterised to be useful.
Often this serves a dual purpose in that more is learnt about 
the receptor during the process of characterisation. The 
subunit specificities of Mabs can be determined by
125immunoprecipitation of [ I]-labelled receptor subunits
(Tzartos and Lindstrom, 1980; Tzartos et al., 1981 ; Gullick 
and Lindstrom, 1983) or by 'Western' blotting (Gullick and 
Lindstrom, 1983). The specificity can be more precisely defined
125against peptide fragments of [ID-labelled receptor subunits 
(Gullick and Lindstrom, 1983). Mab binding sites can also be 
mapped on native receptor by using competitive binding 
techniques (Tzartos and Lindstrom, 1980; Tzartos et al., 1981 ) 
and by analysis of the formation of complexes on sucrose 
gradients (Conti-Tronconi et al., 1981a).
The use of polyclonal and Mab probes in various aspects of AChR 
structure function and biosynthesis is described in the next 
sections. The specific contribution of Mabs as probes of AChR 
is summarised in Table 5, page 26 •
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Table 5 The contribution of Mabs to the understanding of the 
nAChR
I FORMATION GAINED 
Arrangement of nAChR subunits
Structural homology between 
receptor subunits
Structural homology between 
nAChRs of different species
Receptor heterogeneity 
Transmembrane nature of nAChR
Means of purification of nAChR 
Mechanisms of receptor function
Biosynthesis of nAChR
Nature of immuno-daminant 
region
Specificities of anti-(nAChR) 
antibodies in the sera of MB 
patients and in EAMG
Nature of neuronal nAChRs
REFERENCE
Fairclough et al., 1983 
Kubalek et al., 1987
Tzartos and Lindstrom,1980 
Tzartos et al., 1981 
Froehner et al., 1983 
Gullick and Lindstrom,1983
Tzartos and Lindstrom,1980 
Gomez et al., 1981 
Mochly-Rosen and Fuchs, 1981 
Tzartos et al., 1981 
Tzartos et al., 1983 
examples :
James et al., 1983 
Mehraban et al., 1984 
Souroujon et al., 1985 
Whiting et al., 1986c
Froehner et al., 1983 
Lindstrom et al., 1984 
Sargent et al., 1984 
Young et al., 1985 
Ratnam et al., 1986 a and 
b (and references therein)
Lennon et al., 1980
Momoi and Lennon, 1982, 1984
Souroujon et al., 1983 
Donnelly et al., 1984 
Mihovilovic and Richman, 1984 
Wan and Lindstrom, 1985 
Blatt et al., 1986 
Fels et al., 1986
Merlie et al., 1984
tzartos and Lindstrom,1981 
Tzartos et al., 1981 
Tzartos et al., 1983
Tzartos and Lindstrom,1981
Tzartos et al., 1982 
Vincent, 1983 (for review)
see page35 for details
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3.1 Abs as probes of receptor structure
Mabs specific for the 06 , j3 , KtcS subunits of receptor have 
been found and in addition, some Mabs have been found that 
cross-react with more than one subunit (Tzartos and Lindstrom, 
1980; Tzartos et al., 1981 ; Gullick and Lindstrom, 1983; 
Froehner et al., 1983). This cross reactivity between subunits 
by Mabs provided evidence for structural homology of receptor 
subunits within the same species. Additionally, Mabs have 
demonstrated homology between AChR subunits from various species 
(Table 5).
Both polyclonal antibodies and Mabs have demonstrated the 
extent of similarity among AChRs from various species (Lindstrom 
et al., 1978ab;Tzartos and Lindstrom, 1980; Gomez et al., 1981; 
Mochly-Rosen and Fuchs, 1981; Tzartos et al., 1981 ; Tzartos 
et al., 1983). Many Mabs are species-specific, others 
cross-react with a limited number of species and some bind to 
all species tested. Greatest cross-reactivity was observed by 
anti-(Xsubunit Mabs (Tzartos and Lindstrom, 1980; Tzartos et 
al., 1981 , 1983).
Competitive binding techniques (Tzartos and Lindstrom, 1980; 
Tzartos et al., 1981 ) have shown that the majority of 
antibodies (both polyclonal and Mab) raised against native 
receptor are directed against a small immunodominant region or 
main immunogenic region (MIR) on the receptor. Several studies 
have shown that the MIR is a conformationally-dependent 
antigenic determinant (Tzartos and Lindstrom, 1980; Tzartos et
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al., 1981 ). The MIR is located an the extracellular surface of 
<X/~subunits but is distinct from the ACh binding site and the 
carbohydrate moiety (Tzartos and Lindstrom, 1980; Gullick et 
al., 1981). The MIR is present on al 1 species examined to date 
and so is conserved through evolution although its function is 
not understood. Peptide mapping experiments have localised the 
MIR to between DC residues 46 and oC 127 (Ratnam et al., 1986a). 
More recently Tzartos and co-workers (1988) have more precisely 
defined the MIR region in human AChR to DC-residues 67-76, using 
Mabs to synthetic peptides of the DC-subunit of human AChR.
A corollary of using Mabs to detect similarities between species 
is that they can be used to detect differences (for example see 
James et al., 1983). Indeed, Mabs have provided evidence for 
immunological differences between types of receptor, namely, J 
and EJ forms of AChR (see Introduction, page14 ) (Mehraban et 
al., 1984; Souroujon et al., 1985; Whiting et al., 1986c).
The findings of structural homology and dissimilarity by Mabs 
and polyclonal antisera were confirmed by cDNA sequencing of the 
receptor subunits (see Introduction, page15).
3.2 Abs as probes of the transmembrane disposition of the nAChR 
Early studies using polyclonal anti-(AChR) serum (Tarrab-Hazdai 
et al., 1978) and proteolytic degradation (Strader and Raftery, 
1980; Wemogle and Changeux, 1980; Anderson and Blobel, 1981; 
Wennogle et al., 1981) provided evidence that AChR is a 
transmembrane protein. Studies using anti-(AChR) Mabs have 
confirmed these findings and shown that all five subunits are
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exposed in the cytoplasm (Froehner et al., 1983; Lindstrom et 
al., 1984; Sargent et al., 1984; Young et al., 1985).
The cellular positions of the amino (N-) and carboxy (C-) 
termini are important in predicting the subunit folding pattern 
in the lipid bilayer, however this area of work remains 
contentious. Studies on the biosynthesis of AChR (Anderson and 
Blobel, 1983) and using domain specific Mabs have provided 
evidence that the N-terminus is located extracellularly (Neumann 
et al., 1984). The location of the C-terminus, however, is 
still a subject of debate. Immunological evidence, using domain 
specific Mabs (Lindstrom et al., 1984; Young et al., 1985; 
Ratnam et al., 1986b) and a model based on the primary sequence 
structures of the subunit polypeptide chains (Finer— Moore and 
Stroud, 1984) have suggested that the C-terminus is located 
cytoplasmically. Hence, indicating that the N- and C- termini 
are on oppsite sides of the membrane and that an odd number of 
membrane spanning polypeptide regions exist. A more recent 
study by McCrea and co-workers (1987) has demonstrated that the 
J) disulphide bridge of AChRs from Torpedo electric organ is 
extracellular, a finding most easily reconciled with an 
extracellularly located N- and C- termini and hence an even 
number of transmembrane crossing per subunit. These findings 
are in agreement with the early working models proposed by 
Claudio et al., (1983); Devilliers-Thiery et al., (1983) and 
Numa et al., (1983). The difficulty of accurately predicting 
the tertiary structure of the nAChR is highlighted by these 
conflicting results.
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3.3 Abs as probes of the orientation of the PQ—subunits within 
receptor monomers
The order of the AChR subunits around the ion channel is 
fundamental in understanding the mechanism of action of the 
receptor. The orientation of cC -subunits within the receptor 
complex has been determined by using anti-(AChR) Mabs 
(Fairclough et al., 1983; Kubalek et al., 1987) and OC-BGT
(Holtzman et al., 1982; Oswald and Changeux, 1982; Kubalek et 
al., 1987) as probes. There is consensus that the two 
OC~subunits are diametrically opposed (Zingsheim et al., 1982; 
Kubalek et al., 1987). A recent representation of the 
arrangement of the receptor subunits is given in Figure 3 
(page 24).
3.4 Abs as probes of receptor function
Affinity-purified AChR can be reconstituted into model membranes 
and can retain function with ion channels similar to those 
observed in intact muscle (Anholt et al., 1984). These model 
receptor systems have proved useful for the analysis of the 
effects of antibody binding on ion channel activity. Mabs which 
bind at or near the ACh binding site and block AChR function 
have been reported (Souroujon et al., 1983; Mihovilovic and 
Richman, 1984). Additionally, Mabs which are specific for the 
cytoplasmic domains of the AChR have been shown to inhibit 
function (Blatt et al., 1986) and these Mabs have directly 
implicated the 8 and ^  subunits in ion-channel gating.
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3.5 Abs as probes of nAChR biosynthesis
Both polyclonal and Mabs raised against the subunits of AChR 
have made it possible to identify newly synthesised receptor 
subunits. Specific antibodies were shown to immunoprecipitate 
all four nascent chains of newly—synthesised AChR, translated by 
Torpedo mRNA in cell free proteins synthesising systems (Mendez 
et al., 1980; Anderson and Blobel, 1981) and in microinjected 
Xenopus ooctyes (Sumikawa et al., 1981). A study by Anderson 
and Blobel (1981) demonstrated that all four subunits of Torpedo 
receptor are synthesised as individual polypeptides. However, 
cell-free translation of mRNA coding for the four receptor 
subunits does not lead to the binding of 00-BBT or to the 
assembly of the resulting subunits to the 002, , V, S ,
complex and this has limited their use. The use of the muscle 
cell line BC3H-1 has overcome these limitations. Radiolabelled 
subunit-specific Mabs have been employed in this system to 
establish a time course for the processes leading ultimately to 
the localisation of the receptor in the membrane. This sequence 
involves synthesis ('’v'lmin), (maturation resulting in ability 
to bind Od-BGT and conformationally dependant Mabs; l-30min), 
assembly (30-90min) and transport (90-150min). A detailed 
account of AChR biosynthesis is given by Merlie et al., (1984).
3.6 Studies of neuronal nAChRs using Mabs
nAChRs are known to occur not only at neuro-ef fee tor junctions
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in electric tissue and skeletal muscle but within the autonomic 
nervous system, on chromaffin cells, in the gut, the spinal cord 
and the brain. Early attempts to identify these receptor sites 
were based on the use of 06 -BGT (Schmidt et al., 1980).
However, the failure of this toxin to antagonise nicotinic 
responses in the mammalian CMS and autonomic nervous system 
(Schmidt et al., 1980) has called into question its suitability 
as a probe for the neuronal receptor. Mabs have been used as 
alternative probes in the identification, localisation and 
characterisation of putative nicotinic receptors in neurons.
The picture of nAChRs in the central nervous system (CNS) is 
complicated and it appears that the CNS may contain AChRs that 
bind 06 -BGT and AChRs that do not. Such findings suggest a 
diverse family of AChRs and the evidence behind these findings 
will be discussed briefly.
Early studies by Patrick and Stallcup in 1977 demonstrated the 
presence of functional AChRs which did not bind 06“BGT and also 
of non-functional C>6"*BGT-binding proteins. 06HBGT binding 
proteins have been reported in some instances purified from 
various CNS sources (Oswald and Freeman, 1979, 1981; Norman et 
al., 1982; Wonnacott et al., 1982; Dolly and Barnard, 1984; 
Conti - Tronconi et al., 1985; Whyte et al., 1985; Whiting 
and Lindstrom, 1987a). The central <X/”BGT binding protein is 
similar to peripheral AChR (Barnard and Dolly, 1982) and shows 
limited immunological cross-reactivity with anti-(peripheral 
nAChR) antibodies (Norman et al., 1982; Wonnacott et al., 1982;
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Mehraban et al., 1984; Mills and Wonnacott, 1984).
Analysis of the subunit composition of toxin affinity-purified 
central receptor from chick optic lobe has revealed three 
(Conti-Tronconi et al., 1985) and more recently four subunits 
(Barnard et al., 1986). The toxin binding component isolated 
from rat brain also comprised four subunits (Whiting and 
Lindstrom, 1987a). These latter studies, imply conservation of
An alternative probe of neuronal nicotinic receptors has been 
radiolabelled nicotine. Using this ligand, high affinity 
nicotine binding sites were separated from OC-BGT bindings 
sites in an affinity purification scheme (Wonnacott, 1986; 
Whiting and Lindstrom, 1986a, b). These studies add to the 
evidence provided by pharmacological comparisons (Marks and 
Collins, 1982; Rapier et al., 1985) and regional distribution 
studies (Clarke et al., 1985) that the OC -BGT and high affinity 
nicotine binding sites in mammalian brain are separate 
functional entities. The significance of this is not understood. 
Purification of the nicotine binding protein has been attempted 
using the 6-hydroxyethyl (Abood et al., 1983) and 
6-hydroxymethyl (Abood et al., 1987) derivatives of nicotine as 
affinity ligands. A successful approach has been the use of 
anti-(AChR) Mabs as affinity ligands and this has been exploited 
by Whiting and Lindstrom in the isolation, purification and
subunit stoichiometry of peripheral receptors
(see Figure 4, page 35 )
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characterisation of neuronal AChR subtypes from chicken and rat 
brain (Whiting and Lindstrom, 1986a, b, 1987a, b, see Figure 4, 
page35 ). However, one disadvantage of using Mabs as affinity 
ligands is that the protein obtained is in a non-functional 
form. In spite of this, an insight into the structural 
heterogeneity of neuronal AChR subtypes has been gained. Two 
AChR subtypes, 06 p (from chicken) and Oc^ >' (from rat) have been 
isolated. These subtypes were found to have identical affinity 
for (-)-nicotine. Their 0C -subunits are similar or identical 
and share some antigenic determinants with OC-subunits from 
AChRs of electric organ and muscle. These subtypes, OCp , and 
OOp'j are however, distinguishable by their p subunits, which 
have different Mr values (see Figure 4, page 35)* the case
of neuronal receptors the ACh binding site has been localised to 
the larger molecular weight subunit rather than the lowest 
molecular weight subunit ( CO in the muscle nAChRs. Recently an 
anti-(MIR) antibody generated against Torpedo electric organ has 
been used to localise, histochemically, neuronal nAChRs in rat 
brain. The areas stained with this antibody paralled those 
areas of the brain exhibiting [3H]-nicotine binding (Deutch et 
al., 1987).
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Fig 4 Use of Monoclonal Antibodies in the Study of Central 
nAChRs
Mab 35 (anti-MIR antibody) 
raised to AChR from Electrophorus 
electricus
v
Cross-reacted with an AChR from chickenA
brain .
Chick brain AChR bound nicotine with high 
affinity but did not bind oi -BGT 2 .
Subunit subtvoes: Mr OC (49,000), (59,000)
v
Mabs raised to the chicken brain AChR
Identified a second chicken brain AChR 
Subunit subtvoes; Mr 00 (49,OCX)), j£' (75,000)
Binds Mab 35 weakly
-------------> Mab 270
3
Cross-reacts with AChR from rat brain 
Subunit subtypes; Mr ot (51,000), ^'(79,000)
p 1 Mr (79,000) from rat and chicken brain 
was specifically labelled wtih MBTA and 
therefore carries the AChR binding site ^  .
1. Swanson et al., 1983
2. Whiting and Lindstrom, 1986a, b
3. Whiting and Lindstrom, 1987a
4. Whiting and Lindstrom, 1987b.
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4. The involvement of AChR in myasthenia gravis
Myasthenia gravis (MB) is an autoimmune disease characterised by 
muscle weakness and rapidly fatiguing neuromuscular transmission 
(Simpson, 1960).
4.1 The neuromuscular junction in MG
A defect at the post-synaptic membrane was implied by a 
number of findings: the post—synaptic membrane of MB patients
appears highly simplified at the EM level and binds less 
iodinated 06-BGT than normal control post—synaptic membranes 
(Fambrough et al., 1979). This latter observation directly 
suggested the involvement of the nAChR in the disease. The 
various physiological changes at the M U  of myasthenic patients 
(see Figure 5, page 37 ) result in decreased efficiency of 
synaptic transmission, which if reduced to below threshold 
values, will result in failure to trigger an action potential 
and muscle contraction.
4.2 The autoimmune nature of MG
The association of MG with other autoimmune diseases, the 
occurrence of thymic abnormalities in a high percentage of MG 
patients and the beneficial effects of thymectomy and steroid 
therapy were several factors pointing to an autoimmune origin in 
MG (see Harrison and Behan, 1986).
Evidence for an autoimmune response directed against AChR was 
provided by Patrick and Lindstrom (1973) when they showed that
3?
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The MG junctions show a normal pre-synaptic terminal, a simplified 
post-synaptic membrane with reduced numbers of AChR, sparse shallow 
folds where complement-mediated focal lysis results in shedding of 
membrane fragments (containing AChR and £3) into the synaptic cleft, 
and antigenic modulation, involving antibody cross-linking of AChR, 
internalisation and proteolysis. The synaptic space is widened as a 
result of the loss of membrane.
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immunisation of rabbits with purified nAChR produced an 
experimental disease (Experimental AutoimmLne Myasthenia Gravis; 
EAMG), with many similarities to MG.
The animal model has proved useful for the study of MG and 
possible immunotherapy (for review on EAMG see Harrison and 
Behan, 1986). This led to the discovery by Almon et al., (1974) 
that immunoglobulin, from some myasthenic patients could inhibit 
06-BGT binding to AChRs in detergent extracts of rat muscle. 
Following the development of a more sensitive radioimmunoassay 
AChR-binding antibodies were detected in 077. of patients with MG 
(see Lindstrom, 1979; Lindstrom et al., 1981).
4.3 The pathogenic role of anti-(AChR) antibodies
The key role of circulating anti-(AChR) antibodies in the
pathogenesis of MG has been inferred from a number of studies.
In EAMG, myasthenic symptoms can be produced by passive transfer 
of IgG from myasthenic patients (Toyka et al., 1975, 1977), 
antibodies from myasthenic animals (Lindstrom et al., 1976) or 
Mabs (eg: Lennon and Lambert, 1980). Placental transfer of 
anti-(AChR) antibodies gives rise to neonatal MG (Keesey et al., 
1977). Immunoglobulin and the C3 complement component are found 
at the degenerating myasthenic endplate (see Engel, 1987).
Plasma exchange can also cause a temporary improvement in muscle 
strength in MG, paralled by a fall in serum anti-(AChR) antibody 
levels (Dau et al., 1977).
Circulating anti-(AChR) antibodies play a key role in reducing 
the number of effective receptors at the myasthenic endplate.
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The mechanisms involved are similar in MG and EAMG and can be 
divided into three broad categories :
1. Direct blockage of AChR
Direct blockade of receptor sites by antibody has been shown 
to occur in skeletal muscle cultures (Drachman et al., 1977; 
Fulpuis et al., 1981). Myasthenic immunoglobulins have also
125long been known to block binding of [ I]-q(,-BGT to 
detergent solubilised AChR (Almon et al., 1974; Lennon, 
1976; Vincent and Newsom-Davis, 1979).
2. Effect on Turnover of AChR
An increase in receptor degradation rate can be shown both 
in vitro and in vivo. It is triggered by antibody alone and 
is dependent upon the ability of IgG to cross-link receptors 
(Drachman et al., 1978; Conti-Tronconi et al., 1981b) and 
the divalent nature of the antibodies (see Figure 6,
page 40 ) •
Morphological studies indicate that such cross-linking 
causes re-distribution of AChR in the membrane followed by 
enhanced endocytosis.
3. Complement-dependent membrane lysis
The evidence for the complement-mediated destructive effect 
of anti-(AChR) antibodies is mainly indirect. IgG, C3 and 
the final lytic component, C9, have been found at the 
myasthenic endplate and degenerated membrane fragments found 
in the synaptic space of animals with EAMG and in MG 
patients. An excellent review of these studies is given by
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Figure 6 Inter and intra-molecular cross-linking of 








Engel (1987). Recently work by Childs et al., (1985) has 
demonstrated directly the lytic effects of anti-(AChR) 
antibodies an rat muscle cells, with 9 of 13 myasthenic 
serum samples showing complement-dependent myolytic 
activity.
4.4 Cellular immunity in MB
As in all autoimmune diseases, the immune system in MG responds 
to a 'self' antigen in an inappropriate way,. This may be due
to: (a) an alteration in the antigen causing it to be perceived
as 'non-self'; (b) defective control of the immune system 
allowing it to respond to a normal antigen or (c) a combination
of both. Examining point b, it is conceivable that
proliferation of autoantibody-forming B-cells could result from 
either a decrease in the number and/or function of suppressor 
T-cells, or an increase in the number and/or function of helper 
-T cells.
Hence, many workers have sought evidence for abnormalities in 
the cellular immune system in MG by comparing the proportions of 
B and T lymphocytes in MG patients with those of normal controls 
and by studying in detail the role of T-suppressor (Ts) and 
T-helper (Th) cells in MG by functional and cell surface marker 
assays (reviewed by Lisak et al., 1985: Harrison and Behan,
1986). While the results are conflicting, the majority of 
reports point to increased B-cell and decreased T-cell 
populations in both the thymus and peripheral blood in MG.
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The importance of regulatory T-cell function in MG is inferred 
from the fact that susceptibility to MG is associated with the 
MHC antigens (Oosterhuis et al., 1981) and several experiments 
support the concept that AChR-specific T cells are important in 
the aetiology and immune regulation in MG. Peripheral blood 
lymphocytes (PBL) are sensitised against AChR in MG, and undergo 
proliferation when incubated with AChR from electric eel 
(Abramsky et al., 1975; Richman et al., 1976, 1979 ) and 
Torpedo electric organ (Canti-Traneoni, 1977, 1979, 1902; 
Hohlfield et al., 1984). Proliferative responses of PBL from MG 
patients and controls to human AChR peptides have also recently 
boon studied (Hare our t et al., 1987; Hohlfeld et al., 1987).
The T-cell recognition site(s) on the AChR have not been as 
clearly defined as the antibody-binding sites. One approach to 
this problem has been through the isolation of T-cell lines 
specifically reactive to the AChR (see Harcourt and Jermy, 1987 
for brief review). Indeed T cell lines have been produced which 
are specific for Torpedo AChR (Hohlfeld et al., 1984; Fujii and 
Lindstrom, 1987). However, due to the requirement of large 
amounts of AChR protein needed to assay and maintain such cell 
lines, T cell lines specific to human AChR have proved difficult 
to obtain, although the use of synthetic peptides corresponding 
to human AChR may circumvent this problem (Fujii and Lindstrom,
1987). Nevertheless, it is proving possible to locate important 
T-cell recognition sites of T cell lines by using synthetic 
peptides corresponding to the human OC—subunit in proliferative 
assays (see Harcourt and Jermy, 1987). It appears that the
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immunodominant T-cell recognition sites lies an the same subunit 
as the MIR but is distinct from this important antibody binding 
site (Hohlfeld et al., 1987).
An alteration of immunoregu 1 ation seems likely to be necessary 
for the maintenance of the autoimmune response in MB, however 
the origin of the autoimmune response in unknown. The 
possibility of it being initiated by an external factor such as 
a virus or bacterial infection has been studied. Stefansson et 
al., (1985) discovered that AChR cross-reacts with proteins of 
Escherichia coli, Proteus vulgaris and Klebsiella pneumoniae and 
proposed that this cross-reactivity may be the cause of an 
immune attack directed against AChR. However, the average 
spectrum of antireceptor antibody specificities is the same in 
MG patients and in rats immunised with purified receptor
(Tzartos et al., 1982) suggesting that the immunogen in MG is
intact human receptor rather than a single cross-reacting 
determinant on a bacterium or virus. There is however 
considerable evidence that the autoimmune reaction in MB may 
originate within the thymus gland.
4.5 The thymus in MG
The association between the thymus and AChR is of special
interest in view of the involvement of the thymus in MG. A high
incidence of thymic abnormalities are associated with MG (Thomas 
et al., 1982; Bofill et al., 1985) and thymectomy is beneficial 
in many MG patients (Oosterhuis, 1981; Hankins et al., 1985).
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Changes in thymic lymphocyte populations have also been reported 
in MG (reviewed by Lisak et al., 1985; Harrison and Behan,
1986). The presence of AChR in the thymus has been demonstrated 
by a number of methods, including the use of anti-(AChR) 
antibodies.
Thymus cells, that have many histological characteristics of 
striated muscle were initially described by Mayer in 1888.
These cells, later named 'myoid cells' (Hammer, 1905) show 
cross-reactivity with anti-skeletal muscle antibodies (Van de 
Geld, 1966). More recently, cells that are typical of skeletal 
muscle cells in culture have been cultured from thymuses of rat 
(Kao and Drachman, 1977; Wekerle et al., 1975), mice (Wekerle 
et al., 1981) and humans (Kao and Drachman, 1977). These cells 
express surface AChRs.
A recent study by Kirchner et al., (1987) using anti-AChR 
specific Mabs has reported the presence of AChR epitopes on 
thymoid cells from myasthenic and non-myasthenic individuals. 
Extracts of thymus tissues from a wide variety of vertebrate 
species also contain AChR (Lindstrom et al., 1976; Ueno et al., 
1980; Raimond et al., 1984). Immunological cross-reactivity 
between a thymic component and anti-(AChR) antibodies has been 
reported (Aharanov et al, 1975).
Both thymic epithelial cells (Engel et al., 1977, Matsumoto et 
al., 1986; Kirchner et al., 1987) and thymic lymphocytes (Fuchs 
et al.,1980; Horvat et al., 1983; Pizzighella et al., 1983b; 
Riviera et al., 1987) have been reported to bear AChR. The 
latter studies employed antibodies against the nAChR to detect
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cross-reactivity by immunofluorescence (Fuchs et al., 1980; 
Horvat et al., 1983; Pizzighella et al, 1983b* Riviera et al.,
1987) and radioimmunological techniques (Fuchs et al., 1980).
Ohe Mab, raised against the ACh binding site of the receptor, 
was found to interfere with the inhibitory effect of 
succinylcholine on mouse thymocyte proliferation and cyclic AhP 
production (Pizzighella et al., 1982), directly implicating a 
role for cholinergic ligands modifying cellular functions of 
thymocytes through the presence of a functioning membrane AChR. 
Thymic cells cultured from MB patients are capable of producing 
anti-(AChR) antibodies (see Table 6, page46) and can also 
selectively enhance the production of anti-AChR antibodies from 
PBL in vitro (Vincent et al., 1978; Newsom-Davis et al., 1981a, 
b; Willcox et al., 1984). It has been suggested that the 
enhancing cell type is a specific antigen-presenting cell 
(Willcox et al., 1984). A cell line producing anti-(AChR) Mabs 
has been established from the thymus of a MG patient (Kamo et 
al., 1982).
4.6 AChRs on peripheral blood lymphocytes 
The presence of muscarinic AChRs on lymphocytes has been well 
established (Dulis et al., 197^; Gordon et al., 1978; Lopker 
et al., 1980; Zalcman et al., 1981; Atweh et al., 1984; Adem 
et al., 1985, 1986b) by direct binding studies. There are 
however indications that AChRs with nicotinic properties are 
also present on lymphocytes and this may represent further 
diversification in the family of nAChRs already described. Many 
of the studies used to identify this receptor have examined the
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Table 6 Reports of Anti-AChR antibody synthesis by peripheral 
blood and thymic lymphocytes from MS patients
Anti-AChR synthesis bv: Reference
Cultured blood lymphocytes Clarke et al., 1979
Vincent et al., 1979 
Newsom-Davis et al., 1981a 
Lisak et al., 1983a, 1984 
Willcox et al., 1984 
Fujii et al., 1986 
Kaufman and Oger, 1987
Thymic lymphocytes Vincent et al., 1978,1979
Ohta et al., 1980 
Newsom-Davis et al.,1981a 
Scadding et al., 1981 
Lisak et al., 1983b 
Willcox et al., 1983,1984 
Fujii et al., 1984,1985,
1986
Monoclonal anti-(AChR) antibody Kamo et al., 1982
secreting cell line from MG
thymus
Increased production of anti-(AChR) Newsom-Davis et al.,
synthesis of PBL by addition of 1981a, b
irradiated autologous thymic cells Willcox et al., 1984
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effect in vitro of cholinergic ligands on PBL proliferation 
(Richmcn and Amason, 1979; Richman et al., 1981; Menard and 
Rola-Pleszczynski, 1983). Other studies have described an 
inhibitory role for carbachol in E-rosette formation (Mizuno et 
al., 1982a, b). These latter studies suggested that nAChRs may 
be present an a subset of human T cells.
Direct binding of iodinated 06 -BGT has de monstrated specific 
binding sites on FBLs from myasthenic patients which are not 
present on normal control PBL (Morrell, 1979, 1981). Specific 
binding sites for H]-nicotine have also been found on normal 
human lymphocytes (Davies et al., 1982; Adem et al., 1985, 
1986a) and human granulocytes (Davies et al., 1982; Hoss et 
al., 1986).
The precise function of nAChRs on PBLs in unknown. Whaley et 
al., (1981) demonstrated that C2 synthesis by human monocytes is 
modulated by a nAChR, whereas Maslinski et al., (1980) described 
a nicotinic receptor on rat lymphocytes that may be involved in 
ACh transport.
The possible presence of AChR on PBL has important implications 
in MB. It could act as a potential autoimmunogen but also as a 
target for circulating anti-(AChR) antibodies. Studies 
demonstrating immunological cross-reactivity of anti-(AChR) 
antibodies with a nicotinic receptor on lymphocytes have been 
limited. Immunological cross-reactivity of myasthenic sera and 
a component on normal human PBL has been reported (Mischak and 
Dau, 1981) and other workers (Shimizu, 1980; Arimori et al.,
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1981) have observed changed membrane ultrastructure and 
micro-viscosity in peripheral T lymphocytes from myasthenic 
patients: changes which can be reproduced in vitro by addition
of myasthenic serum to normal lymphocytes. Further work 
examining the nicotinic receptor on PBL and possible 
immunological recognition by anti-(AChR) antibodies, using Mabs 
as specific probes, may help to clarify this situation.
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Aims of the Project
Both polyclonal and monoclonal antibodies have proved invaluable 
tools for the study of nAChR from various tissue and species 
sources. Workers have used these antibody probes in the study 
of novel receptor types of the central nervous system where the 
receptor content is smaller and pharmacologically distinct from 
that at the neuromuscular junction. nAChRs have also been 
implicated to be present on lymphocytes and the presence of this 
receptor is of relevance in the disease myasthenia gravis. 
Studies of this receptor type have been limited in comparison to 
other receptor types, hence this thesis is concerned with the 
examination of this novel receptor.
The thesis is divided into five sections. The first deals with 
the purification and characterisation of nAChR and the second 
and third, the production and characterisation of polyclonal and 
monoclonal antibodies against this receptor. The final two 
sections concern the study of nAChR on lymphocytes with the 




1. Sources of AChR
Torpedo marmorata electric organs were purchased from Institut
o
de Biologie Marine, Arcachon, France and stored at -00 C.
Bovine fetal calves were obtained fresh from the local slaughter
house. Muscle from the fore and hind limbs were removed and
o
frozen in liquid nitrogen before being stored at -00 C for up to 
three months.
Human adult muscle was supplied by local hospitals and was 
obtained from lower limb amputations resulting from severe 
vascular disorders. Within 15 minutes of amputation, calf 
muscle was dissected free from fat, tendon and skin and
o
immediately frozen in liquid nitrogen and stored at -00 C for up 
to two months.
2. Immunoreaaen ts
Blood samples were obtained from normal volunteers within the 
department. Myasthenic blood samples were obtained from local 
hospitals. All blood samples were collected with 10IU heparin 
per ml of blood.
Goat anti-(human IgG), Goat anti-(rabbit IgG), Rabbit anti-(BSA) 
and Rabbit anti-(human Fabjx) antisera were gifts from 
colleagues.
Rabbit anti-(mouse IgG) and Goat anti-(mouse IgG) antisera were 
prepared as described in Methods, Section B. Rabbit anti-
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(fetal calf AChR) antisera were prepared as described in 
Methods, Section B.
Rabbit anti-(Torpedo AChR) antisera was a kind gift from Dr 
Wonnacott.
Mouse anti—neuro filament and mouse anti BSA ascites fluid 
were gifts from colleagues.
Rabbit IgG coated ACA beads were a kind gift from Dr A Jehanli.
Protein-A conjugated Sepharose 4B beads were from Pharmacia 
Ltd., Hounslow, UK.
Normal mouse and normal rabbit sera were prepared from animals 
obtained from the University's animal house.
Sheep red blood cells were obtained in Alsever's solution from 
Tissue Culture Services, Slough, UK.
Freund's complete and incomplete adjuvants were from Miles Lab., 
Stoke Poges, Slough, UK.
Enzyme-conjugated second antibodies and substrate reagents for 
ELISA studies were obtained from Sigma Chemical Company, Poole, 
Dorset, UK.
ELISA plates were obtained from NUNC, Roskilde, Denmark.
3. Tissue Culture Reagents
RPM1-1640, Modified Eagles Medium, fetal calf serum, donor horse 
serum, antibiotics, selection media for Mab production and
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Ficoll-Hypaque separation medium were obtained from Flow Labs, 
Irvine, UK.
Tissue culture plates and flasks were obtained from Nunc, 
Roskilde, Denmark.
Mouse myeloma cell line X63 - Ag8. 6. 5. 3. was a gift from Dr 
K. Thompson.
Collagen prepared from rat tails was kindly provided by J. Ward 
(protein concentration 0.75 mg/ml).
4. Counting Instruments
125[ I ] was counted in a LKB 1280 Ultragamma counter.
a
C H] was counted in a Packard Tri-carb scintillation counter 
(Model 3255).
5. Rad ioc hemica1s
All radiochemicals were obtained from Amersham International 
(Amersham, Bucks., UK). Carrier free NaC^^I] in dilute NaOH 
(iOOmCi/ml) was stored at room temperature and was used within 
three weeks of its activity reference date.
l-quinuclidinyl-(phenyl - 4^H) benzilate (C3H]-QNB)
o
(46Ci/mmol) was stored at -20 C.
(-)-[N-methyl- ^ H]-nicotine ([3H](-)-nicotine) (60-B5Ci/mmol) 
was stored at -20°C.
Optiphase (Safe) scintillation fluid was obtained from LKB 
Pharmacia, Mi1ton Keynes, Bucks., UK.
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6. Liaands
OC-BGT from Bunaarus multicinctus was purchased from Boehringer 
Corp., Mannheim, W. Germany, as a lypholised powder.
Naia naia siamensis venom was obtained from Miami Serpentarium, 
Florida, U.S.A.
Benzoquinonium chloride was a generous gift from Stirling 
Winthrop Inc., Rensselaer, N.Y., U.S.A.
Atropine, d-tubocurarine,. dihydro-j^-erythroidine,
hexamethanium, carbachol, acetylcholine, decamethanium, nicotine
hydrogen ( + ) tartrate, nicotine (-) ditartrate,
1-1-dimethyl-4-phenyl piperazinium iodide and anti­
acetylcholinesterase inhibitors physostigmine and BW 284C51 were 
kind gifts from colleagues.
7. Chemicals
Standard laboratory reagents were obtained from Sigma Chemical 
Company, Poole, Dorset, UK. BDH Chemicals, Kingston-upon-Thames 
or Aldrich Chemical Company Ltd., Gillingham.
"Aged" chromic chloride was a kind gift from Dr A Jehanli.
Gel filtration reagents were supplied by Pharmacia Ltd., 
Hounslow, U.K.
Ion-exchange resins, DEAE cellulose filter discs, GFB and GFC 
glass fibre discs were obtained from Whatman Laboratory Sales 
Ltd., Maidstone, Kent, UK.
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Nitrocellulose paper and Amicon concentrators were from 
Millipore, Molsheim, France.
Polyethylenimine and lactoperoxidase was obtained from Sigma 
Chemical Company, Poole, Dorset, UK.
SECTION A
PURIFICATION AND DETECTION OF AChR
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1251. Preparation of C I D-label led PO-BGT
1.1 Iodination of OC-BGT
12506-BGT was iodinated with I by the chloramine-T method 
(Hunter, 1967) as modified by Urbaniak et al., (1973). The 
procedure was carried out at room temperature and unless 
otherwise stated, all solutions were made up in 50mM potassium 
phosphate buffer, pH 7.4
125Carrier— free Na [ ID in dilute sodium hydroxide 
(1'OOmCi/ml, 20^L) was added to OC -BGT (2.5nmoles, 4^L). To 
start the reaction, chloramine T (0.5/C w/v, 20^L) was added. 
After constant stirring for 1 min the reaction was terminated by 
the addition of 0.0167. (w/v) sodium metabisulphite (1.5 ml), 
followed by IX (w/v) potassium iodide (40<^ uL).
125The labelled protein was separated from free [ I D  by passage
through a Sephadex 6-25 column(20cm x 1cm) pre-equilibrated in
lOmM potassium phosphate buffer, pH 7.4, containing 17. (w/v)
BSA. Labelled protein was eluted with the same buffer.
Fractions (20 x 1ml) were collected and samples (5/4L) were
counted for radioactivity. The peak fractions containing 
125 °[‘•LJID“00“BGT were pooled, stored at 4 C and used within 3 
weeks.
125The specific radioactivity of the [ ID“06_BGT was calculated 
assuming 1007. recovery of protein.
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1251.2 Determination of the biological activity of VUJ Ill-o(.-BGT
T25The biological activity of the [ *■ I]-0CHBGT was determined by 
measuring the proportion that could be bound by a large excess 
of purified Torpedo marmorata AChR in the absence and presence 
of an excess of the competitive antagonist BZQ. Triplicate 
samples of Torpedo AChR (20pmol, ICOjiL) were incubated with 
(-T25 I]-ot-BGT (0.2pmol, 5CJliL) for 90 min at 23°C in the presence 
and absence of BZQ (25mM, SOjaL), followed by filtration through 
DEAE-cellulose filters, as described in Section A 2.2.
2. Assay of AChR activity
All the assays described involve the incubation of AChR with an 
1?5excess of [ I ]-oc-BGT. Non-specific binding was determined by 
carrying out parallel incubations in the presence of a large 
excess of BZQ (2.5mM, SO^L). Assay totals consisted of
125[ L I]-0C”BGT (2.5-4.0nM, 50yjL) alone. Assay blanks, to 
determine the non-specific binding of radioligand to the
125filters, comprised [I]-0C-BGT and buffer.
2.1 Detergent soluble AChR
AChR was assayed in 'crude' detergent extracts of muscle or 
electric organ by two procedures.
2.1.a Ammonium sulphate precipitation method
This procedure is adapted from that described by Meunier et al., 
(1972).
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Triplicate samples of the receptor (lOC^ uiL) were incubated (45 
min, 23 C) with [ ^  I]-o6-BGT (2.5-4.0nM, 50^L) in extraction 
buffer, comprising lOmM potassium phosphate buffer, pH 7.4, 
containing Z/. (v/v) Triton X-100. Saturated ammonium sulphate 
(133^L), was then added to give a final concentration of 40%
o
(v/v). Following incubation (16h, 4 C) the samples were diluted 
with 407. (v/v) ammonium sulphate solution and the precipitates 
were filtered on Whatman GFC glass fibre filter discs (2.5cm 
diameter) and washed (3 x 1 ml) with the same solution by vacuum 
filtration on a Millipore filter apparatus. The filters were 
then counted for radioactivity.
2.1.b Polvethvleneimine-treated GFC filtration method
©
Samples, as above, were incubated (90 min, 23 C) and then 
filtered on GFC filters which had been presoaked in 0.37. (v/v) 
polyethyleneimine (PEI), pH 10 (1 in 33 dilution of 107. (v/v) 
stock PEI in distilled water) for lh prior to use, as described 
by Bruns et al., (1983). The filter discs were then washed 
under vacuum with lOmM potassium phosphate buffer, pH 7.4, 
containing 0.17. (v/v) Triton X-100 and then counted for 
radioac tivi ty.
2.2 DEAE - cellulose filtration method
Purified AChR was assayed by a method derived from Schmidt and
Raftery (1973). Triplicate serial dilutions of receptor (lOC^ uL)
in toxin binding assay buffer (TBA), lOnfi potassium phosphate
buffer, pH 7.4, containing 0.1% (w/v) BSA, 17. (v/v) Triton X-100
o
and 0.017. (w/v) sodium azide were incubated (90 min, 23 C, or
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overnight , 4 C) with I?^ I]-OC-BGT (4.0-10 nM, 5(^ jd_). Each 
sample was diluted with TBA buffer (1 ml) and applied to a 
double thickness of pre-moistened (with TBA buffer) DEAE-81 
cellulose filter discs (2.5cm diameter). The discs were washed 
(3 x 1ml) with TBA buffer under vacuum and the filters were then 
counted for radioactivity.
Subtraction of the counts obtained in the presence of BZQ gave
specifically bound radioactivity in the test sample. To ensure
125a sufficient excess of V Lmi I3-0C.-BGT, serial 2-fold dilutions of 
the receptor samples were made in the appropriate buffer whereby 
a linear relationship between dilution number and precipitated 
radioactivity was obtained.
The toxin binding capacity of AChR preparations is defined as
125the amount of [ I]-oC-BGT bound per ml of AChR solution 
(pmol/ml) by the following calculation :
125[ I]-0C”BGT = com (-BZQ) - cpm (+BZQ) x pmol x sample x 10 
bound cpm (total) toxin dilution
(pmol/ml) added
3. Purification of AChR
AChR, was extracted by using detergent from Torpedo electric 
organ, fetal calf and human adult skeletal muscle and was 
further purified from Torpedo and fetal calf by affinity 
chromatography. The methods used are based on those described 
by Stephenson et al., (1981) and Gotti et al., (1982).
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3.1 Extraction procedure
Frozen tissue (200-300g) was coarsely chopped and homogenised
(Waring blender, maximum speed, 1 min) in 4 vol of buffer A
(lOmM potassium phosphate , pH 7.4 containing ImM EDTA, O.lmM
PMSF, O.lmM benzethonium chloride, 2mM benzamidine hydrochloride
and bacitracin; 50(^xg/ml). The homogenate was centrifuged 
o
(10,000g, lh, 4 C), and the resulting pellet was homogenised, as 
before, in 1 vol of Buffer A containing Z/. (v/v) Triton X-100
o
(extraction buffer) and stirred for 2-4h at 23 C or overnight at
o o
4 C. The resulting extract was centrifuged (100,000g, lh, 4 C) 
and the supernatant or 'crude' extract was filtered through 
glass wool.
Varying volumes of the extract were retained for use in RIA 
(Methods, Section B2.1) and for the estimation of toxin binding 
activity (Methods, Section A2).
3.2 Affinity chromatoaraohv
AChR was purified from the detergent extract by using an
affinity column comprising Naia naia siamensis oc -toxin coupled
to Sepharose 4B.
3.2.1 Purification of 06 -toxin from the venom of Naia naia 
siamensis
OC “Toxin was purified from the crude venan of Naia naia
siamensis by using a modification of the method described by
Cooper and Reich (1972).
Crude venom(l-2g), dissolved in distilled water (10-20ml) was 
applied to a phosphocellulose column (30cm x 2.5cm),
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pre-equilibrated in lOmM potassium phosphate buffer, pH 6.0. By 
using the same buffer, the column was extensively washed to 
remove non-bound material, until the optical density (A290nm) 
returned to base level. Bound protein was eluted using a linear 
gradient of 10mM-500mM potassium phosphate buffer, pH 6.0,
(600ml of each) at a flow rate of 70ml/h. Fractions (14ml) were 
collected and the optical density (A280nm) was measured.
Fractions comprising each major protein peak were pooled and
solid ammonium sulphate was added to give saturated solutions
o
(760g/L). After stirring for 16h at 4 C, the precipitates were
collected by centrifugation (30,000g, 10 min, 4°C). After
dissolving the precipitates in distilled water they were 
o
dialysed (16h, 4 C) against several changes of distilled water 
(3 x 4L). The non-dialysable material was lypholised and stored 
at 4°C. The protein content of each peak was determined by the 
method of Lowry et al., (1951).
The 06-toxin content of each peak was assayed by competition
125with I]-C6-BGT for binding to purified Torpedo marmorata 
AChR. AChR (0.3pmol, IOOjjlL), in TBA buffer (Section A 2.2), was
o
pre-incubated (30 min, 23 C) with the oc—toxin test sample
125(2CJUL). After the addition of C I]-oc-BGT (0.3pmol, 50j*L), in
o
the same buffer and incubation (60 min, 23 C) the amount of
[125 l]-oc-BGT bound to AChR was determined by the
DEAE-cellulose filtration method (Section A 2.2). The samples
195were serially diluted until less than 507. inhibition of [,X-'I]- 
0C -BGT binding was observed.
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3.2.2 Preparation of the PC -toxin affinity resin 
The Od-toxin purified from Naja naja siamensis crude venom was 
coupled to cyanogen bromide (CNBr) activated Sepharose 4B (March 
et al., 1974) by following the method of Lindstrom et al.,
(1981).
3.2.2a CNBr activation of Sepharose 4B
The procedure was carried out in a fume cupboard and the
o
solutions used were maintained at 4 C throughout. Packed 
Sepharose 4B beads (50ml) were washed slowly with 0.1M NaCl 
(1L), followed by distilled water (500ml) on a scintered glass 
funnel under mild suction.
The beads were resuspended in distilled water (100ml) and
©
stirred over ice with 2M sodium carbonate (100ml) to 4 C. CNBr, 
dissolved in acetonitrile (2g/ml) was added to the bead 
suspension to give a final concentration of 50mg/ml beads.
O
After stirring the beads for 2 min at 4 C, the mixture was 
rapidly filtered and washed with distilled water (500ml).
3.2.2b Coupling of the DO-toxin to activated Sepharose-4B 
Purified oc -toxin (25mg) was dissolved in ice-cold 0.2M sodium 
hydrogen carbonate (100ml) adjusted to pH 9.4 with 5M NaOH. The 
optical density (A280nm) of the resulting solution was measured 
before adding the ot-toxin solution to the activated Sepharose
O
4B beads. The mixture was stirred overnight at 4 C and then 
rapidly filtered and the filtrate retained for the measurement 
of the optical density (A280nm). Thus the amount of 0C-toxin 
bound to the beads could be assessed. The beads were
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subsequently washed with distilled water (400ml) resuspended in
1M glycine (200ml, pH adjusted to 9.0 using 10M NaOH) and
o
stirred overnight at 4 C to block unreacted groups. In order to
remove traces of non-covalently absorbed material the beads were
finally filtered and washed sequentially with 0.1M acetate
buffer, pH 4.0, containing 1M NaCl (100ml), and 0.1M borate
buffer, pH 8.0, containing 1M NaCl (150ml). This washing
procedure was repeated four times, after which the beads were
equilibrated in lOmM potassium phosphate buffer, pH 7.4,
o
containing 0.17. (v/v) Triton X-100, and stored at 4 C in the 
presence of 0.027. (w/v) sodium azide.
After use, the affinity beads were regenerated by washing with 
the same buffer containing additionally 0.5M NaCl (500ml), 
followed by this buffer without NaCl (500ml).
3.3 Adsorption of AChR from detergent extracts
Detergent extracts of AChR (usually 200-300ml) were stirred
o o
(2-4h, 23 C or overnight, 4 C) with the oc -toxin Sepharose 4B
beads (20ml packed volume). The beads were then washed
alternately on a scintered glass funnel with 10mM potassium
phosphate buffer, pH 7.4, ImM EDTA, O.lmM benzethonium chloride,
O.lmM FMSF, 0.027. (w/v) sodium azide and 0.17. (v/v) Triton-100
(Buffer B) containing 0.5M NaCl and Buffer B alone (3 x 350ml of
each). Any residual AChR present in the washing, representing
the 'non-bound' fraction was retained and assayed for toxin
binding activity (Section A 2.2).
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3.4 Elution of AChR from the 06-toxin beads
Two methods were used to elute the AChR from the 06-toxin beads.
3.4.1 Usino carbamvlcholine
o o
The beads were stirred (4h, 23 C or overnight, 4 C) with 0.5M
carbamylcholine in Buffer B (50ml), followed by washing with
Buffer B alone (50ml). The eluate was dialysed against Buffer B 
0 ef
(3 x 2L, 4 C) to remove^the carbamylcholine. The AChR protein
was concentrated by passage through a column (1 x 10cm) of
DEAE-cellulose (DE52), pre-equilibrated in Buffer B. The
o
column was washed, at 4 C with Buffer B (100ml) and the receptor
protein was eluted with the same buffer containing 0.5M NaCl.
Fractions (l-2ml) were collected and samples assayed for
[125 l]-oc-BGT binding activity (Section A 2.2). The peak
fractions containing the AChR protein were pooled and dialysed
against Buffer B (3 x 2L) to remove NaCl. The purified AChR
preparation was finally assayed for toxin binding activity. The
o
receptor protein was stored at 4 C in the presence of 0,027.
(w/v) sodium azide.
3.4.2 Using benzoouinonium chloride
The washed affinity beads were packed into a column (2cm x Bern) 
and the receptor protein eluted with lOmM BZQ in Buffer B, 
directly onto the DE-52 ion-exchange column. The BZQ was
o
recirculated (overnight, 4 C), through both of the columns by 
using a peristaltic pump. The DE-52 column was washed free of 
BZQ with Buffer B (30ml) and final elution of protein was 
carried out as described above by using buffer B containing 0.5M 
NaCl.
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A general scheme for AChR purification is shown in
Figure 7 (page66 ). Variations in the purification procedure
of AChR from different tissues is shown in the Table 7 below.
Table 7










Electric Organ overnight 4°C overnight 4°C
Fetal Calf Muscle 4h 4°C 2h 23°C
Human Skeletal 4h 4°C — —
Muscle overnight 4°C - -
3.4 Determination of the specific activity of AChR
preparations
The specific activities of AChR preparations in detergent 
extracts and purified samples were expressed as pmols 
IJ-06-BGT binding sites per yULg protein.
3.5 Protein estimation
Protein was determined by the method of Lowry et al., (1951) 
using BSA as standard. For samples containing Triton X-100, the 
sodium carbonate reagent contained additionally 5% (w/v) sodium 
dodecyl sulphate (SDS; Nang and Smith, 1975).
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Figure ^  General Scheme for AChR purification
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Elution with 0.5 M NaCl
Purified AChR
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4. Characterisation of purified AChR
4.1 SDS-PAGE
SDS-PAGE was performed according to the method of Laemmli (1970) 
using slab gels (16cm x 10cm). The running gel was composed of 
107. (w/v) acrylamide and the stacking gel was 57 (w/v) 
acrylamide.
AChR samples containing 10-50jxq of protein (Lowry estimation) 
were boiled for 2 min with sample buffer (27 (w/v) SDS, 107 
(v/v) glycerol, 57. (v/v) mercaptoethanol, 0.0017. (w/v) 
bromophenol blue (tracking dye) in 0.625 M TRIS, pH 6.8 before 
loading.
The following proteins were used as molecular weight markers :
Protein________Mr
p galactosidase 120,000
phosphorylase b 94,000 
IgM, jX chain 74,000
BSA 65,000
IgG, if chain 50,000
aldolase 40,000
carbonic anhydrase 29,000
The running buffer consisted of 25mM Tris/192mM glycine buffer 
containing 0.17. (w/v) SDS and 107. (v/v) 2-mercaptoethanol. 
Samples were run into the stacking gel at 20mA and then 
e 1 ectrophoresed at 30mA until the tracking dye was 1cm from the 
bottom of the slab gel.
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The gel was stained for protein using 0.057. (w/v) Coomassie Blue
R250 in 12.57. (w/v) trichloroacetic acid (TGA), overnight at 
o
23 C. The gels were destained by washing, with repeated changes 
of 12.57. (w/v) TCA.
4.2 Gel filtration of Torpedo AChR
Purified Torpedo (7mg) was chromatographed on an ACA-34 column 
(2.2cm x 81cm) equilibrated in lOmM potassium phosphate buffer, 
pH 7.4 containing 0.17 (v/v) Triton X-100. After application of 
the sample, the protein was eluted from the column at a flow 
rate of 30ml/h and fractions (4.4ml) were collected. Samples 
(20<^ jiL) of each fraction were assayed for protein (Section A 
3.5) and the protein peaks were pooled and assayed for oc -toxin 
binding activity (Section A 2.2). The column was calibrated 
with standard proteins of known molecular weight and the 
fractions were assayed for protein.
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RESULTS
1. Preparation of 11-label led 06-BGT 
1=1 Iodination of P6-BGT
06-BGT was iodinated by the chloramine T method (Methods,
Section Al). A typical elution profile from G25 Sephadex column
is shown in Figure?) (page?1 ) and Table8 (page?1 ) summarises
-IOC
the values obtained for the incorporation of ['*■-'I] into protein
125and the specific activity of the [ I1-OC-BGT preparations.
1.2 The biological activity of 11-Od-BGT 
The biological activity of [^5 i]-oc-BGT was assessed by its 
ability to bind to a 100 molar excess of Torpedo AChR (Methods, 
Section A1.2).
125The biological activity of the [ I]-06”BGT preparations are
given in Table?) (page71) and is defined as :
Biological activity = ft-* 13 bound x 100 7.
TOTAL C125 ID added
2. Assay of AChR activity
Determination of the tissue content of AChR was dependant upon a 
suitable assay system. Ammonium sulphate precipitation of 
[125 I]-0C-BGT labelled AChR is an established method for samples 
containing large amounts of soluble protein such as detergent 
extracts. The use of a simple filtration assay such as that 
described using PEI treated filters (Methods, Section A. 2.1.b) 

















Table §  Summary of the iodination of 06-BGT
Mean + S.E.M.(n) 
% incorporation of J^2S i j  into protein 92 - 1.4 (12)
Specific radioactivity (Ci/mmol) 750 - 3.4 (12)
% Biological activity 58 - 3.2 (6)
(n is the number of determinations).
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2.1 The use of PEI coated filters in the assay of I]-CX/-BGT 
binding to detergent extracts of AChR
The non-specific retention of I ]-CC”BGT on PEI treated GFC
filters and untreated GFC filters in the ammonium sulphate assay
in the absence of AChR (the equivalent of 'assay blanks') were
125compared over a range of [ I3-0C-BGT concentrations 
(Figure 9 , page74). The non-specific binding for both assay
125conditions was linear with increasing amounts of [ I]-Od-BGT
and for PEI treated filters, this represented 17. of the total
125 I3-0C-BGT added. The equivalent value for the ammonium 
sulphate assay using untreated GFC filters was considerably 
higher at 6.97..
The quantitative aspects of the two systems for the assay of 
detergent extractable AChR from human and fetal calf muscle were 
compared (Table9 a, below). The ammonium sulphate assay 
detected slightly more toxin binding activity than the PEI/GFC 
assay. However, the PEI/GFC assay was more reproducible, with 
good replicates. Also, the non-specific binding of
125[ I ]-OC~BGT expressed as 7. of the total binding was
significantly smaller using PEI/GFC filtration than in the 
ammonium sulphate method (Table9 b, below).
Table 9 a Quantitative comparison of PEI/GFC filtration and 
ammonium sulphate precipitation in the assay of 
detergent solubilised AChR
AChR measured (pmol/ml)
Extract PEI/GFC ftmn.SCW (GFC)
Human Muscle 0.54 0.57
Fetal calf 0.85 0.90
?3
Table 9 b Comparison of nan—specific binding in the ammonium 
sulphate and PEI/GFC assay
Non-specific binding as 7. of the total binding
Extract PEI/GFC friM.S04 (GFC)
Fetal calf 32.6± 2.68 64.3 ± 2.59
Results expressed as mean ± SE. of three determinations at 1/4, 
1/8 and 1/16 dilutions of fetal calf extract.
3. Purification of AChR
AChR Mas purified from two tissue sources, Torpedo electric 
organ and fetal calf skeletal muscle. AChR was also extracted 
from human adult skeletal muscle. A cocktail of protease 
inhibitors and anti-bacterial agents was used throughout to 
minimise degradation by proteolysis.
Essentially two steps were critical for the purification of 
receptor. Firstly, the detergent extraction of AChR from its 
membrane environment and secondly the use of an 06-toxin 
affinity resin.
3.1 Extraction conditions
AChR isolated from mammalian sources is known to be susceptible 
to proteolytic degradation (Dolly, 197^; Einarson et al., 1982) 
in contrast to Torpedo AChR. In order to minimise proteolysis 
and obtain good yields of receptor, the time period and 















Figure 9 Comparison of Non-specific binding to GFC filters 
in the PEI and ammonium sulphate assay systems
20
0 125 250
c.p.m. added ( x 10’ ^  )
The non-specific retention of £251] - DC-BGT on PEI treated 
GFC filters (no AmmS04 precipitation) (-• -) and untreated 
GFC filters (AmmS04 precipitation) (-O-) was compared over 
increasing concentrations of u2SIJ -o^-BGT (0-16nM).
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For fetal calf and human skeletal muscle tissue sources the
O o
extraction conditions of 4h at 4 C and overnight at 4 C were
o
compared. An extract sample (5ml) was removed after 4h at 4 C,
125centrifuged and assayed for [ I]-oC-BGT binding by the PEI/GFC
filtration method (Methods, Section A2.1.b). This procedure 
was repeated after further extraction overnight. Similarly the
o o
extraction conditions of 4h at 23 C and overnight at 4 C were 
compared for Torpedo electric organ (TablelO below).
TablelO : Comparison of the efficiency of detergent extraction
under different conditions of temperature and time
TISSUE SOURCE
pmols/g original tissue
EXTRACTION CONDITIONS TORPEDO FETAL CALF HUMAN MUSCLE
4h at 4° C N.D. 1.24 0.85
4h at 23^C 671 N.D. N.D.
overnight at 4°C 682 1.30 0.98
N.D. Not determined
For fetal calf and Torpedo electric organ, additional stirring
overnight resulted in increases in yield of only 57. and 27.
respectively. Hence, in order to reduce proteolysis extraction 
o
for 4h at 4 C was routinely used.
Maximum yield of AChR from human skeletal muscle was obtained 
when additional stirring with detergent overnight was used.
This resulted in an increased in yield of 147. This could 
result from the more fibrous nature of the tissue source.
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The conditions used for the preparation of detergent extracts of 
AChR from the various tissue sources are summarised in Table 7
(page65).
3.2 AChR content of the tissue sources
The AChR content from the sources used here (Torpedo electric 
organ, fetal calf and adult human skeletal muscle) is reflected 
in the amount of AChR extractable by detergent, as assessed by 
[125 i]-0C-bgt binding (Methods, section A2.1) assuming good 
extraction. Hence, using the optimised extraction procedures 
described in Results, section A.3.1 the 06-toxin binding per 
gram of starting material can be obtained (see Tablell below). 
As expected, Torpedo electric organ was shown to be an extremely 
rich source of AChR having, approximately a 500-fold higher 
receptor content than human and fetal calf muscle.
Table 11 Comparison of the AChR content of tissue sources
DETERGENT EXTRACT YTFl n 
TISSUE SOURCE pmoles OC -toxin binding sites/g
ORIGINAL TISSUE
Torpedo Electric organ 050 - 1403; 948 t 200 (n=5)
Fetal calf muscle 1.06 - 2.64; 195 - 0.23 (n=15)
Adult human skeletal muscle 0.4 - 1.88; 1.13- 0.20 (n=10)
Results are expressed as range; mean + S.E.M. (n)
3.3 Stability of Detergent Extracts of AChR
The stability of detergent extractable AChR was assessed by
175[ I]-0C“BGT binding at various time periods after preparation. 
Crude detergent extracts of human and fetal calf muscle were
l i ­
very stable (FigurelOa and b) and could be stored for 
up to three months without appreciable loss of toxin binding 
ability. The stability of detergent extracts of Torpedo 
electric organ were not examined.
3.4 Od-Toxin affinity chromatography
Purified OC-toxin was coupl ed to Sepharose 4B beads before 
being used as affinity ligand in the purification of AChR.
3.4.1 Purification of OC-toxin from the venom of Naia naia 
siamensis
The purification of the 06-toxin from crude venom was by 
ion-exchange chromatography on a phosphocellulose column 
(Methods, Section A.3.2.1). A typical elution profile is shown 
in Figure'll . The o6“to><in was identified by its 
ability to inhibit the binding of C ®  I3-DC-BGT to Torpedo AChR. 
Peaks A (non-bound) and F did not inhibit toxin binding to AChR, 
whereas peaks C and D showed the strongest inhibition. The 
results are summarised in TablelZ (pageSO). The overall 
recovery of protein from the column was 65%. The fractions 
corresponding to peaks C and 0 were pooled separately and 
lyophilised.
3.4.2 Preparation of the 06-toxin affinity beads 
Lyophilised 06-toxin from peak C was coupled to CNBr activated 
Sepharose 4B beads (Methods, Section A3.2 2b). 60-70% of the 
06-toxin added was consistently coupled to the resin.
The AChR binding efficiency of freshly prepared beads was tested 




















Figure10 Stability of Detergent Extractable AChR
a. Foetal Calf AChR
• •
time (days)
b. Human Adult AChR
t im e  (days)
Figure 11 The elution profile from phosphocellulose ion exchange 
chromatography in the purification of 06 -toxin from 



















Table 12 Summary of the purification of PC-neurotoxin from Naja naja siamensis
Dilution giving 50% pmol.es Specific
inhibition of Total Od-toxin activity Purification
Peak f 25 ij -Ot-BGT binding protein(mg) (total) (pmol/mg) Factor
Crude venom 1.0 x io-5 1750 2.32 X 10* 1.32 X ios -
A (non-bound) No inhibition 326 - - -
B 3.89 x io'3 131.4 9.0 X io5 6.8 X 103 X 0.05
C 1.20 x io's 368.0 1.75 X io9 4.75 X 10s X 3.59
D 5.98 x 10 ~s 65.6 1.43 X 10* 2.17 X 10* X 1.64
E 7.89 x io‘s 198.5 2.09 X 10* 1.05 X 10* X 0.79
F No inhibition 58.4 _ _ _
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purified Torpedo AChR. The beads were usually able to bind 
3.0-3.5 nmol AChR/ml of gel. There was no appreciable loss in 
binding efficiency over a period of one year provided that the
o
beads were stored at 4 C and regenerated after use (Methods, 
Section A3.2 2b).
3.4.3 Adsorption of AChR using P6-toxin affinity beads
06-Toxin - Sepharose beads were used to adsorb AChR from the
detergent extracts of Torpedo electric organ and fetal calf
muscle. The optimal binding of AChR from these sources to the
o
06-toxin beads was assessed at 23 C, by removing samples of the 
affinity beads/extract at intervals. Following centrifugation, 
the supernatants, containing 'non-bound' AChR were then assayed 
for I]-o6~BGT binding activity (Methods, Section A2.1).
Near maximal binding of AChR occurred after 2-3h of stirring
(Figure12 ). To reduce the time spent in the purification of
fetal calf AChR, a stirring time of 2h was chosen as 867. of the
available AChR was bound by the beads. In the routine
purification of fetal calf AChR, the affinity beads, under these
conditions bound 84t 4.1% (n=7; meant S.E.M. (n) ) of the
available AChR in the detergent extract. In the preparation of
purified Torpedo AChR, the affinity beads routinely bound 95 t
1.07. (n=6 ; mean! S.E.M.) of the available receptor, using
o
stirring times of 4h at 23 C or overnight. There was no 


















Figure 12 The Binding of Detergent Extractable AChR to OG-Toxin Affinity Beads





3.4.4 Elution of AChR from the 00 -toxin affinity beads
Two cholinergic ligands, carbamylcholine or BZQ were used to 
elute AChR specifically from the 06 -toxin beads (Methods, 
Section A3.4). The main difference in the use of the two 
ligands was the necessity for an additional dialysis step when 
carbachol was employed, in order to remove the agonist before 
passage through the DE-52 ion-exchange column. With BZQ, AChR 
could be eluted from the 06 -toxin beads directly onto the 
ion-exchanger. Hence, the use of BZQ reduced the overall 
purification time by approximately 12h. It was also possible to 
re-use the BZQ solution several times for the purification of 
AChR.
The efficiency of the two agents for eluting AChR from the 
06-toxin affinity resin was compared. Rjrified Torpedo AChR 
was adsorbed onto 06—toxin beads and equal volumes of beads 
incubated with carbachol (0.5M) or BZQ (lOmM) for 90 min, then 
packed into columns (1 x 7cm) and the carbachol or BZQ recycled 
5 times. The eluant was dialysed overnight against Buffer B 
(Methods, Section A3.4) and the nan-dialysable material assayed 
by DEAE cellulose filter assay (Methods, Section A2.2). The two 
methods were equally efficient in eluting Torpedo AChR from the 
affinity resin (TablelB below) but the use of BZQ elution was 
preferred because of the shorter time involved.
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Table 13 Comparison of the Efficiency of Carbachol and BZQ 
elution
125Elution Agent 7. Recovery of [ 13-0G-BGT
binding activity from extract
Carbachol (0.5M) 16.3 ± 2.3X
BZQ (lOmM) 16.0 ± 2.97.
The results are tie meantS.E. of 2 experiments.
3.4.5 Yield of purified AChR from Torpedo electric organ and 
fetal calf muscle
The recovery of purified AChR can be expressed as a percentage
of the detergent extractable activity as assessed by
[125 i]_0CHB6T binding, and the yield as the recovery of purified
AChR per gram of starting tissue. The yields and recoveries of
AChR between the tissue sources varied greatly and the results
are summarised in Tabled. The results closely parallel the
yields of detergent extractable AChR per gram of starting tissue
(Table 10 , page75 ) and again reflects the difference in
receptor content of the starting tissue. This is also
highlighted in the results for the degree of purification
obtained in the preparation of Torpedo AChR and fetal calf AChR.
Because Torpedo electric organ provides such a concentrated
source of nAChR, only a low purification factor was necessary
to purify it to near homogeneity. The yields and recoveries of
AChR from the same tissue source also varied and this is
discussed later (Discussion, Section A).
3.4.6 Storage and stability of purified AChR
o
Purified Torpedo AChR was stored at 4 C in the presence of 
sodium azide and was relatively stable with respect to oo-toxin








Recovery of AChR 
as % of extract 
activity




organ 2.5-5.9; 5.1 ±0.82,(6) 20-40;
2 7 ±  4.5,(6)
23-36; 30 - 3.0,(6) 174-333; 228 t  33 (6)




Results are expressed as range; mean ± S.E.M., (n).
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binding activity for periods up to 2 months. For example, one 
preparation of Torpedo AChR retained 857. of the OC -toxin 
binding activity after a period of storage of 10 weeks.
Analysis of the AChR preparation was carried out by using 
SDS-PAGE (Results, Section A4.1). The degradation products were 
removed by gel filtration (Results, Section A4.2).
Purified fetal calf AChR stored under identical conditions could 
be kept for up to 2 weeks without significant losses (<10%) in 
0 6 -toxin binding activity. In a trial experiment purified 
fetal calf AChR was frozen at -20°C in the presence of 10% (v/v) 
glycerol. However, after a storage period of 2 weeks under 
conditions of freezing, 83% of the original pG“toxin binding 
activity was lost, indicating that freezing impairs the 
structural integrity of the receptor.
4. Characterisation of purified AChR
The subunit composition of purified AChR from Torpedo and fetal 
calf AChR was studied by SDS-PAGE. Purified Torpedo AChR was 
also subjected to a gel filtration procedure to assess 
proteolytic degradation.
4.1 SDS-PAGE analysis
SDS-PAGE of purified AChR from Torpedo electric organ and fetal 
calf skeletal muscle was carried out in order to investigate the 
subunit composition of the protein, according to the procedure 
described in the Methods, Section A.4.1.
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Estimations of subunit apparent molecular weights were made by 
comparing the electrophoretic mobility of the unknown species 
relative to mobilities of marker proteins of known molecular 
weight. Electrophoretic mobility was plotted against log 
molecular weight for standard proteins (Figure'll). A separate 
calibration curve was included in every experiment. The average 
Rf and Mr values of the standard proteins were subjected to 
linear regression analysis and gave a good linear relationship 
with r2 = 0.92.
Following SDS-PAGE purified fetal calf AChR consistently showed 
5 major bands of apparent molecular weight (Mr) 39, 46, 48, 52 
and 57K, lower (<30K) molecular weight components were also 
observed.
Purified Torpedo AChR consistently showed 4 major bands of Mr 
39 , 47 , 52 and 62K, and the typical pattern of protein bands 
observed following staining by Coomassie Blue is shown in 
Figured. These values agree well with published values; these 
being 40K, 45K, 50K and 60K (Conti-Troncani and Raftery, 1982). 
Hence it was possible to assign the 39K band as the <X/ -subunit, 
the 47K as the -subunit, the 52K band as the $ -subunit and 
the 62K as the S  -subunit. Two additional bands were 
repeatedly observed corresponding to Mr 43K and 66K.
4.2 Gel filtration of Torpedo AChR
Chromatography of purified Torpedo AChR was performed as
described in Methods, Section A4.2. The receptor used had
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Figure14 Calibration of 10% polyacrylamide gel under 
denaturing conditions using standard proteins
Carbonic Anhydraso (Mr 29,000)
Aldolase (Mr 40,000)
•  IgGH (Mr 50,000)
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The relationship between the molecular weight of the standard 
proteins with their Kav value where Kav represents the fraction 
of the stationary gel volume which is available for diffusion 
for that protein.
89
and the chromatographic procedure was used to assess proteolytic 
degradation.
The column was calibrated with standard proteins of known 
molecular weight (Figuresl5a and b ) by calculating Kav values, 
where Kav represents the fraction of the stationary gel volume 
which is available for the diffusion of a given solute species 
and can be calculated by the following equation.
Kav = Ve - Vo where Ve = elution volume
Vt - Vo Vo = void volume
Vt = total volume of the 
packed column bed.
Two protein peaks were observed when the Torpedo AChR 
preparation was chromatographed (Figure16 ). These 
peaks represent proteins of molecular weights of 400K and 
respectively. Following analysis of protein content and
\7LS[ I]-PC-BGT binding activity had specific activities of 
and 0.036 0C -toxin binding sites/ymg protein, for peak i 
peak 2 respectively.
The specific activity of the Torpedo AChR preparation applied to 
the column was 1.23 pmols 0C -toxin binding sites/^Ag protein 
and hence the removal of small proteolytic fragments in peak 2 
improved for specific activity of the preparation of AChR by a 





4.2.1 Analysis of the protein peaks by SDS-PAGE


































Peaks 1 and 2 represent proteins of molecular weight 
400K and 13K respectively.
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Torpedo AChR (see previous section) were analysed by SDS-PAGE. 
Peak 1, appeared very similar to the original AChR preparation, 
showing protein bands corresponding to Mr values of 39, 47, 52 
and 62K. In both peak 1 and the original unchromatographed AChR 
preparation a 43K band was observed but no band corresponding to 
a Mr of 66K was observed. Peak 2 showed no protein bands; the 
breakdown products being of low molecular weight (13K by gel 
filtration).
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FIGURE 17 SDS-PAGE Analysis o f AChR from 
Torpedo marmorata
SDS-PAGE analysis o f AChR prepared from  Torpedo 
e lec tric  o rgan , illu s tra tin g  the four subun its  oc,p ,# ,<? 
as w ell as the contam inating protein a t 4 3k
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DISCUSSION
This chapter describes the purification and characterisation of 
nAChR protein from Torpedo electric organ and fetal calf muscle 
for use as immunogens in the production of polyclonal and 
monoclonal antibody probes (Section B). Additionally, nAChR was 
solubilised from adult human skeletal muscle for the 
characterisation of the antibodies produced (see Section B). 
Accordingly the purification of the nAChR from these tissue 
sources will be discussed here.
Advances in the isolation and characterisation of nAChR can be 
largely attributed to the discovery of 06-neurotoxins (see 
Introduction, page 9 ), which are highly specific for the ACh 
binding site. Two CO-neurotoxins have been used in this work; 
fl/.-naja-naia toxin as an affinity ligand in the purification of 
nAChR and radio label led 06~BGT for the quantitative assay of 
nAChR.
For a radiolabelled ligand to be of use in detecting small 
quantities of receptor, it must have high specific activity 
whilst retaining biological activity. Tritiated radiolabelled 
ligands are usually indistinguishable from the native ligand and 
have long shelf-lives. However, tritiated compounds usually 
have lower specific activities than those achieved by radio- 
iodination. Nevertheless, tritiated derivatives of DO-B3T have 
been prepared and used in nAChR studies, (see Dolly and 
Barnard, 1984). However, tritium labelling procedures are 
complex, whereas iodination methods are relatively simple. In
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addition, counting C^^I] is less laborious than counting r H]. 
Hence, iodination of OG-BGT was selected for routine use.
The preparations of I J-06-BGT had consistently high specific 
radioactivities with biological activities of 55-617. (Results, 
Section Al). Loss of biological activity may be due to damage 
by the powerful oxidising agent, chloramine T, used as the 
catalyst in the iodination procedure. Alternatively, it may 
result from radiation destruction, caused by the decay products
12Sof [ I ] .  It was however accepted that the problems associated 
with radioiodination of 06-BGT were outweighed by the high 
specific activities achieved, which enabled the detection of 
small quantities of AChR ('vfmols).
Triton X-100 was shown to be an effective agent for the 
solubilisation of AChR from its membrane bound state (Results, 
Section 3.2). The use of Triton-XlOO to solubilise AChR, 
however, has some disadvantages. The detergent absorbs strongly 
at 290nm and therefore necessitates the use of a modified Lowry 
procedure, rather than simple spectroscopic estimation of 
protein concentration. Triton X-100, by forming a micelle round 
the AChR, can also make the estimation of the molecular size of 
AChR difficult. However, the use of the neutral detergent 
Triton X-100 has several advantages over the ionic detergents 
sodium cholate and deoxycholate. The latter have been found to 
affect the ligand binding properties of the receptor, by causing 
a shift from high affinity states to medium and low affinity 
states, by allosteric interactions. (Introduction, page 6 ).
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Triton X-100 maintains the receptor as a homeogeneous, high 
affinity population (Sugiyama and Changeux, 1975). Ionic 
detergents can also interfere with SDS-PAGE analysis and 
ion-exchange chromatography of the receptor protein. Hence, 
Triton X-100 provided the best choice for use in this study.
Although it is impossible to determine the absolute AChR content 
of muscle and electric organ, it is reasonable to assume that it 
will be reflected in the [^ 25 I]-0C-BGT binding capacity of the 
detergent extract of the tissue sources. This is, in turn, 
dependent upon the efficiency of extraction, the ability of all
125AChR present to bind [ I]-06-BGT and the use of a reliable
quantitative assay.
The efficiency of the detergent extraction procedure is
125difficult to assess because the [ I]-06~BGT binding capacity
of the resulting pellet (Pellet, P2; see Figure 7 > page 66 ) 
was not determined and this may be difficult due to its fibrous 
nature. Hence, a comparative study examining the efficiency of 
detergent extraction, under different conditions of temperature 
and time, using one tissue sample from each source was under­
taken. Mammalian muscle has increased protease levels compared 
with Torpedo electric organ, (see Anholt et al., 1984), and
extraction of AChR from fetal calf and human muscle was carried 
o
out at 4 C. Extraction of Torpedo AChR was sometimes performed 
at room temperature (Results, Section 3.1). Anti-protease 
agents were present in all buffers to limit proteolysis and the 
use of these agents will be discussed in a later section.
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Two different assay procedures were used for the estimation of
AChR in detergent extracts, both relying upon the ability of
AChR to bind [ ^ 5 ^ - ^ - bgt (Methods, Section A.2). The use of
(NH4)2 S04 to differentially precipitate the receptor protein
and the receptor-toxin complex is a we11--established method
(Meunier et al., 1972). However, this assay tended to give high
non-specific binding and poor replicates (Results, Section
A2.1). An alternative procedure used PEI-treated filters to
IOC
separate free and non-bound [ltmJ I ]-06-BGT. The PEI imparts a 
net positive charge to the filter, which retains the acidic 
[125 i]-D6-BGT AChR complex (pi 5.2; Conti-Tronconi and 
Raftery, 1982). This assay proved to be quantitatively similar 
to the (NH4)2 S04 method but had greater reproducibility and 
lower non-specific binding (Results, Figure 9 and Table 9 a and 
b). Additionally, an overnight incubation step which has been 
reported to be critical for the (IVH4)2 S04 assay (Lotwick, 1985) 
could be avoided in the PEI method.
The AChR yields from Torpedo electric organ, fetal calf and 
human skeletal muscle varied from one preparation to another 
(Results, A3.2). Because of the inconvenience of obtaining 
fresh stocks of electric organ at frequent intervals from France 
(Materials ), the electric organs were collected, frozen and 
used over a period of 22 months and variability in the observed 
yield of Torpedo AChR may result from deterioration over this 
time period.
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Yields of AChR obtained from mammalian muscle were consistently 
lower than those obtained from Torpedo (Results, Section A3.2) 
and this necessitated the use of a bulk source of tissue. In 
this study, amputated limbs from patients with ischemic vascular 
disease were used as a source of human muscle. This has many 
advantages over the use of post-mortem tissue, becaiuse autolysis 
and hence proteolysis could be limited by immediate dissection 
of the tissue and freezing. The tissue was usually used within 
three weeks of freezing and the deterioration over this time was 
probably minimal. It is also possible that tissue stored at
o
-90 C may lose its 06-toxin binding activity during the 
freeze-thaw cycle. However, there was no evidence to support 
this. Several workers have noted variability in yields of AChR 
from human sources (Table 15 ) and this is most likely because 
of the inherent variability in the tissue samples used.
Ischemia may result in partial denervation of the muscle and 
hence cause proliferation of EJR (Introduction, page 14 ), 
providing a richer source of AChR. It is however difficult to 
assess the AChR content of normal healthy innervated muscle for 
comparison. Momoi and Lennan (1982) reported very low yields of 
AChR (0.04-0.14 pmols/g muscle) from patients with bone cancer. 
However, this source cannot strictly be described as 'normal'.
In a more recent study (Lotwick, 1985), muscle from a road 
traffic accident was used and the value quoted, 0.39 pmol
195[ ^J I]-(XH3GT binding sites/g muscle, is at the lower end of the 
range of values obtained in this thesis (Results, Table 11 ).
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Detergent extracts of fetal calf muscle gave, in general, higher 
yields of AChR than human muscle (Results, Tablell ). However, 
the yields obtained in this study were generally lower than 
those quoted by Einarson et al., (1982) and Gotti et al., (1982) 
(see Table16, page99). In the latter studies, small fetal 
calves (26cm-51cm) were used, whereas this work employed a wider 
range of fetal calf sizes (26cm-90cm). The higher concentration 
of AChR in small fetal calves is probably due to the presence of 
EJR and also to the small size of the muscle fibres, making 
solubilisation easier. As the fetal calves become older, and 
hence larger, the muscle will became innervated and result in a 
decrease of AChR content. Hence the variability in yield found 
in this present work may reflect the differences in AChR density 
during muscle development. Similarly, human fetal muscle has 
been found to be a much richer source of AChR than adult muscle 
(Turnbull et al., 1985; Table15).
Both fetal calf and adult human skeletal muscle detergent
1?^extracts were stable with respect to ['*•" I]-0C_BGT binding 
activity (Results, Section A3.3). However, this may not reflect 
the true state of the receptor complex since the 06-BGT binds 
only to the -subunit. The p , & and S subunits of Torpedo 
amd fetal calf AChR have been shown to have greater protease 
sensitivities than the relatively protease-resistant DC-subunit 
(Lindstrom et al., 1980; Einarson et al., 1982, respectively).
A more precise means of assessing receptor integrity would be by 
immunoprecipitation wtih radiolabelled subunit specific 
polyclonal or monoclonal antibodies.
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Table 15 Yield of ftChR from fetal calf and 
human adult skeletal muscle
Yield (pmolOC-toxin binding 
Source of Tissue sites/a wet weight tissue) Reference
Fetal calf muscle 4.1
2.5-5,3
1.6-2.84
Einarson et al., 
1982 











































Human fetal 0.99 
0.6-1.9
Turnbull et al., 
1985 
Lotwick, 1985
NB: Where ranges are not quoted by the author the mean value is
given.






io ” 3 )
Yield of Purified 
AChR (pmol/g tissue)
Speci f i c 
Ac tivi ty 
(nmol/mg)
Ref erence
40, 45, 50, 60
39, 47, 52, 62
41, 50, 53, 56
42, 44, 49, 55, 58













Einarson et al., 
(1982)





3 \2Sthe yield and specific activity of AChR preparations are quoted as mols I -cc-BGT binding 
si tes/g protein.
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AChR was purified from fetal calf muscle and Torpedo electric 
organ by affinity chromatography an immobilised 06-naja naja 
toxin (Methods, Section A3.2). The methods used were aimed at 
reducing the time taken for the purification to a minimum, to 
limit proteolysis. Homegenisation and extraction of tissue 
results in the rupture of organelle membranes, ultimately 
leading to the release of proteolytic enzymes. Hence 
anti-protease agents were included in all buffers.
Early preparations of purified AChR from Torpedo electric organ 
and mammalian sources gave inconsistent subunit patterns (see 
Conti-Tronconi and Raftery, 1982, for review) and were due to 
proteolytic degradation of the receptor. Hence, a cocktail of 
protease inhibitors (EDTA, PMSF), antibiotics (bacitracin) and 
bacteriocides (sodium azide) was used in the extraction and 
purification procedures. The protease inhibitors, PMSF and 
EDTA, have been shown to reduce the proteolytic degradation of 
AChR purified from Torpedo (Lindstrom et al., 1980) and 
vertebrate sources (Schorr et al., 1981). Similarly the 
protease inhibitor, iodoacetamide, has also been shown to reduce 
the proteolytic degradation of the receptor (Dolly and Barnard,
1984). However, these reagents have been reported to inactivate 
the toxin binding activity of chick muscle receptor (Sumikawa et 
al., 19823)and human receptor (Turnbull, 1984) and hence were 
not used in this work.
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OC-Naja-naja toxin coupled to Sepharose 4B was used as an 
affinityAto absorb AChR from detergent extracts and was found to 
be a highly efficient absorbant in this present study; the 
resin bound 00-967. of the AChR present in crude detergent 
extracts (Results, Section A3.4.3). The0C~toxin beads used in 
this work were highly substituted as defined by the criteria of 
Gotti et al., (1982); binding 3.0-3.5nmol AChR/ml affinity 
resin, a value similar to that reported by Einarson et al.,
(1982). The absorption of AChR from fetal calf detergent 
extracts to immobilised toxin (95%) was, however greater than 
that reported by Einarson et al., (1982) and Gotti et al.,
(1982), who report 677. and 49-607. absorption of AChR 
respectively.
Both BZQ and carbamylcholine were equally efficient in eluting 
receptor protein from the 06-toxin affinity resin (Results, 
Section A3.4.4). However, the BZQ method was preferred because 
the procedure was faster and easier. The subsequent recoveries 
of AChR from Torpedo and fetal calf muscle were similar (10-367.) 
Results, A3.4.5) and compares well with results of other 
workers. Gotti and co-workers (1982) have reported that the use 
of low od-neurotoxin-substituted beads rather than a more highly 
substituted resin improves the recovery of AChR from the 
affinity ligand. Indeed an increase from 87. recovery to 227. was 
reported. These values are well within the range of recoveries 
found in this work using highly substituted beads and it was 
therefore concluded that little advantage would be gained from 
using a less substituted resin. The elution of AChR from the
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OL-toxin affinity ligand is the most costly in terms of loss of 
AChR, and the only partial recovery of AChR may be due to the 
high affinity of the OC~toxin for AChR (Lee, 1979).
The variability in yields of purified AChR from Torpedo and
12Sfetal calf muscle paralleled the variability in C I]-#-BGT 
binding activity of their respective detergent extracts. The 
possible reasons behind this have been discussed previously.
The yields found in this present study were within the ranges 
quoted by other workers (Table 16 )•
The degree of purification of AChR can be expressed by specific 
activity in terms of moles of 06-neurotoxin binding sites per 
milligram of protein. Theoretically, the specific activity of a 
pure sample of Torpedo AChR should be 8nmols/mg. The values 
for the specific activities of purified fetal calf and Torpedo 
AChR found in this study (Results, Section A3.4.5) and quoted by 
other workers (see Table16 ) fall below this ideal. Low 
specific activities may result from a number of factors: 
presence of contaminating non-receptor proteins, errors in toxin 
calibration and/or protein determination. Analysis by SDS-PAGE 
did, indeed, reveal the presence of contaminants (Results, 
Section 4.1) and the significance of these contaminants is 
discussed below. Over-estimation of the protein concentration 
is likely to be a significant factor in giving low specific 
activity values, as, in most cases, it was at the lower end of 
the sensitivity of the assay. Also the receptor present in a 
detergent micelle may behave differently from the standard
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protein used in the assay. Uhder— estimation of the number of
125 I]-06-BGT binding sites in the purified receptor may have 
occurred due to the iodinated toxin having less than 1007. 
biological activity (Results, Section A1.2). Additionally, the 
receptor is exposed to high concentrations of agonist 
(carbamylcholine) or antagonist (BZQ) during elution from the 
06-toxin affinity column and this is thought to cause 
desensitisation of the receptor, producing changes in its
125conformation and loss of ability to bind [ I]-D£-BGT 
(Changeux, 1981).
This latter phenomenon may contribute to the low (10-367.) 
recovery of 06-toxin binding activity after absorption by the 
D6-naia naja siamensis affinity resin.
Purified fetal calf AChR was found to be less stable with
125respect to [ I]-06“BGT binding activity than the detergent
counterpart (Results, Section A3.3 and Section A3.4.6), 
indicating that the purified protein is more susceptible to 
proteolysis. This may be due to relative concentrations of 
receptor in crude and purified preparations or to the 
concentration of Triton X-100, which could serve to protect the 
receptor from proteases, in the different samples. Indeed 
purification of the receptor may lead to increased exposure to 
proteases and accelerate its loss of toxin-binding activity. 
AChR purified from human fetal muscle is known to be highly 
unstable with respect to 0C-toxin binding ability when compared 
to human adult receptor (Turnbull et al., 1985).
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Freezing the receptor in the presence of glycerol was 
detrimental to the 0C-toxin binding capacity of the preparation 
(Results, Section A3.3). This is in contrast to the findings of 
Lindstrom et al., (1981), but is in agreement with those of 
Turnbull et al., (1985). This controversy may be explained by 
differences in the rate of cooling of the samples. Difference 
between fetal calf AChR and adult AChR may reflect structural 
differences between the two receptor types; (J and EJR) human 
fetal receptor has been shown to have a lower carbohydrate 
content than adult AChR (Turnbull et al., 1985), and there 
appear to be major differences in metabolic stability between J 
and EJRs (see An holt et al., 198 If for a review of differences).
In contrast, purified Torpedo AChR showed relatively stable 
OC-toxin binding activity and this has been noted by other 
workers (Lindstrom et al., 1981). However, analysis of a 10 
week-old preparation of Torpedo AChR by gel filtration (Results, 
Section A4.2) revealed the presence of small degradation 
products of molecular weight, 13K (Results, Section A4.2) 
indicating that proteolysis had occurred over this time period. 
The major peak comprising AChR protein was of molecular weight 
400K and this value is in agreement with those quoted by other 
workers using gel filtration (see review by Cdnti-Tronconi and 
Raftery, 1982). The experimental evaluation of the molecular 
weight by gel filtration has yielded values that are 
consistently higher than those obtained by X-ray diffraction 
(250-310 KD) and sedimentation (330 KD) (Conti-Tronconi and 
Raf tery, 1982). This discrepancy may be due to the asymmetric
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shape of the AChR molecule (Introduction, page 20 ) which may 
retard the passage of the protein through the gel.
The technique of SD5-PAGE proved to be an accurate and 
reproducible method for identifying the four subunits of 
purified AChR and their molecular weights; this is highlighted 
by the close linear relationship between the average Rf values 
and average Mr values (Section A4.1; Figure14 ). However, in 
the case of Torpedo AChR, two extra bands were seen at 66K and 
43K. The 66K band was proteolysed completely on storage and 
this may represent acetylcholine esterase, whereas the 43KD 
contaminant was observed after the preparation was subjected to 
a gel filtration procedure (Results, Section A4.2). This may 
imply that this component was tightly associated with the 
receptor protein. Other workers have also noted the presence of 
43KD proteins which appear to be distinct from the abundant 
cytoskeletal protein actin. Three types of 43KD protein have 
been reported and at least one of these has phosphatase 
activity. The proteins are cytoplasmic membrane components and 
are co-distributed with the AChR. The proteins are apparently 
important in stabilising the receptor in the membrane as removal 
by alkali (pH ^  10.5) makes the AChR protein more sensitive to 
proteolysis and heat inactivation. Mabs have been documented 
which react with 43KD proteins and a 43KD protein can be 
chemically cross-linked to the p -subunit of the AChR (see 
AnhoIt et al., 1984 for a review of 43KD proteins).
SDS-PAGE analysis of purified fetal calf AChR revealed the
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presence of 5 major bands of Mr 39, 46, 48 , 52 and 57K. These 
values correspond to those reported by Einarson et al., (1982) 
(41, 50, 53 and 56K) and by Gotti et al., (1982) (42, 44, 49, 55 
and 5BK). In this latter study, the 44K protein was reported to 
be actin and it is likely that the 46K protein band observed in 
this present study was a contaminating non-receptor protein such 
as the proteins already discussed above or actin. This latter 
possibility could be examined further by using anti-actin 
antibodies as described by Gotti et al., (1982). Hence the 
protein bands observed can be assigned to the receptor subunits 
as follows s 39K (06), 48K ( ), 52K ( # ) and 57K (S  ) -
However, further analyses by using anti-subunit specific Mabs or 
sequencing techniques would help verify this. Additionally, the 
affinity labels BAC and MBTA (see Introduction, page 1 9 ) could 
be used to identify precisely the 06-subunit for both purified 
Torpedo and fetal calf AChR.
Biochemical, immunochemical and protein sequencing evidence 
overwhelmingly indicates that AChRs from mammalian and electric 
organ sources are fundamentally similar. However, there are 
differences in electrophoretic mobility of the respective 
subunits of the receptor protein from these sources as found in 
this study and by other workers (Tabled ). This can be 
explained by a number of factors; experimental error; 
proteolysis, inherent differences in primary structure or 
molecular weight differences due to differences in 
post-translational modifications such as glycosylation and 
phosphorylation. The extent of glycosylation of each respective
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subunit would lead to variation in molecular weight observed by 
SDS-PAGE. All four chains of Torpedo AChR are known to be 
glycosylated (Introduction 12 ) and there appear to be potential 
N-glycosylation sites present on the OC, p , tf, S  and £  
subunits of fetal calf AChR (Noda et al., 1985; Takai et al.,
1985). However, little as yet is known about the extent of 
glycosylation of each subunit.
From cDNA data, Torpedo and fetal calf AChRs it is evident that 
the receptors from these sources have different primary 
structures with respect to amino acid composition and in the 
number of amino-acids which comprise each submit. AChR mature 
submits OC , ^ , * .  S comprise 437, 469, 489 and 501 amino 
acids (Numa et al., 1983), whilst fetal calf AChR comprises 437, 
481, 497 and 561 , with the £  submit having 471 amino acids 
(Noda et al., 1983c; Tanabe et al., 1984; Tokai et al., 1984; 
Kubo et al., 1985; Takai et al., 1985). These studies thus 
emphasise structural heterogeneity between receptors from 
different sources.
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METHODS
1. Preparation of general immunological reagents
Several immunological reagents were used throughout this work
and their preparation will be described here.
1.1 Purification of mouse IqG
IgG was purified from normal mouse serum (NMS) by affinity 
chromatography on immobilised Protein A (Ey et al., 1978).
1.2 Preparation of rabbit and ooat anti-(mouse IqG) antisera 
Normal mouse IgG, (2mg/ml, 1.0ml), previously dialysed against
O
PBS (2L, 16h, 4 C), was emulsified with Freund's complete 
adjuvant (FCA; 1.0ml) and injected intramuscularly at one site 
in each hind leg of a rabbit or goat. The injections were 
repeated at 3 week intervals using IgG emulsified in Freund's 
incomplete adjuvant (FIA). Blood samples (10ml) were taken 
from the immunised animal 8 days after each injection to allow 
the determination of anti-(mouse IgG) antibodies. When an 
adequate titre was reached, the animal was bled out. The blood
o
was allowed to clot (overnight, 4 C), then centrifuged (500g, 20
o o
min, 4 C), and the serum collected and stored at 20 C in the
presence of 0.02/C (w/v) sodium azide. An adequate titre was one
in which no more than 10(^jlL of antiserum was needed to effect
125total precipitation of [ I]-DC-BGT labelled AChR-antibody 
complex. This complex was obtained by incubation of a fixed 
volume (l<X^ uL) of mouse anti-(Torpedo AChR) Mab supernatant, (as 
defined by ELISA, Section B2.2) supplemented with NMS (5pL),
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with a constant volume of [^^I]-06-BGT labelled Torpedo AChR in 
a RIA procedure (Section B 2.1).
2. Detection of Anti-(AChR) antibody activity
2.1 RIA procedure
A RIA procedure similar to that described previously by 
Lindstrom et al., (1981) was used to detect anti-(AChR)
125antibodies. The method involved immunoprecipitating [ I]- CO 
-BGT- AChR - antibody complexes with an anti-globulin antiserum 
(Section B 1.2).
AChR (0.5nM) was incubated (45 min, 23°C) with an excess of 
^25i]-o<>-BGT (S.OmM) in the presence and absence of BZQ 
(2.5mM). The toxin-AChR complex (lOO^L) was incubated
o
(overnight, 4 C) with antisera (IjuL), appropriately diluted in 
normal serum. The labelled AChR - antibody complex was
precipitated by the addition of second antibody (Section B 1.2)
o o
and incubated for 2h at 23 C or overnight at 4 C. The
precipitated complexes were separated by centrifugation (300g,
10 min, 4°C), the pellets washed (3 x 1ml) with RIA buffer (lOmM
potassium phosphate buffer, pH 7.4, 0.15M NaCl, 17. (v/v) Triton
X-100 and 0.017. (w/v) sodium azide) and then counted for
radioactivity. Assay blanks used nan-immune serum. Subtraction
of the counts obtained in the presence of BZQ, from counts
obtained in the absence of BZQ, gave specifically bound
radioactivity in the test sample. All tests were carried out in
triplicate.
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The antibody titre was expressed as moles of specific (Xy-BGT 
binding sites precipitated per litre of serum.
For the screening of antibody production \>y hybridomas, (Section 
B 4.6), hybridoma culture supernatant (lOOpL) replaced immune 
sera. NMS (^ )uiL) was used as a carrier protein and 
immunoprecipitates were formed by addition of goat/rabbit 
anti-(mouse IgG) antiserum (Methods B 1.2). Additional controls 
comprised 'spent' culture medium from X63 myelomas and an 
un-re la ted Mab.
2.2 ELISA procedure
Purified Torpedo or fetal calf AChR (5jug/ml in 0.05M sodium 
carbonate buffer, pH 9.6 or PBS) was coated onto microtitre 
plates (lOOfiL/well) by one of two methods :
a) indirectly by using microtitre plates which had previously
o ___
been incubated (2h, 23 C) with poly-L-lysine (50jJLg/ml in PBS) or 
OC-BGT (5^ ug/ml in 0.05M carbonate buffer, pH 9.6), followed by 
washing (3 x lOmin) with washing buffer (PBS containing 0.057. 
(v/v) Tween-20 and 0.017. (w/v) thiomersol). AChR in PBS alone 
was then added.
b) directly by using AChR in PBS or carbonate buffer. In some 
instances, detergent extract of fetal calf AChR was used.
 o o
After incubation with AChR (2h, 37 C or overnight, 4 C), the
plate was washed as described earlier. Unreacted active sites
O
of the wells were blacked by incubation (30 min, 37 C) with 
washing buffer containing 17 (w/v) casein (10^uL/wel1). After
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further washing, diluted antisera (lOOjlL) was added and
o
incubated overnight at 4 C. Following washing, as before, the
appropriate alkaline phosphatase conjugated second antibody was
added (IOO^ aL; l/500dilution in washing buffer containing 17.
o
(w/v) casein), incubated (2h, 23 C), washed again and freshly
prepared substrate solution was added (lOOyjiL p-nitrophenyl
phosphate, lmg/ml in 0.1M glycine/NaCH buffer, pH 10.4,
containing ImM MgC12.H20 and ImM ZnC12). After incubation
o
(usually 30 min, 23 C) the enzyme reaction was stopped by 
addition of 2M NaOH (2<^ aL) to each well. The absorbance at 
405nm was read photometrically using a Titretek Uhiscan.
Normal serum and unrelated immune serum were used as negative 
controls. Cross-reactivity between AChR and conjugate was 
assessed by incubating AChR coated wells with buffer containing 
17. (w/v) casein (ie: without 1st antibody) and the conjugate
alone. Positive controls were immune sera defined by RIA 
(Methods, Section B 2.1) with established anti-(AChR) antibody 
activity. These controls were run with each assay.
For the screening of antibody production of hybridomas, 
hydridoma culture supernatant (lO^uL) replaced immune sera. 
Additional controls comprised 'spent' culture medium from X63 
myelomas and an un-related Mab.
2.3 Passive haemagQlutination assay
Sheep red blood cells (SRBC) coated with Torpedo AChR were used 
in a haemagglutination test to determine antibody titre.
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2.3.1 Attachment of AChR to SRBC
Fresh SRBC were coated with AChR by the chromic chloride
procedure of Ling et al., (1977). The receptor was dialysed
against saline (0.14M NaCl; 2L, overnight) before use. SRBC
(lml) in Alsever's solution were washed 5 times by alternate
o
suspension and centrifugation (200g, 10 min, 23 C) in saline.
Aliquots of a 107. (v/v) suspension of SRBC (lml) were
o
centrifuged (300g, 10 min, 23 C) and a solution of purified 
Torpedo AChR (0.3mg, 300jiL in saline) was added to the pellet. 
The suspension was mixed on a vortex; 'aged' chromic chloride 
(600^ iL, 60^ ig) was added dropwise and the mixture was overlaid
o
with saline (lml) and left overnight at 4 C. The cells were 
washed repeatedly, as above, until haemolysis had stopped with 
Hanks balanced salt solution (HBSS) comprising 0.14M NaCl,
1,46mM CaCl2, 0.amMMg2 SOlf- , 5.36rrt1 KC1, 0.73rrf1 KH2P01+, 15mM 
NaHC03 and llmM glucose, pH 7.3. The SRBC pellet was finally 
resuspended to give a 2.57 (v/v) solution in HBSS containing
o
additionally 57. (v/v) fetal calf serum (FCS) and stored at 4 C. 
SRBC were also coated with BSA/ovalbumin in a similar manner.
2.3.2 Passive haemaaalutination procedure
Serial dilutions of antiserum or hybridoma culture supernatant 
were prepared in 50j.lL volumes of HBSS containing 57. (v/v) FCS in 
round-bottomed microtitre trays. AChR-coated SRBC (2Syd_ of 2.57. 
(v/v) was added and the end-point read by the settled pattern
o
observed after 2-4h incubation at 23 C.
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1252.3.3 [ IH-OC-BGT binding assay on AChR coated SRBC
I]-0C“BGT (l.Opmol) was added to receptor coated SRBC (KjpiL
of 2.57. (v/v) suspension). Non-specific binding was determined
in parallel tubes by the addition of 2*5mM BZQ (20^L). HBSS
containing 57. (v/v) FCS was added to give the final assay volume
o
(200jjL) and the mixture was incubated (90 min, 23 C). The cells 
were then washed (3 x 0.5ml) by using the same buffer and 
alternate resuspension and centrifugation (3 min, low speed, 
microfuge). The pellets were counted for radioactivity. Assay 
totals were [^5 I]-D6_BGT (1.0 pmol) alone. SRBCs coated with 
BSA/ovalbumin were treated similarly.
3. Production of Polyclonal anti-AChR antibodies
3.1 Anti-(fetal calf AChR) antisera
Two rabbits were immunised intramuscularly with purified fetal 
calf AChR (Methods, Section A3) which had been previously 
concentrated using an Amicon concentrator, dialysed against PBS 
(3 x 2L) and emulsifiedlfan equal volume of FCA. Purified AChR 
(40^ ig/ml) was used for the first injection and subsequent 
injections were made at 10 day intervals by using purified 
protein (2^ /mg/ml) in FIA. Animals were bled from the ear vein 2 
days before the next injection, and the anti-AChR activity of 
the serum assessed by RIA (Section B 2.1). The rabbits were 
sacrificed when signs of physical distress were observed. The
o
blood was allowed to clot (overnight, 4C), centrifuged (500g,
o o
20 min, 4 C), and the serum collected and stored at -20 C in the 
presence of 0.027 (w/v) sodium azide.
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3.2 Anti-Torpedo AChR antisera
Rabbit anti-(Torpedo AChR) antisera was readily available in the 
laboratory.
4. Preparation of Monoclonal Antibodies
Several general procedures are common to all aspects of tissue 
culture work and these will be briefly described here.
4.1 General cell culture procedures
Aseptic procedure was used throughout in a sterile-air laminar 
flow hood (Microflow, Dent and Hellyer, Andover, Hampshire, UK). 
Plasticware (Nunc), all media and their supplements were 
obtained sterile. All other reagents were either autoclaved 
(120 C, 201b/in , 30 min), or filter sterilised under positive 
pressure through sterile filter units (pore size O.^ jti diameter) 
before use.
All cell lines were maintained in complete culture medium 
consisting of RPM1 1640 culture medium supplemented with 107. 
(v/v) heat-inactivated (56°C, 30 min) FCS, glutamine (2mM), 
penicillin (100 IU/ml) and streptomycin (100^LLg/ml). The cells
O
were maintained at 37 C in an atmosphere of 957. relative 
humidity and 57. COa,.
Cell viability was assessed by using Trypan blue dye exclusion 
(27. (w/v) Trypan blue in PBS) as described by Hudson and Hay
(1983). Cells were counted using a haemocytometer counting 
chamber (Improved Neubauer ruling).
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4.2 Immunisation of mice for Mab production
Purified Torpedo and fetal calf AChR (Methods, Section A 3) were 
used as immunogens for the production of anti-(AChR) Mabs.
Female Balb/c mice (6 weeks old) were immunised 
intraperitoneally with AChR which had previously been dialysed 
against PBS (3 x 2L) and emulsified in FCA. Subsequent 
injections were made using AChR in FIA. The volume of AChR 
injected ranged from 0.5-lml representing 8-35 pmols toxin 
binding sites (fetal calf) and usually 0.3ml Torpedo AChR 
representing 100-400 pmols toxin binding sites. Usually 2-3 
booster injections were made 2-3 weeks apart, with a final 
immunisation of AChR, in PBS only, given 3-5 days prior to 
fusion. The serum antibody titres were monitored by RIA 
(Section B 2.1) to ensure that the mice were responding to the 
antigen.
4.3 Maintenance of X63 cell line
The hypoxanthine, aminopterin, thymidine (HAT) sensitive 
plasmacytoma cell lines X63.Ag8.6.5.3 (X63; Kearney et al., 
1979) was used as the fusion partner for Mab production.
The X63 cell line was passaged through complete culture medium
_ 5
containing 8-azaguanine (2 x 10 M) to eliminate any 
revertants which were not HAT sensitive. Prior to a fusion, 
cells were maintained in logarithmic growth phase and had 
viability of greater than 907..
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4.4 Preparation of macrophage feeder layers
Macrophages were harvested from the peritoneal cavity of Balb/c 
mice (6 weeks old) using a method described by Hudson and Hay
(1983). Cells were plated out at 10^ macrophage feeder 
cells/l(X^ utiL/wel1, and were prepared either the day before or the 
same day as the fusion was carried out.
4.5 Fusion procedure
Immune spleen cells from Balb/c mice were fused with X63 cells 
using polyethylene glycol (PEG 1500) as described by Hudson and 
Hay (1983).
An immunised mouse was killed and the spleen removed aseptically 
and placed in a petri dish containing PBS (10ml). A suspension 
of spleen cells, free of cell clumps, was prepared and a viable 
cell count was performed (Section B 4.1).
The spleen cells and myeloma cells were mixed in a ratio of 10
to 1 respectively, in a 50ml centrifuge tube, centrifuged (500g, 
o
10 min, 23 C), washed once in serum-free medium (25ml) ,
recentrifuged and the supernatant discarded. The cell pellet
o
was dislodged and mixed by gentle tapping and warmed to 37 C in 
a water bath; subsequent steps were also carried out at this 
temperature. PEG solution (lml), comprising 507. (w/v) PEG in 
PBS, pH 7.2, containing additionality 107. (v/v) DMS0, was added 
slowly with constant shaking of the cell mixture. The cells 
were shaken for a further 90 sec, diluted slowly by the gradual 
addition of PBS (lml) over a 1 min period and a further aliquot
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(20ml) over the next 5 min. The cells were centrifuged (200g,
o
10 min, 23 C) and the pellet was resuspended in complete culture 
medium (50ml). The cell suspension was seeded over 5 x 96 well 
tissue culture plates (lOOpL/well) containing macrophage feeder 
layers (Section B 4.4). The following day, culture medium 
containing HAT was added (100jl_/wel 1) to give the requisite HAT 
concentration required for the selection of hybrids
-4- -?
(hypoxanthine, 10 M; aminopterin, 4 x 10 M; thymidine, 1.6 x 
10"SM).
After 8 days, culture supernatant was removed (100^U_/well) and 
replaced by the same volume of fresh culture medium containing 
hypoxanthine and thymidine only (HT medium) and this procedure 
was repeated every 3-4 days.
Screening for antibody production by ELISA (Section B 2.2) was 
carried out when the wells were half confluent. When positive 
clones were identified, they were expanded by transfer to 4 well 
culture dishes and cloned (Section B4.6). During this period of 
expansion, culture supernatant was pooled for use in the RIA 
(Section B 2.1) to confirm the anti-AChR specificity.
Frozen stocks were made of each uncloned positive cell line as 
an insurance against failure during cloning.
4.6 Cloning of hybridomas
Cloning of antibody producing hybridomas was achieved by 
limiting dilution. The hybridomas were plated out over 
macrophage feeder layers (Section B 4.4) at 5 cells/well, 1
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cell/well and 1 cel1/2 wells, using one culture plate for each 
dilution. After 1-2 weeks, colonies were visible and 
supernatants from those wells thought to contain one colony (by 
inspection of the well under the microscope) were screened for 
antibody activity. Positive wells were expanded as above and 
frozen stocks kept after each cloning. The cloning procedure 
was repeated three times to ensure homogeneity. Stocks of Mab
O O
supernatant were stored sterile at -20 C or at 4 C in the 
presence of 0.017. (w/v) thiomersol.
4.7 Crvopreservation of Cells
Healthy, actively dividing cells were centrifuged (200g, 10 min, 
o
23 C), the supernatant removed and the cells resuspended at 10 x
t» ©
10 cells/ml in complete culture medium and left at 4 C for 30
min. An equal volume of freezing mixture (507. (v/v) FCS
o
containing 107. (v/v) DMSQ in culture medium, 4 C) was added 
slowly, with shaking and samples (lml) were transferred to 2m 1 
freezing vials. The vials were placed in the liquid/vapour 
phase of nitrogen for 24h before being transferred for storage 
in liquid nitrogen.
4.8 Recovery of Frozen Cell Cultures
Vials were removed from liquid nitrogen storage and the contents
o
were thawed quickly in a 37 C water bath. The vial's contents
were transferred to a centrifuge tube containing complete
o o
culture medium (10ml) at 23 C, centrifuged (200g, 10 min, 23 C).
The supernatant was removed and the cells were resuspended in
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5
fresh medium at a density 10 cells/ml. The cells were then 
left to recover in 4-well culture dishes.
4.9 Large scale culture of hybridomas
After three cloning procedures, large scale culture of positive
2
hybridomas was carried out in 175cm /000ml tissue culture 
flasks. The cells were kept in logarithmic phase growth by 
dilution in complete culture medium and when a sufficient cell 
number was achieved for the production of ascites fluid, the 
cells were allowed to reach the stationary phase of growth by 
leaving them for 24-48 hours before harvesting the cells by
o
centrifugation (20g, 10 min, 23 C). The cells were resuspended 
and washed once in sterile PBS by centrifugation (200g, 10 min,
o 3
23 C) and finally resuspended in PBS at 1.5 x 10 cells/ml.
4.10 Production of Ascites Fluid
Prior to the innoculation with hybridoma cells, Balb/c mice were 
injected intraperitaneally with pristane (0.5ml, 2, 6, 10, 14 - 
tetramethylpentadecane). The mice were then rested for 2-0 
weeks. Hybridomas (1.5 x 10^ cells/mouse), as prepared above, 
were injected intraperitaneally. When ascites fluid had 
accumulated, as evidenced by abdominal swelling, the mice were 
sacrified, the abdominal cavity exposed and the ascites fluid
collected using a pasteur pipette. The fluid was then
o o
centrifuged (500g, 15 min, 4 C) and stored at -20 C in the
presence of 0.017. (w/v) thiomersol.
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1. Purification of mouse IqG and the production of goat and 
rabbit anti-(mouse IoG) antiserum
The recovery of IgG subclasses IgGl, 2a and 2b by affinity
chromatography on immobilised Protein A (Methods, Section Bl.l)
was 487. assuming the serum concentration of the IgG subclasses
to be about 8mg/ml in a Balb/c mouse (Hudson and Hay, 1983).
The second antibody for precipitating immune complexes in the 
RIA was prepared by immunising rabbits or a goat with IgG 
prepared from NMS (Methods, Section B1.2). The resulting 
anti-serum was monitored for the production of antibodies by the 
RIA procedure (Methods, Section B2.1). Adequate titres were 
obtained after 4 or 5 injections of purified mouse IgG. Figure 1 
shows a typical saturation curve for the precipitation of 
receptor— antibody complex by increasing volumes of anti-(mouse 
IgG) antiserum. A summary of the results obtained from each 
series of immunisations is shown in Table1? .
2. Fl TFtA for the detection of anti-(AChR) antibodies
An ELISA system (Methods, Section B2.2) was used to detect 
anti-(AChR) antibody activity in culture supernatants, as this 
provided the quickest and most convenient method of screening 
large numbers of hybridoma culture supernatants by direct 
transfer from culture plates to ELISA wells.
Although this method of detecting antibody has been documented 
(Norcross et al., 1980; Drfyer et al., 1983; Hinman et al.,
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Figure iff Saturation curve for the precipitation of 
receptor-antibody complex by increasing 
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Table 1?- Summary of results obtained from the preparation of 
goat and rabbit anti-(mouse IgG) antiserum.________
Rabbit Number of Volume of antiserum 
Injections required for
precipitation of 
AChR-Ab complex ( j j L )















1983; Kawanami et al., 1984; Jailkhani et al., 1986), this 
method had not been used previously in the laboratory for 
screening culture supernatants, hence a number of parameters of 
the assay were studied by using anti-(AChR) immune sera 
(Methods, Section B3).
2.1 Choice of antiaen-coating buffer for the direct attachment 
of AChR to the ELISA well
Coating the ELISA well with antigen is the initial step in this
assay system. Two coating buffer systems were compared, ie:
carbonate buffer, pH 9.6 and PBS, pH 7.2. The buffer systems
\25were assessed by incubation with an excess of [ I]-o£-BGT and
unlabelled OC -BGT (see Tablel8 below ) to detect AChR bound
£
to the wells. Approximately 8 x 10 cpm/well was added to each 
wel 1.
Table Comparison of coating buffers for the direct attachment 
of AChR to ELISA wells
Coating Antigen Coating Buffer cpm [ l2^ I]-oc-BGT
_________________________________________________bound/wel 1______
Torpedo AChR Carbonate pH 9.6 25744 528 (8)
(5ymg/ml )
PBS pH 7.2 14070 139 (8)
Fetal calf AChR Carbonate pH 9.6 1240 35 (5)
(5ymg/ml ) PBS pH 7.2 654 65 (5)
Results are expressed as mean 'll S.E. (n) where n is the number 
of determinations.
126
The carbonate buffer was more effective for coating ELISA plates 
with Torpedo and fetal calf AChR. This buffer was subsequently 
used in all ELISA experiments when antigen was used to directly 
coat ELISA plates. However, approximately 20 fold less 06-BGT 
binding sites were detectable when plates were coated with fetal 
calf AChR than Torpedo AChR, using both buffers. This may be 
due to the difference in specific activity of the two receptor 
preparations: Torpedo AChR (4 pmols (XL-toxin binding sites/jjLg
protein) and fetal calf (0.6 pmols od--toxin binding sites/j^g 
protein). Thus, for a given amount of fetal calf receptor 
protein coated a smaller fraction represented AChR protein.
2.2 Indirect coating of AChR bv using polv-L-lvsine 
Antigens may be indirectly coated onto ELISA wells by 
poly-L-lysine spacer arms and this method was exploited for 
coating Torpedo and fetal calf AChR onto ELISA plates. The
19C
binding of V*~ I3-0OBGT, as described above, was used to assess 
the efficiency of this method. The results are shown below
(Table 19 )-
Table 19 The use of polv-L-lvsine in the AChR ELISA method
Coating Antigen cpm I]-0C-BET
Coating Antigen________Buffer_____________ bound/wel 1_______
Torpedo AChR PBS, pH 7.2 40208 + 1238 (5)
(5jjig/ml )
Fetal calf AChR PBS, pH 7.2 3896 + 498 (5)
(5yiQ/ml )
Poly-L-lysine — 203 + 54 (5)
The results are expressed as mean ± S.E. (n) where n is the 
number of determinations.
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Precoating ELISA wel Is with poly-L-lysine improves the 
efficiency of AChR binding to wells compared with the direct 
coating method (Results B2.1). Hence, poly-L-lysine pre-coating 
was used for all future assays using fetal calf AChR but was not 
used for anti-Torpedo AChR assays, as further studies showed 
that direct coating of AChR in this case provided a sensitive 
assay (see below). Also, this avoided the possibility of 
detecting antibodies which may cross-react with the coating 
agent.
Rabbit anti-(Torpedo AChR) antiserum (antiserum T; Methods, 
SectionBB) was used to construct a titration curve to assess 
the sensitivity of the Torpedo AChR directly-coated assay for 
the detection of anti-(AChR) antibodies (Figure 19 ) • The 
antiserum T and NRS were diluted over the range 1/50 to 
1/40,000. The NRS gave negligible background readings whilst 
the response was linear for the anti-AChR antibody over the 
range 1/4000 to 1/0000. Cross-reactivity of the enzyme 
conjugate with wells alone or wel IS coated with AChR gave 
negligible 00 readings.
The anti-AChR titre of the antiserum, as determined by RIA 
(Methods, Section B2.1) was 2yHM. Taking the limit of detection 
for antibody in the ELISA as a 1/20,000 dilution, the assay can 
detect antibody levels of 10~,oM and is thus a sensitive assay 
system.
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2.3 Optimum coating concentration of Torpedo AChR for ELISA 
Purified Torpedo AChR was diluted (O.lng - 30yug/ml) in 
carbonate buffer, pH 9.6 and used to coat ELISA wells. The 
optimum coating concentration of AChR was determined by the 
maximum absorbance obtained using an excess of antiserum T (i/30 
dilution in PBS). NRS and rabbit anti-(BSA) at the same 
dilution were used to assess the non-specific binding of rabbit 
sera to Torpedo AChR.
Maximum absorbance readings under fixed concentrations of 
conjugate, substrate and first antibody were achieved at an 
antigen concentration of greater than 4jxg/ml (see 
Figure20). Thus, a coating concentration of 5^JLg/ml was 
chosen for all subsequent assays; this was feasible because 
purified Torpedo AChR preparations have consistently high 
specific activities (Results, Section A.3). This coating 
concentration was also economical in terms of the amount of 
receptor used.
2.4 Titration of rabbit anti-(fetal calf AChR) antisera
Two rabbit anti(fetal calf AChR) antisera, FI and F2 (Results, 
Section B3) were used to assess the ELISA system using purified 
fetal calf AChR as antigen on poly-L-lysine coated microtitre 
wells. Serial dilutions of the two antisera and MRS (1/10 - 
1/5120) were used to construct the titration curves (Figure21 ).
It was apparent that the amount of antigen coated onto the 










Figure 19 Titration of Rabbit anti-(Torpedo AChR) antiserum 
by ELISA
- 2,6
Login Reciprocal Dilution of Serum
Antiserum T (—O  ~) NRS (-#-) were serially diluted over the
range 1/50 to 1/40,000 to construct the titration curve.
Each point for figure19 and 20 is the mean of triplicate 
determination^
Figure 20 Determination of the optimum coating concentration 
of Torpedo AChR
Log [TORPEDO AChR) Jig m!
AChR (O.lng - 30/xgml ' ) was used to coat ELISA wells (Methods, 
Section B22). The optimum coating concentration of Torpedo AChR 
was determined by using antiserum T (1/30 dilution (~0“)*
NRS (-#-) and Rabbit anti-BSA (-□-) were used to assess non­
specific binding.
Figure 21 Figure 22
Titration of rabbit anti-(fetal calf AChR) 
antisera on fetal calf-AChR coated indirectly 
by poly-L-lysine.
Titration of rabbit anti-(fetal calf AChR) 
antisera by using detergent extract of fetal 







Antisera FI ( -#-), F2 (-Q-) and NRS (-Q-) were serially diluted over the range 1/10 to 1/5120 
(Figure 21 ) and 1/100 to 1/12600 (Figure 22 )• Each point is the mean of determinations made
in triplicate.
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higher concentrations of antibody and the optical densities 
obtained at these concentrations were low. It was not feasible 
to increase the amount of purified fetal calf AChR coated onto 
the wells due to the limited amount of protein available .
Hence, an alternative assay system using plates pre-coated with 
OC-BGT, followed by incubation with fetal calf detergent extract 
was examined. An 06 -BBT coating concentration of 5 ^jug/ml was 
chosen for this assay system, since this had proved effective in 
the assay procedures described by Hinman et al., (1983) and 
Jailkhani et al., (1986).
The titration curves of antisera FI and F2 obtained using this 
method are shown in Figure 22. This assay system was 
approximately ten times more sensitive than using poly-L-lysine 
and purified fetal calf (Figure 21), with a good range of 
optical density over the antiserum dilution and neglible 
backgrounds using NRS.
This system was used for the screening of anti-(fetal calf AChR) 
secreting hybridomas.
3. Preparation of anti-(fetal calf AChR) antisera 
Purified fetal calf AChR was effective as immunogen in the two 
rabbits examined (Methods, Section B1.2). The development of 
anti-(fetal calf AChR) titnes, as determined by RIA (Methods, 
Section B2.1) using C^^I]-06-BGT labelled fetal calf AChR is 
shown in Table 20 (below) after injection of purified AChR at 
day 0, 10, 20 and 30. Pre-immune sera from both the rabbits had 
no detectable anti-(fetal calf AChR) titre.
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Table Development of anti-(fetal calf AChR) antibody titres 
in rabbits
10” x Anti-(AChR) antibody titre (M) 
Days after first Rabbit 1 Rabbit 2




37 not determined 700
38 320 Rabbit killed
Rabbit killed
After 3 injections of AChR, both rabbits developed signs of 
physical distress, ie: floppy ears and muscular paralysis of
the hind limbs, and the rabbits were sacrificed. Maximum titres 
occurred just before the onset of physical distress and the 
titre fell just before the rabbits were killed.
4. Preparation of Monoclonal Antibodies
4.1 Purity of AChR used as antigen and immunisation of mice 
Purified Torpedo amd fetal calf AChR (Methods, Section A3) with 
specific activities of approximately 3.5 and 0.6 pmols of oc -BGT 
binding sites/^xg of protein respectively were used as 
immunogens in Balb/c mice (Methods, Section B4.2). The purity 
of the preparations were analysed by SDS-PAGE (Results, Section 
A4.1).
The antibody response in the immunised animals was monitored by 
a RIA procedure (Methods, Section B2.1) at various time 
intervals. The results are shown in Table 21 . To varying
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Table 21 Antibody Titre of mouse serum after immunisation with 
purified AChR
Injection AChR (pmols) Day of Titre
Day_______ Injected_______ Test Bleed x 10~10 M
Mouse 1 0 100 0 0.9
30 100 NOT DETERMINED
65 300 68 2630
Mouse used for Fusion Tl. day 68
Mouse 2 0 100 0 1.2
21 150 25 600
78 400 81 5370
Mouse used for Fusion T2. day 81
Mouse 3 0 12 0 1.2
18 16 20 25
33 20 38 85
39 30 42 127
Mouse used for Fusion FI . dav 42
Mouse 4 0 8 0 0.9
15 18 19 12
38 20 42 59
45 25 48 87
Mouse used for Fusion F2. day 48
Mouse 5 0 15 NOT DETERMINED
15 15 19 286
34 30 38 478
Mouse used for Fusion F3. day 38
Mice 1 and 2 were immunised with Torpedo AChR, mice 3, 4 and 5 
were immunised with fetal calf AChR.
All titres were determined by RIA (Methods, Section 2.1).
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degrees, all the mice produced antibody titres against AChR but 
throughout the immunisation period none showed signs of physical 
weakness such as muscle weakness, characteristic of EAMG.
Higher titres were obtained when mice were immunised with 
Torpedo AChR than fetal calf AChR. This may be due to the 
higher specific activity of the Torpedo AChR preparations and 
hence the larger immunising doses.
4.2 Summary of fusions and the development of the clones 
obtained
Hybrid clones were produced from all fusions carried out 
(Table 22 ) with an average of 367. (n = 5) of the wells seeded 
showing growth. However, of these fewer wells contained clones 
producing antibodies towards AChR.
The fusions using fetal calf AChR as immunogen were less 
successful than those employing Torpedo AChR. Two positive 
clones were obtained but these proved to be unstable with 
respect to antibody production and lost activity on expansion 
and cloning (Table 22 ). Two clones resulting from the Torpedo 
AChR fusion showed similar characteristics, however five stable 
hybrids (clones Bll, Cll, EB, C7 and Ell) were obtained and were 
cloned 3 times without loss of antibody production (Table 22 ). 
These hybrids were grown as ascites in Balb/c mice and 
subsequently characterised. Several of the mice showed signs of 
physical distress but it was difficult to determine whether any 
weakness observed was due to EAMG or to the trauma of ascites 
production. These Mab will be referred to as Mabs Bll, Cll, E8, 
C7 and Ell.
Table 22 Summary o f the fusions carried o u t and the fate and developmenf 
o f  the clones obtained.
Fusion No of Wells No of Wells No of Wells 


















Bll x 3 YES
Cll x 3 YES
E8 x 3 YES
Ell Lost activity 
cn cloning
B6 Lost activity 
cn cloning
-
C7 x 3 YES
Ell x 3 YES
- - -
H5 Lost activity 
cn expansion 
and dming






Fusions T1 and T2 employed Torpedo AChR as the immunogen.
" FI, F2 and F3 employed fetal calf AChR as the immunogen.
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DISCUSSION
EAMG has been produced in a number of animals by injecting AChR 
purified from a number of species (see Lindstrom, 1979 for 
review). The disease was first described in rabbits by Patrick 
and Lindstrom, (1973) using purified eel receptor and indeed the 
majority of studies have used electric fish AChR to induce EAMG. 
There are, however, few reports of the induction of EAMG by 
using mammalian AChR (see Harrison and Behan, 1986) and only one 
other report, other than this present work has reported EAMG 
induced in rabbits using fetal calf AChR (Lindstrom, 1979). In 
this present work maximum anti-(fetal calf AChR) titres occurred 
just before the onset of EAMG, after which the titre fell 
sharply (Results, Section B3) and this correlates well with the 
findings of other workers using similar amounts of electric fish 
AChR as immunogen (Lindstrom, 1979).
EAMG in this present study was assessed by observation only, and 
this could have been further verified by studying 
electromyographic responses to repeated nerve stimulation. 
Alternatively the effects of an anti-acetylcholinesterase drug, 
such as neostigmine could have been used to see if the drug 
could eleviate the symptoms of the disease. Unlike the rat 
model of EAMG there appears to be no distinction in rabbits 
between the early acute and later chronic phases of the disease 
and indeed anti-immunogen antibody titres have been reported to 
show a general correlation with disease severity in rabbits (see 
Harrison and Behan, 1986). In general, the AChR content of
13?
muscles from the immunised animal is reduced due to the 
pathological activity of the antibodies (see Introduction, 
page 38) and this activity is dependent upon the level of
anti-(rabbit AChR) antibodies and the extent of cross-reactivity
of host receptor with rabbit anti-(fetal calf) AChR antibodies. 
Hence it would have been interesting to monitor these factors 
during the course of the immunisation program. Similarly the 
levels of anti-D6—BGT binding site antibodies which could 
interfere directly with neuromuscular transmission would have 
provided a useful adjunct to these studies as anti-'site' 
antibodies have been reported in rabbit anti-Torpedo AChR 
antisera by other workers (see Harrison and Behan, 1986). 
Although these studies were not carried out, partial
characterisation of the two anti-(fetal calf antisera) FI and F2
is given in Results, section C2 and discussed in Section C.
Screening culture supernatants for antibody requires a reliable 
and rapid assay procedure and in this present work an ELISA 
system was developed for this purpose. The assay proved to be a 
valuable asset for screening hybridomas and re-clones, as a 
large number of assays could be performed quickly and accurately 
in a short period of time. The ELISA system has several 
advantages over the RIA procedure under these circumstances, as 
the RIA procedure relies on a constant supply of iodinated- OC 
-BBT, with good biological activity whereas the commercial ELISA 
reagents are of a relatively uniform standard and stability. 
Additionally there is no need in the ELISA method for large 
quantities of second immunoprecipitating antibody or Protein A
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reagents and the washing procedures are much simpler to perform 
than in the RIA.
The binding of antigens to plastic or polystyrene wells relies 
fundamentally on electrostatic interactions, hence the choice of 
coating buffer may have an effect on the efficiency of this 
interaction. In this present work carbonate buffer proved to be 
more effective than PBS in coating plates with purified receptor 
(Results, Section B2.1). This finding is in agreement with 
reports by other workers (Norcross et al., 1900; Dwyer et al., 
1983; Kawanami et al., 1984).
Under optimum conditions of coating Toroedo AChR antigen the 
ELISA procedure was able to detect levels of antibody comparable 
to the RIA and was similar in sensitivity to that quoted by 
other workers (Norcross et al., 1980; Hinman et al., 1983). 
Specificity for anti-AChR antibodies in the ELISA was 
demonstrated in that rabbit sera known to have a high titre 
against BSA did not react with AChR bound to the wells. Also, 
non-specific binding of NRS immunoglobulin or enzyme conjugate 
to the AChR or to the well itself was negligible (Results, 
Section B2.3).
Less success was obtained in this present study by using direct 
coating of fetal calf AChR than with Torpedo AChR (Results, 
Section B2.1) and this has been previously reported by Dwyer et 
al., (1983). One of the difficulties is having enough purified 
protein of high specific activity to coat the plates. Two 
additional approaches were used to increase the sensitivity of
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the ELISA using fetal AChR. The first employed poly-L-lysine 
and purified receptor and indeed an increase in the binding of 
AChR was observed over the direct coating method (Results, 
Section B2.2), in agreement with the findings of Kobayashi et 
al., (1984). The polymer is a basic amino acid and presumably 
increases the electrostatic attraction between the negatively 
charged antigen to the solid phase. This indirect coating 
method however has been associated with increases in 
non-specific antibody binding (Ko bayashi et al., 1984) although 
this was not noted in this present study. One other potential 
drawback to the use of poly-L-lysine is the possibility that 
certain antigenic determinants of the AChR may couple 
preferentially to poly-L-lysine and will not, hence, be detected 
by this assay system.
The second method involved the indirect attachment of receptor 
protein from detergent extracts of fetal calf muscle by D6-BGT. 
This resulted in an increase in sensitivity of the assay system 
for detecting anti-AChR antibodies (Results, Section B2.4) and 
similar approaches have been successfuly employed by other 
workers (Norcross et al., 1980; Hinman et al., 1983, Jailkhani 
et al., 1986; see Table23 for a summary of ELISA systems 
described to date). This method has the advantage that it does 
not depend upon the purification of AChR, however it should be 
noted that antibodies directed at or near to the 06-BGT binding 
site of AChR will not be detected using this method. Direct 
coating of detergent extracts of mammalian muscle has also been 
reported (Kobayashi et al., 1984; Jailkhani et al., 1986) this,
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has however the disadvantage of the possibility of binding 
nan-AChR proteins present in the extract to the plate, whereas 
the use of 06-BGT specifically isolates the AChR from the 
extract and washing procedures ensure that the other proteins 
are removed. Another method, described in the literature is 
indirect coating by a flab intermediate, (Dwyer et al., 1983) 
this system obviously depends upon the availability of a 
suitable Mab. The ELISA thus developed in this present study 
provided the basis for the detection of anti-AChR directed Nabs.
Table 23
ELISA systems described to date for the 
detection of anti-AChR antibodies
Details Reference
Direct coating of purified 
receptor
Norcross et al., 1980 
Kawanami et al., 1984 
This Thesis
Direct coating of receptor extract Kobayashi et al., 1984
Jailkhani et al., 1986
In-direct coatino of purified 
receptor bv : —
06-BGT Norcross et al., 1980 
Hinman et al., 1983
poly-L-lysine This Thesis
Indirect coating of receptor 
extract bv : -
Nab Dwyer et al., 1983
poly-L-lysine Kobayashi et al., 1984
06-BGT Jailkhani et al., 1986 
This Thesis
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All immunogens were emulsified in FCA or FIA before being 
injected into animals. The production of the oil emulsion 
ensured that the antigen was released slowly into the animals 
circulation and the additional presence of bacteria in FCA 
helped to stimulate the animals immune response to antigen after 
the first injection. The immunisation of mice with Torpedo and 
fetal calf AChR resulted in the detection of anti-(AChR) 
antibodies in their sera. However, despite this antibody 
response, which in the case of mice immunised with Torpedo AChR 
resulted in very high anti-(AChR) titres (Results, Section B, 
Table19 ) none of the mice appeared to suffer from symptoms of 
EAMG. Strains of both mice and rats vary in their 
susceptibility to this experimental disease and although the 
Balb/c strain has been shown to be genetically susceptible to 
EAMG, mice within a susceptible breed can show resistance (Fuchs 
et al., 1976) and this was also demonstrated in this present 
work.
The plasmacytoma fusion partner has been shown to rescue 
preferentially large recently activated B lymphocytes rather 
than terminally differentiated plasma cells (Samoilovich et al., 
1987). Hence, for Mab production a final injection of AChR was 
given 2-4 days before the fusion procedure on the rationale that 
this should localise recently activated B lymphocytes in the 
spleen.
The fusion of mouse spleen cells and the myeloma cell line was 
carried out by using PEG. Although PEG is very toxic to cells
1 4 2
this agent appears to promote the close apposition of cell 
membranes by reducing membrane charges, while the presence of 
DMSO helps to modify the cell membrane and enhance fusion. By 
using a short exposure time (1 min) of the cells to the fusion 
mixture toxicity to the cells was minimised and this was 
reflected in the good growth of hybridoma colonies after the 
fusion procedure (Results, Section B, Table22).
The number of anti-(AChR) secreting clones detected represented 
only a small fraction of the total number of clones screened.
Of these 4 clones were unstable and lost specific antibody 
production during cloning. This loss of antibody producing 
clones may be due to overgrowth by non-antibody producing cells 
in the original fusion well or random chromosome loss, as cell 
division proceeds, which may lead to loss of chromosomes coding 
for antibody production. The loss of specific antibody 
production by anti-(AChR) secreting colonies has also been 
reported by Mehraban et al., (1984). Cloning by limiting 
dilution resulted in five stable anti-(AChR) secreting cell 
lines (Results, Section B, Table 22) and the properties of these 
Mabs is reported and discussed in the following section.
SECTION C
CHflRftCTERISATIQN CF POLYCLONQI SND rtJCCLONPL
PNTI BODIES TO AChR
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METHODS
The production of polyclonal and monoclonal antibodies to nAChR 
from fetal calf muscle and Torpedo electric organ has been 
described in Section B. Following this a preliminary 
characterisation of the antibodies was carried out. This 
Section summarises the methods used.
1. Titres and cross-reactivity of polyclonal antisera
The titres and cross-reactivities of the polyclonal antisera T , 
FI, F2 (Methods, Section B3) were determined using syngeneic 
and xenogeneic AChR prepared from Torpedo electric organ, fetal 
calf and human muscle using the procedure given in Methods, 
Section B.2.1.
In a comparative study the titres were also determined using the 
passive haemagglutination technique (Methods, Section B.2.3).
2. Antigenic characterisation of Torpedo anti-(AChR) Mabs 
Several methods were used for a preliminary characterisation of 
the Torpedo anti-(AChR) Mabs: Bll, C7, Cll, EB, and Ell. The 
titre of both the ascites fluid and culture supernatant forms of 
the Mab were determined, whilst the majority of the cross­
reactivity studies were carried oiit using ascites fluid.
2.1 Titre and cross-reactivity studies of Mab ascites fluid and 
Mab culture supernatants
The titre and cross reactivity of anti-(AChR) Mab ascites fluid
ouct
was carriedAusing a RIA procedure and passive haemagglutination 
assays as given above.
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The titre of the Mabs supernatant was also studied by ELISA 
in addition to RIA and haemagglutination studies (Methods, 
Section B2). An adaptation of the ELISA technique was also used 
to examine the cross-reactivity of the Mab supernatant with 
nAChR expressed by cultured rat myotubes.
2.1.1 Determination of cross-reactivity of Mab supernatant with 
AChR expressed by rat myotubes by ELISA
Cell cultures of rat myotubes were prepared and after 7 days,
the expression of nAChR was assessed by BGT binding,
the cultures were then fixed and the interaction of the
anti-(AChR)- Mabs with the expressed receptor was determined by
ELISA. The following sections give the methods used.
(a) Culture of rat myotube monolayers 
Before cell culture, tissue culture plates coated with 
photo-polymerised collagen gel (see Childs et al., 1905) were 
prepared.
Collagen solution (see Materials lmg/ml in distilled water)
was mixed with riboflavin (Flavin mononucleotide, 0.057. (w/v))
at a ratio of 4:1 (v/v). Samples of this mixture (30jjJ) were
spread in the dark over the surface of each tissue culture well.
The gel was photo-polymerised by exposure to fluorescent light
o
in the laminar flow cabinet for lh and dried overnight at 37 C. 
The plates were then washed for 2-3min with distilled water and 
incubated with growth medium (Dulbecco's Modified Eagles Medium 
supplemented with 107. (v/v) Donor Horse serum, 0.157 (w/v) 
glucose, lOOIU/ml penicillin and 100jxg/ml streptomycin) for at 
least 30min before the addition of cells.
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Myo tube cultures were prepared from the thigh muscles of 1-2 
day-old neonate white GFHB rats, according to the method 
described by Childs et al., (1985).
Rats were decapitated and the bodies placed in 707. (v/v) ethanol
z+for lOmin. Hind limbs were then removed and washed in Ca - and 
Mgz+- free Balanced Salt Solution (BSS).
Dissection of limbs was then carried out under a Swift binocular 
viewer at X10 magnification. After removal of the skin, tissue 
surrounding the bone was stripped and placed in a 35mm plastic 
dish containing BSS (1ml). The tissue was then minced with fine 
iridectomy scissors to produce a slurry and transferred with 
washing to a sterile plastic tube (final volume, 8.5ml). 
Deoxyribonuclease I (lmg/ml, 0.5ml) was added to prevent any 
cell clumping induced by deoxyribonucleic acids released from 
dead cells.
Crude trypsin solution (2.57. (w/v), 1ml) was added and the
o
tissue suspension was incubated for lh at 37 C with intermittent
mixing. The cell suspension was then centrifuged (400g, 5min., 
o
23 C) and the tissue pellet resuspended in 5m 1 of growth medium. 
Following the mechanical disruption of the tissue by the 
repeated passage of the tissue through a small bore glass 
pipette (15-20 cycles), the mixture was left to stand for 3 min 
and the supernatant, containing the single cell suspension was 
removed for filtering. Growth medium (5ml) was added to the 
remaining tissue and the tissue disrupted as before. The 
combined cell suspensions were filtered through two layers of
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nylon bolting cloth (5^ |um aperture) to remove remaining cell 
aggregates and tissue clumps. The cells were counted using 
Trypan Blue (Methods, Section B4.1) and added to precoated
5
culture plate at a final density of 2.5 x 10 cells per well in
o
growth medium (1ml). The cultures were grown at 37 C in an 
atmosphere of 107. carbon dioxide in air, the growth medium being 
replaced every 3 days. Contamination of the cultures by 
fibroblasts was minimised by treating 3-day-old cultures with 
fluorodeoxyuridine (15pg/ml) for 72h.
The cell viability of the prepared cells was greater than 907.
b
and the yield of cells per limb was 1.27 x 10 (mean of two 
preparations).
Myotube cultures were routinely examined under a Zeiss inverted 
phase-contrast microscope before and after all assays to 
identify any culture wells in which the myotubes had become 
detached from the surface as a result of the washing 
procedures.
125(b) C I]-oc-BGT binding to rat myotube cultures
Replicate myotube cultures were washed twice with growth medium
o
and incubated for 30min at 23 C in fresh medium with or without 
decamethonium (0.275ml ,lmM). OC-BBT (25jtl, 300nM,
Methods, Section Al) was then added to all the cultures and
d
incubated for 60min at 23 C. The cultures were then washed 
three times with growth medium (0.75ml, 2-3min) followed by two 
brief washes with PBS (0.75ml). The bound radioactivity 
associated with the cells was solubilised by incubation with
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NaOH (O.IM, 0.3ml) for 30min at 23 C. The contents of each
culture well were then transferred to LP3 tubes. Each culture
well was then further incubated with NaOH (0.1M, 0.2ml) for 
o
15min at 23 C and the washings transferred to LP3 tubes for 
counting.
Specific 251 -36T binding to the cultures was calculated 
from s
total cpm (in the _ non-specific cpm (in the
absence of decamethonium) presence of decamethonium)
Specific Radioactivity 
(cpm/pmol [12311-OC-BBT)
(c) Cross-reactivity study by ELISA
o
On day 7 rat myotube cultures were fixed and maintained at 4 C 
until use in 0.04/C (w/v) paraformaldehyde (diluted from 4/C (w/v) 
stock paraformaldehyde pH 7.4, containing additionally 90mM 
sodium phosphate buffer and 0.02% (w/v) NaCl).
For cross-reactivity studies with anti-(Torpedo) AChR Mabs, the
fixative was removed and the cultures washed with PBS (3 x 1ml).
PBS containing 57. (v/v) MRS was then added (1.0ml) and left for
lh to block non-specific binding. After removal of 0.75ml of
blocking agent, anti-(Torpedo AChR) and control Mab supernatant
and normal culture medium (250)jL) was added to the culture
wells. Each determination being made in triplicate. After
o
incubation (2h, 23 C), the supernatants and culture medium were 
removed and the cultures washed (3 x 1ml) with PBS containing 57. 
(v/v) MRS. Horseradish peroxidase conjugated goat anti-mouse
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IgG(0.5ml, 1/500 dilution in PBS/57, (v/v) NRS) was added and 
incubated (lh, 23°C) and the cultures then rinsed in PBS (3 x 
lml) alone. The binding of cross-reacting antibody was then 
detected by the addition of substrate solution (0.5ml) 
consisting of 0.5M sodium acetate, pH 6.0, 0.17. (w/v) 3, 3^ 5, 5* 
- tetramethylbenzidine (TMB) and 0.0057. (v/v) H202. After 
30min the reaction was stopped by the removal of 100^1 L of 
reaction mixture to microtitre wells containing H2S04 (25^ jlL,
2M). Separate assay blanks consisted of culture wells treated as 
above but with the omission of conjugate and another with 
substrate. The absorption at 450nm was measured by using the 
mixture substrate solution (lOOyuL) and H2S04 (25^xL) alone as a 
back-off reading.
2.2 Determination of the subunit specificity of the Mabs 
The nAChR is composed of four different subunits (Introduction, 
Section 2) and antibodies produced to nAChR may thus be directed 
against any of the four subunits. Hence it is possible to 
determine the subunit-specificity of anti-(nAChR) antibodies by 
first separating the subunits by SDS PAGE then transferring them 
onto nitrocellulose sheets for immunodetection (Western 
blotting).
(a) Electrophoretic transfer of AChR protein 
The method of Bittner et al., (1900) was used for the 
electroelution of AChR protein onto nitrocellulose paper. 
SDS-PAGE gels were run as described in Methods, Section A4.1 . 
Coomassie staining was omitted and the gel was equilibrated in 
distilled water for lOmin followed by equilibration for 30min in
150
transfer buffer (25mM sodium phosphate buffer pH6.5, containing
107. (v/v) methanol). A 'sandwich' of filter paper, gel,
nitrocellulose and filter paper, all presoaked in transfer
buffer, was assembled. This was then placed into the transfer
o
tank (Transblot 1, BIQRAD) containing transfer buffer at 4 C,
such that the nitrocellulose sheet was facing the anode.
Electroelutian was carried out at constant voltage (12V) for 14h 
o
at 4 C.
(b) Protein staining of nitrocellulose sheets
The strips of nitrocellulose containing electrotransferred 
reference proteins and AChR proteins were stained using India 
ink as described by Hancock and Tsang, (1983).
The strips were equilbrated in PBS containing 0.17. (v/v) Tween
o
and 0.17 (w/v) thiomersol for lh at 37 C prior to the addition
of a solution of India ink (l^ tl/ml PBS/Tween buffer, as above).
o
After the staining procedure (lh, 23 C, with constant shaking), 
the nitrocellulose strips were destained using distilled water.
(c) Immunobinding of anti-(AChR) antibodies
For these studies the nitrocellulose strips containing AChR 
protein were preincubated with PBS containing 17. (w/v) casein. 
This helped to reduce the non-specific binding of the peroxidase 
conjugated second antibody to the nitrocellulose paper.
o
The strips were incubated (overnight, 4 C) with appropriately 
diluted test antibody. All dilutions were made in PBS 
containing 17. (w/v) casein and suitable working dilutions were 
1/5 for monoclonal culture supernatants and 1/100 for antisera
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in a final incubation volume of 4mls. The strips were then
o
washed with PBS/casein (3 x lOmin, 4 C) and incubated with the 
relevant horseradish peroxidase conjugated second antibody, 
(diluted 1/1000 in PBS/casein) for 2h at 4°C. The strips were 
then washed as before and then finally washed with PBS alone.
The binding of cross-reacting antibodies was visualised by
o
incubation (10-15min, 23 C) with freshly prepared substrate 
solution (0.02% (w/v) 3-amino-9-ethylcarbazole in 50mM sodium 
acetate buffer, pH 5.0, 0.037. (v/v) hydrogen peroxide). The 
reaction was stopped by washing with distilled water.
2.3 Determination of the Mab immunoglobulin subclass 
The method used is essentially similar to that described for 
Western blotting (Methods, Section C2.2) and here only the minor 
differences will be given.
Standard anti-immunoglobulins (IgGl, G2a, G2b, S3 and M) were 
spotted onto nitrocellulose strips, pre-washed in 50mM Tris 
buffer, pH 7.4, containing 200mM NaCl. Dilutions of monoclonal 
antibody supernatant (diluted 1/10) and NMS (diluted 1/100) were 
made in the above buffer containing 17. (w/v) casein. The 
conjugate used was horseradish peroxidase conjugated rabbit 
-anti (mouse IgG) (diluted 1/1000> and the stain used was 
3-amino-9-^ethy 1 carbazo 1 e.
Spent culture medium from X63 myelomas was used as a negative 
control, with a Mab AJ3 of known immunoglobulin subclass a 
positive control.
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2.4 Determination of Mab affinity
The affinity of each Mab for Torpedo AChR was determined by 
varying the concentration of [125 I]-&^-BGT labelled AChR using 
the method described by Vincent and Newsom-Davis, (1982). A 
constant amount of Mab supernatant (lOOjjl) was incubated
o
(overnight, 4 C) in a final volume of 550^1 with varying amount 
of [1 ^ 5l]-bC-BGT-labelled AChR (0.05 - 0.45 pmols), followed by 
immunoprecipitation by second antibody and washing as previously 
described for the RIA procedure (Methods, Section B2.1). Non- 
-specific counts were determined in parallel tubes using AChR 
labelled in the presence of excess BZQ. These values were 
subtracted from the total counts to obtain specific counts. The 
results were analysed by Scatehard plots (Scatchard et al.,
1949).
2.5 The interaction of Mab with the cholinergic binding site 
of AChR by inhibition and dissociation assays
The possible interaction of the anti-(AChR) Mabs with the
cholinergic binding site of AChR was studied using two methods
the use of AChR coated SRBC and the use of DEAE filter assays.
2.5.1 Inhibition of [125i]-06-BGT binding to AChR coated SRBC by 
Mabs
The toxin binding assay on receptor coated SRBC (Methods,
Section B2.3.3) was modified to include a pre-incubation with 
Mab supernatant. Coated SRBC (20^1 of 2.57. (v/v) solution) were 
pre-incubated with a suitable dilution of Mab supernatant (30CyxO 
or control Mab anti-(BSA). In parallel tubes non-specific 
binding was determined in the presence of 25mM BZQ (40^ .1). BSS
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containing 57. (v/v) FCS was added to a final assay volume (400p.L)
Following incubation (30min, 23°C), (0.2
o
pmol) was added. Following further incubation (90min, 23 C),
the cells were washed as described previously, (Methods, Section
B2.3.3) and counted. Assay controls contained 'spent' culture
1?^medium and assay totals were ['*■ J I]-ft/-BGT (0.2pmol) alone.
For four preparations of Torpedo AChR-coated SRBC 0.38 -
OjA0.12pmol (mean ± SE) of I]-0<>-BGT were bound per 10ul of
receptor coated SRBC, 2.57. (v/v) suspension.
2.5.2 Effect of Mabs on the inhibition and dissociation of the 
[125l]-^-BGT labelled AChR complex by DEAE filter 
assay
The inhibition of [^^I3-o£-BGT binding to Torpedo AChR by Mabs 
was also studied by using DEAE filters to separate bound toxin 
from free toxin. The final assay conditions were as follows :-
o
Torpedo AChR (20fmols, 100 jjil) was incubated (overnight, 4 C) 
with increasing volumes of Mab supernatant (0-200jjd). in a 
final volume of 300yxl: followed by the addition of a 3-fold
r 1
excess of C ^ 5 I]-o6_BGt (30fmols, 50 ul). After 2h at 23“C the
incubation mixture was applied to DEAE cellulose filter discs 
and washed with TBA buffer and counted for radioactivity. 
Parallel assay tubes contained BZQ at a final concentration of 
2.5mM and the results were expressed as a percentage of the 
counts obtained in the absence of Mab.
Mab supernatants Mab Bll and anti-(BSA) were used as controls.
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The effect of Mab on the dissociation of I]-o6-BGT AChR 
complex was also studied using a similar method to that 
described by Mehraban et al., (1984).
125Torpedo AChR was complexed with a two-fold excess of V l"]-0O 
-BGT in TBA buffer (Methods, Section A2.2 ); 2.5pmol of the 
complex were incubated in a final volume of 2m1 in TBA buffer 
containing 40yjd of ascites fluid or NMS. At intervals, 
aliquots were removed and filtered on DEAE cellulose filters and 
washed extensively with TBA buffer (10ml). Specific counts were 
determined by pre-incubation of AChR with excess BZQ (2.5mM
125final concentration) before addition of [ I]-0c~BGT.
2.6 Investigation of the interaction of Mab with the 
cholinergic binding site of AChR by ELISA
The ELISA also proved a useful method for studying the
interaction of Mabs with the cholinergic binding site of AChR.
Two different studies were used and these are summarised below.
In parallel studies, plates were coated with Torpedo AChR only 
or CX/ -BGT followed by Torpedo AChR in the usual manner (Methods, 
Section B2.2). The plates were then incubated with serial 
dilutions of Mab supernatant and the standard ELISA procedure 
was used thereafter (Methods, Section B2.2).
The effect of cholinergic ligands on the binding of Mabs to 
immobilised AChR was also studied using a method similar to that 
described by Matters and Maelicke, (1983). Serial dilutions of 
Mab culture supernatant were incubated with immobilised AChR in 
the absence and presence of cholinergic ligands.
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ELISA wells were coated with Torpedo AQ-f? as described in
(Methods, Section B2.2). Solutions of cholinergic ligands (50yud)
in PBS containing 0.057. (v/v) Tween were added to each well
except control wells (no ligand), followed by the addition and
mixing of 50yj_l of serially diluted (1 in 2) Mab supernatant.
o
The mixture was incubated (overnight, 4 C) followed by the 
standard procedure of washing, incubation with enzyme-conjugated 
second antibody and development (Methods, Section B2.2). Three 
cholinergic ligands were used carbachol, d-tubocurarine and 
BZQ at final concentrations of 2mM, ImM and 2.5mM respectively.
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Both polyclonal and monoclonal antibodies were produced in this 
work with the aim of using these antibodies in the study of AChR 
on human lymphocytes. The objective of this section was to 
provide basic information on the antigenic specificities of the 
antibodies, and to determine whether any of the Mabs interfered 
with cholinergic ligand binding to AChR, in the hope that such 
antibodies would be of use to study ligand binding to AChR on 
human lymphocytes.
1. Titres. cross-reactivitv and subunit specificities of 
polyclonal antisera
The titres and cross-reactivities of the polyclonal antisera 
raised against Torpedo AChR (designated T) and fetal calf-(AChR) 
(designated FI, F2) (Results, Section B3) were determined by RIA 
(Methods, Section B2.1) by using preparations of AChR from fetal 
calf, human muscle and Torpedo electric organ. The titres of 
the antisera were also assessed by a passive haemagglutination 
assay using SRBC coated with Torpedo AChR (Methods, Section 
B2.3) in a comparative study.
All the antisera (T, FI and F2) had maximum titres against their 
respective syngeneic receptor antigen and this was defined as 
1007. cross-reactivity (Table24, pagel56). Both FI and F2 showed 
little cross reactivity (17. and 0.357. respectively) against AChR 
from Torpedo electric organ. Similar relative activities were 
demonstrated by passive haemagglutination (Table25, page159 ). 
Antiserum T exhibited slight cross-reactivity (0.77.) in RIA 
against human AChR. The antisera FI and F2 showed greater
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cross-reactivity (12.5*/. and 17.07. respectively) with human AChR 
than with Torpedo AChR.
Subunit specificities of polyclonal antisera raised against 
Torpedo AChR were determined by immunoblotting (Methods, Section 
C2.2) when all four subunits (06, S) were found to be
bound.
Table24 Reactivities of rabbit antisera raised against Torpedo 
AChR and fetal calf AChR towards detergent-solubilised 
AChR from human and fetal calf skeletal muscle and 
Torpedo electric organ.
125Titres against various AChR-[ I]- 
oC'-BGT preparations
Antiserum x 10 ^ M
Code__________Immunogen______Torpedo_______Human_____Fetal Calf
T Torpedo AChR 1900(1007.) 15(0.77.) N.D.(-)
FI Fetal Calf AChR 3.5 (17.) 40(12.57.) 320(1007.)
F2 Fetal Calf AChR 2.5 (0.357.) 120(17.07.) 700(1007.)
Figures in brackets represent the 7, cross-reactivity of each 
antiserum with the stated antigen, where 1007. cross-reactivity 
is the titre of an antiserum using syngeneic antigen.
N.D. = Not determined
2. Antigenic characterisation of anti-(AChR) Mabs 
The antigenic characterisation of the anti-(AChR) Mabs Bll, C7, 
Cll, E8 and Ell was studied by using a number of methods. The 
titres of Mab ascitic fluid and Mab supernatants were 
determined as was the cross-reactivity of the antibodies with 
AChR from different species. The subunit specificities of the 
Mabs and the a-^inities of the antibodies for AChR were also 
examined.
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Table25 Comparison of reactivity of polyclonal antisera towards 
Torpedo AChR by RIA and Passive haemmagglutination
RIA Haemagglutination
Antiserum_________titre (nM)_________________Titre_____
T 1900 Is 65536
FI 3.5 Is 256
F2 2.5 Is 8
Control serum N.D. Is 2
Rabbit anti-(Torpedo AChR) antiserum (T) and rabbit anti-(fetal 
calf AChR) antisera (FI) and (F2) were titrated against Torpedo 
AChR coated SRBC (Methods, Section B2.3). RIA titres were from 
Table2^-f pagel58. Control serum (NRS) had no detectable (N.D) 
titre in the RIA. Titration of antisera against BSA/coated SRBC 
showed agglutination in the first well only.
2.1 Titres and cross-reactivities of Mab ascites fluid and 
culture supernatants
2.1.1 Torpedo, fetal calf and human AChR antigens.
Hybridoma cells secreting the monoclonal anti-Torpedo (AChR) 
antibodies Bll, C7, Cll, E8 and Ell were used to produce ascitic 
fluid in congenic mice (Methods, Section B4.10). The titres of 
the ascitic fluids were determined in order to assess their 
cross-reactivities (see Table26, pagel60). The titres were 
expressed as nmoles of ^25 I]-C£-BGT binding sites bound per 
litre of ascites fluid.
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The titres of the Mabs against Torpedo AChR ranged from 
0.03-301nM. The cross-reactivites of the Mabs against AChR from 
mammelian sources varied greatly. Mab Ell had a low titre 
against Torpedo AChR but cross-reacted well with AChR from fetal 
calf and human muscle. All the Mabs reacted to a greater extent 
with fetal calf AChR than with human AChR.
Table 2 6 : Properties of mouse Mabs to Torpedo AChR
Titre (nM) for AChR from
Immunoglobulin Subunit Human
Mab_______class________Specificity Torpedo Fetal Calf Muscle
Bll IgGl 100 4.5 1.51
C7 IgGl * 110 0.6 0.004
Cll IgGl 00, 139 0.75 0.12
E8 IgGl 06 301 2.32 0.35
Ell IgGl * 0.034 o.ooe 0.006
All titres are of ascites fluid using 0.5nM of I]-oc-BGT 
labelled antigen.
# Binding was not observed using Western blotting (Methods, 
Section C2.2).
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Three methods were used to determine the titres of culture 
supernatants. These were RIA (Lindstrom, 1977, Methods, 
Section B2.1), passive haemagglutination assay (Methods, Section 
B2.3), and ELISA (Methods, Section B2.2). The results are given
in Table27 page163 .
The ELISA proved to be a sensitive assay system and enabled 
titration curves of Mab binding against Torpedo AChR to be 
constructed. Figure23(pageJ62) gives examples of titration 
curves obtained for the Mab supernatant C7 and for a low titre 
supernatant Mab Ell. The background absorbance determined by 
using normal culture medium or an irrelevant Mab supernatant was 
negligible. Mab C7 had a detectable titre of 1 in 2560 whereas 
Mab Ell had a titre of 1 in 160. The minimal detection level by 
the RIA for Mab C7 was 1/160 dilution, showing the ELISA system 
to be a more sensitive assay system. Mab supernatants were also 
titrated against Torpedo AChR coated SRBC. However, there 
proved to be little correlation between the agglutination and 
RIA titres.
2.1.2 Cultured rat mvotube AChR as antiaen
The cross-reactivities of Mab supernatants was carried out by
using an ELISA technique with AChR expressed by rat myotubes
after 7 days in culture (Methods, Section C 2.1.1c). At this
17Rstage, cultures were assayed for [l*--'I]-0£-BGT binding sites by 
using an excess of radioligand (Methods, Section C2.1.1b). The
.nr h or
mean specific binding of [ I]-C£-BGT was 52 fmols [ I]-fl£-BGT 
binding sites/culture well (mean from two independent cultures) 
and is within the range quoted by Childs, (1985).
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Log dilution of Mab supernatant
Mab supernatants (-0-, C7; , Ell) and normal culture medium
(-□-) were titrated against AChR by ELISA. Each point is the mean 
of triplicate wells and the standard error shown for Mab C7 is 
representative for the rest of the assay.
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Table 2? Titration of mouse anti-(AChR) Mab supernatants
Antibody Radioimmunoassay Haemagglutination Titre by 
 Titre (nM)____________ Titre____________ ELISA
Bll 100 1:16 N.D.
C7 126 1:1200 1J2560
Cll 139 1:16 N.D.
E0 301 1:64 N.D.
Ell 45 1:0 It 160
Titre detected by RIA (Lindstrom, 1977) and expressed in terms 
of -BGT binding sites.
Haemagglutination titre is given as the dilution at the end 
point.
ELISA titre is given as the dilution at which an absorbance 
level greater than that of the control value is obtained (see
Figure23, page|62) •
N.D. Not determined using the same batch of Mab supernatant.
Cross reactivity was determined by measurement of absorbance 
after incubation with anti-(AChR) Mab or control Mab 
supernatant, followed by incubation with peroxidase-conjugated 
antibody and subsequent development using TMB as substrate 
(Methods, Section C2.1.1c). Three of the Mabs, Bll, Cll and E8 
showed varying degress of cross-reactivity with the nAChR 
expressed by rat myotubes, whereas the Mabs C7 and Ell gave 00 
readings similar to those of the control Mab (see Table2ff, 
pagel64).
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Table Cross-reactivities of Mabs with Rat Myotube
Cultures by ELISA
Test___________________Absorbance 450nm
Control Mab 0.05 + 0.04
Normal culture medium 0.07 + 0.03
Mab Bll 0.2B 4- 0.0B
C7 0.13 + 0.03
Cll 0.31 + 0.02
EB 0.20 + 0.04
Ell 0.09 + 0.02
Results are the mean - SE of three separate culture wells 
prepared from the same culture. Absorbance from substrate alone 
has been subtracted.
2.2 The subunit specificity of anti-(Torpedo AChR) Mabs
The subunit specificities of the Mabs Bll, C7, Cll, E8 and Ell 
were determined by immunobinding of ascitic fluid following 
electro transfer of Torpedo AChR protein from SDS gels onto 
nitrocellulose (Methods, Section C2.2). The positions of the 
stained bands on the immunoblots were compared directly with 
those of a reference strip of nitrocellulose containing 
electroeluted AChR stained with india ink (Methods, Section C 
2.2b).
It was evident that Mab EB bound to the OC-subunit, whereas the 
Mabs Cll and Bll recognised both the 0cand ji subunits. These 
Mabs also bound to very high molecular weight material (Mr>
1 6 5
120Kd). No binding was observed with Mabs C7 and Ell. The 
controls 9 NMS and NRS showed no binding. The results are 
summarised in Table26 (Page 160 )•
2.3 Immunoglobulin subclass of the Mabs
The immunoglobulin subclass of the Mabs (Bll, C7, Cll, E8, Ell) 
was determined by an immuno-dot binding assay (Methods, Section 
B4.12). Standard anti-immunoglobulins (IgGl, G2a, GZb, 33 and 
M) were spotted onto nitrocellulose filters, followed by 
immunoblotting with the 5 Mabs plus controls M*S and a Mab AJ3 
of known immunoglobulin subclass. All the Mabs were shown to be 
IgGl subclass. As expected NMS reacted with all of the 
standards and AJ3 reacted with IgM.
2.4 Affinities of the Mabs towards AChR
The affinities of the Mabs were determined by incubating Mab 
supernatants with 0.06-0.4nM [^^I]-D0-BGT labelled Torpedo AChR 
followed by immunoprecipitation with second antibody (Methods, 
Section C2.3). The binding curves were analysed by Scatchard 
analysis (Figure 24 , Pagel66 ) to obtain values for kd. The 
values obtained are summarised in Table 29 (Page166 ) and were
- t o
in the range 1.76-7.5 x 10 M. These values are within the
ranges quoted for anti-(Torpedo marmorata AChR) Mabs (0.1-7.6 x 
• to
10 M; Whiting et al., 1986) and anti-(Electrophorus electricus 
AChR) Mabs (3.2-30 x 10 °M; Tzartos et al., 1981).
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Figure 24 Scatchard plots for the determination of the affinity 
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100jllL of culture supernatant of each Mab was used in all cases 
except for Mab Ell where 200 ^ jlLs of supernatant was used to obtain 
a greater range of precipitable counts because this supernatant had 
a low titre.
Table 29 Summary of the results obtained from Scatchard analysis
Affinity Correlation
Mab Symbol Kd x 10“'° M Coefficient
Bll -u - 1.76 0.97
C7 3.62 0.96
Cll - o 2.7 0.96
E8 - o 2.59 0.96
Ell -<>■ 7.50 0.81
!
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2.5 Interaction of Mabs with the cholinergic binding site an 
AChR determined by using inhibition and dissociation 
assays
Sera from patients with MG, which contain antibodies against 
self-AChR have been demonstrated to block the binding of PC-BGT 
to AChR (Almon and Appel, 1975). Similarly, anti-(AChR) Mabs 
have been produced which can interfere with the binding of 
0CH9GT or other cholinergic ligands to the AChR (references in 
Introduction, Page 22 )• Mabs directed against the 
cholinergic site may be useful tools in comparing the binding 
sites of the AChR from different species and different tissues. 
In order to determine whether any of the Mabs produced in this 
study recognised the cholinergic binding site of Torpedo AChR a 
combination of different methods was investigated.
2.5.1 Inhibition of C^^I]-D6~BGT binding to AChR-coated SRBC 
The study of the effects of Mabs on OC-BGT binding to AChR was 
initially determined by using immobilised AChR in the form of 
AChR-coated SRBC (Method, Section C2.4a).
Three Mabs (Bll, Cll and E8) gave no significant inhibition; 
similar values within 107. of the control (anti-BSA Mab) were
125obtained. Two Mabs, C7 and Ell inhibited [ I]-06~BGT binding 
by 4Z/. and 337. respectively, when 300yol culture supernatant was 
used in a total assay volume of 40^ /Ul (Table30 and Figure 25 , 
page 16 8).
1252.5.2 Inhibition of [ I3-&-BGT binding to AChR using DEAE 
filter assay
125To further investigate the inhibition of [ I]-X-BGT binding,
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Table 30 Inhibition of [j*51] -fld-BGT binding to AChR 
coated SRBC by Mab
Mab % inhibition of







Figure 25 Inhibition of Ql2S IJ-OC-BGT binding to AChR SRBC 












Increasing volumes of Mab supernatsints C7 and Ell were used in the 
inhibition assay described in Methods, Section C 2.5.1.
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to Torpedo AChR by Mab C7, the DEAE filter assay (Methods, 
Section C2.4b) was used. To ensure Mab excess, C7 supernatant 
was titrated with [^25 I]-/>6-BGT-labelled AChR in an RIA 
procedure (Methods, Section B2.1) using Torpedo AChR (lOfmols, 
equivalent to 28pM) prelabelled with a ten-fold excess of 3=13- 
oC~BGT. Saturable binding of labelled AChR by Mab C7 was obtained 
by using 20^ ul of supernatant (Figure 2 6 » page 170 ). Hence, 
volumes of C7 antibody greater than 20pl should expose any 
inhibition of [^25 i]-o£-BGT binding to AChR. In order to 
increase the sensitivity of the assay, a 3-fold excess of 
OC -BGT was used in place of the 10-fold excess usually used in 
toxin binding assays (Methods, Section A2.2).
Mab C7 inhibited toxin binding to AChR to a maximum of 507. 
(Figure 27 , page170 ). Control Mab, Bll, and anti-(BSA) Mab 
showed no inhibition of toxin binding, in agreement with the 
previous study using AChR coated SRBC.
2.5.3 Effect of Mabs on the dissociation of the [^^I3“0£-BGT - 
labelled AChR complex
The possibility that Mab C7 could also enhance the dissociation
125of [ I]-o£-BGT from AChR was examined by incubation of 
labelled AChR complex with a large excess of Mab C7 ascites 
fluid (-A/ 4 nmols) followed by removal and filtration of 
samples on DEAE filters at different time intervals (Methods, 
Section C2.4b). The results were expressed as the percentage of 
labelled AChR bound at zero time; non-specific binding was 
determined in the presence of BZQ. Ascites fluid from Mabs Bll, 
Cll and EB and NMS were used as controls. Mab Ell was not used
170
Figure 2 6 Titration of Mab C7 by RIA to ensure antibody
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Figure 27 Inhibition ofE '2S il-OC-BGT binding by Mab by 










because of the low titre of the ascitic fluid (Table 26 ,
page 160 ).
125None of the Mabs examined caused dissociation of [ II-OO 
-BGT-labelled AChR complex over the time period 0-18h.
2.6 Investigation of the interaction of Mab with the 
cholinergic binding site of AChR by ELISA
Adaptation of the basic ELISA method allowed a limited analysis
of the interaction of Mab with the cholinergic binding site on
AChR. The first study uses immobilised 06-BGT to orientate
AChR in such a manner that only sites remote from the
cholinergic binding site are exposed. The second study
examined the effect of various cholinergic ligands on the
binding of Mab to immobilised AChR (Methods, Section C2.5).
2.6.1 The effect of precoating plates with °£-BGT on the 
titration of Mabs against immobilised AChR
Serial dilutions of Mab supernatant were incubated with ELISA
wells which had been coated directly with Torpedo AChR or with
o£-BGT followed by AChR and the results compared (see Figure 28
page*l?2 ). Mabs E8, Cll, C7 and Ell showed negligible binding
to Torpedo AChR when this was attached byOdrBGT to ELISA plates,
whereas the binding of Mab Bll was only partially reduced.
To determine whether the reduced binding of Mab toDt-BGT-AChR 
coated wells was due to less AChR actually being bound by this 
method, the amount of 'non-bound' AChR was pooled from twenty 
wells coated with AChR either directly or indirectly byOt-BGT.
125The [ I]-bd-BGT binding activity of the two pools was
M-2
Figure 28  Comparison of titration curves of Mab supernatants 
on AChR coated and OC'-BGT-AChR coated ELISA wells
Dilution of Supernatant
ELISA wells were coated with Torpedo AChR directly (--- ) or by
pre-coating plates with OC-BGT (- - -) and incubated with serial 
dilutions of Mab supernatant (□Bll; ■  C7; 0  Cll; •  E8; X Ell). 
The results are a composite of individual experiments with each Mab 
supernatant.
Cross-reactivity of supernatants with wells coated with o£ -BGT only 
was negligible. Similarly no cross-reactivity was observed with 
irrelevant Mab supernatant.
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determined by DEAE filtration assay (Methods, Section A2.2). 
There was only a negligible difference (<n/37.) between the 
amount of 'non-bound' AChR present in the two pools, indicating 
that the two coating procedures bind approximately similar 
amounts of AChR.
2.6.2 Effect of cholinergic ligands on binding of Mab to 
immobilised AChR
The effects of the cholinergic ligands, carbachol,
d-tubocurarine and BZQ on the binding of Mab supernatants to
immobilised AChR were examined by using an ELISA (Methods,
Section B2.2). The resulting profiles are given in Figure 29
(page174 ) Mab Ell was not examined because of its low titre
(Results, page 162 ).
The binding of Mabs Bll and Cll were unaffected by the presence 
of cholinergic ligands, whereas the binding of Mab C7 to 
immobilised AChR was decreased. The most effective inhibitor 
was BZQ followed by d-tubocurarine then carbachol. The binding 

















Torpedo AChR immobilised on ELISA plates was incubated with serial 
dilutions of Mabs (Cll, Bll, E8 and C7) in the presence of the 
cholinergic ligands, carbachol (-□-), d-tubocurarine (-■-) and 
benzoquinonium (-#-). Control values (-O-) were obtained in the 
absence of ligand. Each point is the mean of six wells and each 
set of curves is representative of two experiments.
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DISCUSSION
Polyclonal antisera were raised against AChR from Torpedo 
marmorata and from fetal calf muscle. A small library of 
monospecific antibodies, raised against Torpedo marmorata was 
alWs established. Both polyclonal antisera and Mabs were 
characterised with respect to titre and cross-reactivity. In 
addition the Mabs were further studied with respect to affinity, 
subunit specificity and interaction with the cholinergic binding 
site of the AChR.
The usefulness of polyclonal and monoclonal anti-(AChR) 
antibodies as probes of AChR-related molecules is, of course, 
dependent on the properties of the antibodies themselves. A 
major factor concerns their cross-reactivity; ie., do the 
antibodies recognise determinants which are common to AChRs from 
many different species or only those carried by the AChR type to 
which they were raised. The former property, rather than the 
latter, suggests binding to conserved regions of the receptor 
protein and hence such antibodies provide much more useful 
probes for detecting AChR from other tissues.
AChR prepared from fetal calf muscle and Torpedo electric organ 
was able to stimulate the production of a population of 
antibodies which recognised determinants found on AChR from 
xenogeneic sources. This finding is consistent with the highly 
conserved nature of the AChR from various species, as revealed 
by significant homologies in the primary structures
1 ? 6
(Kubo et al., 1985, see Figure30pagel91), similar (but not 
identical) molecular masses of the subunits (Einarsan et al.,
1982) and similar pharmacology and electrophysiological 
properties (An ho It et al., 198lf-). The greater cross-reactivity 
shown by anti-(fetal calf AChR) antisera FI and F2 with AChR 
from human muscle than with Torpedo AChR may represent the 
closer phylogenetic relationship of the bovine and human 
receptor types. Cross-reactivities of anti-(Torpedo AChR) and 
anti-(fetal calf AChR) antisera similar to those found here have 
also been shown by other workers (Lindstrom et al., 1978a,
1979).
125An RIA procedure, using [ I3-D6-BGT labelled AChR, was used to 
assay the antisera. One disadvantage of this method is that it 
does not detect antibodies directed against the 06-BGT binding 
site, although such antibodies appear to be rare in polyclonal 
anti-AChR sera (Karlin et al., 1978; Whiting et al., 1983, 
Lukas, 1981f) suggesting that the 06-BGT binding site is not 
highly immunogenic. One interesting exception, appears to be 
the high proportion of anti-'site' antibodies in polyclonal 
antisera raised to chick muscle AChR (Mehraban et al., 1984) 
although the significance of this is not clear.
Haemagglutination of AChR-coated SRBC provided a simple alterna­
tive assay that is able to detect anti OC-BBT binding site anti­
bodies. This method has been successfully used to detect and 
characterise anti-(AChR) Mabs in a study by Gomez et al.,(1979). 
Haemagglutination by antibody is dependent on the cross-linking
17?
ability of the test antibody. Polyclonal antisera contain, by 
definition, antibodies directed against multiple antigenic 
determinants and so are well suited to this assay. Correlation 
between the titres obtained by RIA and haemagglutination assays 
was not surprising as both methods rely on the recognition of a 
large number of AChR epitopes by the polyclonal antisera. 
Additionally the correlation found suggests that few antibodies 
within the antibody population were directed against the 
cholinergic binding site of AChR.
Mabs are directed to single antigenic determinants and 
cross-reactivity is dependent on the presence of a common 
antigenic determinant, ie: one would expect to see either 100V. 
reactivity or none at all. All the Mabs produced against 
Torpedo AChR cross-reacted with AChR from fetal calf and human 
muscle indicating that the Mabs recognise AChR epitopes common 
within species and this finding again reflects the extensive 
homology between the AChR receptors as shown by sequencing 
studies (see Kubo et al., 1985). Another important factor in 
determining the extent of cross-reactivity observed is the 
binding affinity between the Mab and the cross-reacting epitope. 
All the Mabs showed single site high affinity binding to Torpedo 
AChR (see later for discussion), hence the observed low titres 
of the Mabs against AChR from mammalian sources (Table24-, 
page158) must reflect lower affinity binding and it would be of 
interest to titrate out all the low affinity antibody binding 
sites using high concentrations of labelled antigen to verify 
this. A comprehensive study by Tzartos et al., (1981 ) found
1?8
that Mabs raised against denatured AChR from Electrophorus 
electricus recognised receptors from other species but with 
lower binding affinities. The decreased binding affinities may 
be due to subtle differences in conformation resulting from 
point amino-acid differences between AChRs from various sources.
Although the AChR populations from fetal calf and human muscle 
are likely to contain a mixture of both JR and EJR (see 
Section A for discussion) this is unlikely to affect the 
titres observed since the concentration of antigen was in 
excess. However preferential reactivity of the Mabs to one of 
these receptor forms may have been present. Souroujon and 
co-workers (1985) described four anti-(Torpedo AChR) Mabs which 
showed preferential binding to the denervated form (EJR) of 
receptor of rat muscle. This again may be the consequence of 
different binding affinities due to slight differences in 
structure of the two receptor types and parallels the 
preferential binding of myasthenic sera with EJR (Weinberg and 
Hall, 1979, Dwyer et al., 1981).
Antigenic differences between normal and denervated AChR have 
also been found using Mabs to AChR from human muscle (Whiting et 
al., 1986) using, in part, evidence from staining of frozen 
sections of human endplates and this indeed may represent a 
useful future approach for characterisation of the Mabs 
described here . In this study, AChR expressed by cultured rat 
myotubes was used as a source of EJR and indeed three of five 
Mabs showed cross-reactivity.
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These recognition properties could be further exploited in 
future studies which might investigate whether the antibodies 
cause increased internalisation of AChR or are capable of 
complement mediated cell lysis (see Tzartos and Powitz, 1986 and 
Childs et al., 1985 for the description of techniques). All of 
the antibodies produced were IgGl; this subclass also formed a 
major proportion (75*/.).of the Mabs produced by Whiting et al., 
(1985) against AChR from Torpedo marmorata and represents 387. of 
the Mabs produced in rat against eel, Torpedo and calf AChR 
(Tzartos et al., 1985). Such antibodies should be able to fix 
complement and hence they may be of use in lysis studies.
In contrast to the correlation observed between RIA and 
haemagglutination titres using polyclonal antisera, there was no 
apparent correlation using Mabs. Haemagglutination titres are 
dependent on the cross-linking abilities of the antibodies 
concerned (as discussed previously), and those with high titres 
(Mabs C7 and EB) may show greater degree of intermolecular, as 
apposed to intramolecular cross-linking. The nature of 
cross-linking is in turn dependent on the subunit specificty of 
the Mab involved. Mab E8 showed specificity for the £>C-subunit, 
whereas the subunit specificty of Mab C7 is not confirmed, but 
is most probably -subunit specific (for reasons more fully 
discussed below). These antibodies may bind AChR molecules 
intermolecularly whereas the other Mabs, also having ot-subunit 
specificities (see Table 26) but with low haemagglutination 
titres, may bind AChR intramolecularly. These proposals 
could be verified by the analysis of Mab-AChR
180
complexes by sucrose density gradient centrifugation as 
described by Canti-Tronconi et al., (1981a).
The Mabs C7 and Ell were unable to recognise AChR subunits that 
had been exposed to SDS and transferred to nitrocellulose in the 
Western blot procedure. It is possible that these Mabs bind to 
highly conformationally dependent epitopes, as the subunits 
should be largely renatured following electrotransfer, rather 
than sequential antigenic determinants. Similar conforma­
tional ly dependent Mabs have been described by Tzartos et al.,
(1981). These determinants may be formed by amino acids from 
non-adjacent parts of a subunit or parts of other subunits.
These same antibodies were also capable of partially inhibiting
125[ 13-gc-BGT binding to AChR and it is probable that their 
specificity lies in part, if not all, on the OC -subunit of the 
AChR.
It may be that the Mabs bind with very low affinity to denatured 
AChR (Tzartos and Lindstrom, 1980) and incubation with denatured 
AChR subunits an nitrocellulose paper in this study was carried 
out overnight in the hope of detecting low affinity binding, 
however without success. The use of the more sensitive method 
of radiography, rather than the enzyme detection system, may be 
of benefit here (Lindstrom, 198lp. Analysis of the subunit 
specificity of these Mabs by a method which does not involve 
subunit SDS denaturatian may provide more definitive data. An 
ELISA system in which purified subunits are bound to microtitre 
plates has been described (Lindstrom, 1984), but the sensitivity
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of this method is affected both by how the subunits bind to the 
plastic and by the purity of the subunit preparation. Inspite 
of these drawbacks, this method has been used with success for 
screening Mabs (Tzartos et al., 1986). Another alternative is 
to immunoblot Cleveland type peptide maps (Lindstrom, 1984).
Mabs Cll and Bll reacted with determinants an two different 
subunits, OC and £> . This particular dual specificity appears 
to be uncommon in the literature. However, Souroujon et al., 
(1983) and Tzartos and Lindstrom (1980) have each reported 
similar Mabs. Interestingly, in the latter case, the Mab was 
obtained after the immunisation with native AChR and a purified 
subunit preparation. In early studies, anti-(Torpedo 
OC —subunit) antiserum was shown to recognise Torpedo 
jB> -subunits to a greater extent than the & and S  subunits 
(Lindstrom et al., 1979); a finding that is consistent with 
homology data (Kubo et al., 1985; see also Figure 30 )• Hence, 
the Mabs Cll and Bll may bind to homologous regions of the 
OC and |3 subunits. Mabs have also been prepared which 
recognise homologous determinants on ^  andS  (Froehner et al., 
1983) and even on all four subunits (Gullick & Lindstrom,
1983).
Three of the fives Mabs produced were shown to recognise the 
OC -subunit (Mabs Bll, Cll and EB). This high proportion of 
Mabs recognising the 00 —subunit is not unexpected, as the most 
immunogenic region of the AChR, the MIR, is located on the 
-subunit (see Introduction, Section 3). Indeed, other
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workers have found that about half of the antibodies produced by 
immunisation with native receptor, are directed at this site 
(Tzartos and Lindstrom, 1980; Tzartos et al., 1981 ). 
Immunisation with denatured receptor results in a totally 
different antibody reactivity pattern and the resultant 
antibodies show preferential binding to the cytoplasmic surfaces 
of the subunits (Froehner et al., 1983; Sargent et al., 1984). 
Because the Mabs Bll, Cll and C8 reacted with AChR expressed by 
rat myotubes, it is evident that they recognise extracellular 
determinants. This was confirmed by the ELISA in which all the 
Mabs apparently bound to AChR domains which were in the same 
orientation as the 0C-BGT binding site. Mab Bll, however, 
appeared to bind also to determinants on the periphery of the 
AChR molecule as its binding was only partially blocked by 
coating the plate first with OC-BGT.
It is not possible, from the data, to say whether the Mabs Bll, 
Cll and EB are directed at the MIR without carrying out 
competitive binding experiments (see Lindstrom , 1984 for 
experimental details). The MIR is highly conserved and 
antibodies directed at this determinant are capable of passively 
transferring EAMG. None of the Mabs produced in this study 
appeared to induce myasthenic symptoms in mice during the 
production of ascitic fluid. However, it was difficult to 
distinguish the symptoms of EAMB from those of the trauma caused 
by tumour formation. The MIR is highly conserved and the 
well-defined anti-MIR Mab 35 (Tzartos et al., 1981) has been 
used to detect nAChR at synapses an chicken ganglionic neurones
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(Swanson et al., 1983). This study highlighted the potential 
use of such Mabs as probes since the conventional receptor probe 
OC-BGT failed to detect the receptors at these regions (see 
Introduction, Section 3.6).
The estimation of the affinity of Mabs towards AChR is also 
complicated by their subunit specificities. Mabs that are 
capable of intermolecular cross-linking will give lower Kd 
values, suggesting higher affinity, than a Mab which binds 
intramolecularly. Torpedo AChR is known to exist as dimers, 
which further complicates the determination of Kd. Nevertheless 
the binding studies carried out here provided a relative 
estimate of the binding affinities of the Mabs described.
The Mabs were originally screened by using an ELISA procedure 
and it was possible that antibodies could have been selected 
with specificities directed at the Od -BGT binding site of AChR. 
However, all the Mabs had detectable titres by the RIA 
procedure, using I]-Dd-B6T labelled AChR. Despite this, two 
of the five Mabs (C7 and Ell) inhibited, to a maximum of 50*/!, 
[*I2^ I]-d6BGT b£ncjing AChR. There are reports of such 
antibodies in MB sera and in polyclonal anti-AChR sera (see 
Harrison and Behan, 1986 for review) although their proportion 
is relatively small (Whiting et al., 1983). There are however 
several examples of a similar high incidence of site-directed 
Mabs (Gomez et al., 1979; James et al., 1980; Watters and 
Maelicke, 1983; Mehraban et al., 1984; Whiting et al., 1985) 
although not reported by Tzartos and Lindstrom, 1980. Such Mabs
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can be useful in studying the ligand binding site of the AChR 
(examples Donnelly et al., 1984; Mihovilovic & Richman, 1984; 
Fels et al., 1986) or indeed may affect other functions of the 
AChR, such as channel gating (Blatt et al., 1986). Modifications 
of the RIA procedure (Whiting et al., 1985) have been described, 
as have assays capable of selecting function-affecting 
antibodies (Watters and Maelicke, 1983; Fels et al., 1986).
The Mabs C7 and Ell do not necessarily bind at the OC-BGT 
binding site; it may be that the antigenic determinant is 
situated close enough to the OC-BGT binding site, such that 
binding of the Mab sterically hinders the binding of OC -B6T.
The arm of a bound Mab has a reported diameter of approximately
°  2.
35A and can cover an area of lOnm (Tzartos et al., 1981). It
is also possible that the binding of the Mab results in a 
conformational change in the AChR which leads to occlusion of 
the oC -BGT binding site. Such Mab-induced changes in AChR 
conformation have been proposed by Maelicke et al., (1986), who 
suggest that Mabs cannot be considered as static surface markers 
but rather as ligands which can induce conformational changes 
through allosteric networks.
Partial inhibition by Mabs of oc -BGT binding has also been 
seen by other workers (Whiting et al., 19B5; James et al.,
1983; Mehraban et al., 1984). These findings could indicate 
the presence of two different sites on the same AChR molecule 
or two different populations of AChR. There is no evidence 
for this latter point. The OC-subunits of AChR from 
Torpedo have the same primary sequence (Noda et al., 1982;
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Sumikawa et al., 19B2b; Devillers-Thiery et al., 1983) but 
because the AChR is an asymmetric molecule the two 
OC -subunits have slightly different environments (Kistler et 
al., 1982; Kubalek et al., 1987; see also Introduction,
Figure 3). This may explain the different antigenic 
properties of the two 0C-subunits, as suggested by the 
production of antibodies directed at one rather than both oc -BGT 
binding sites. Of interest, here, is that the ligand binding 
sites of the AChR have also been.shown to be different; having 
a low affinity non-glycosylated site and a high affinity 
glycosylated site (Anholt et al., 1984).
The use of SRBC as a solid support for examining the inhibition, 
by Mab, of OC -BGT binding to AChR was found to be a useful and 
rapid technique. It is, however, improbable that total 
inhibition of [ ,2S I]-OC-BGT binding, by any Mab, would have been 
observed by using this method. The coating procedure could lead 
to several different situations, (i) the target antigenic 
determinant could be modified by binding to the SRBC; (ii) the 
coating procedure could destroy or hide the antigenic 
determinant or (iii) the 0^  -BGT binding site or (iv) both. Total 
inhibition would only be observed if both OC-BGT binding sites 
were readily accessible to the Mab and oc-toxin. It would be 
interesting to carry out the haemagglutination assay in the 
presence of excess 0CHBGT. A similar approach has been used by 
Gomez et al., (1979) to study the effect of cholinergic ligands 
on the binding of Mabs to AChR coated SRBC. However, in these 
studies it should be remembered that the OC -BGT is a large
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molecule (MWt 8,000) and could occlude many antigenic epitopes 
on the receptor other than or including the OC-BGT site, which 
is known to be located between the amino acid residues 125-196 
on the c< -subunit (Wilson et al., 1985; Mulac-Jericevic and 
Atassi, 1986; Neumann et al., 1986). None of the above 
techniques can definitively prove Mab binding at the PC-BGT 
binding site and other techniques such as Cleveland peptide 
mapping or competitive binding methods such as those used in the 
study by Whiting et al., (1985) may more precisely pin-point the 
regions recognised by these Mabs.
The -BGT binding region represents a portion of the
cholinergic ligand binding region of the AChR and several groups
have reported antibodies that cross-react at the transmitter 
binding site rather than at the 0C~BGT binding site (Almon et 
al., 1974; Vincent, 1980; Drachman et al., 1981; Fulpuis et
al., 1980; Mochly-Rosen & Fuchs, 1981). It would, accordingly,
be interesting to use the Mabs C7 and Ell in functional assays 
such as ion flux studies to study their effects (see Souroujon 
et al., 1983). Interestingly, a Mab, with non-cholinergic 
site directed properties, has been reported that interferes with 
agonist-induced ion flux (Donnelly et al., 1984).
Clearly, as wide a range of screening procedures as possible 
should be used in order to detect antibodies with such novel 
properties.
Although Mabs C7 and Ell showed limited but detectable 
cross-reactivity with AChR from fetal calf and human muscle,
18?
they did not recognise AChR expressed by rat myotubes. This 
finding deserves more attention, perhaps using fluorescent 
staining techniques. It does suggest, however, that the region 
of the OC-BGT binding site has both conserved and nan-conserved 
regions, as found by other groups (James et al., 1983; Watters 
and Maelicke, 1983; Mehraban et al., 1984; Whiting et al., 
1985).
The DEAE filter assay provided an alternative and well 
characterised assay system for the further study of Mab C7.
Using this assay, and by ensuring Mab excess over the antigen 
concentration, it would have been posible to determine whether 
the Mab was capable of blocking all, (unlikely in this study 
since the Mabs could precipitate AChR saturated with
125 125[ I]-(k-BGT or only a fraction of [ I]-OC-BGT binding sites. 
The results of the assay actually carried out confirmed the 
findings from the AChR coated SRBC assay for Mab C7 . This 
assay system also provided a means of studying the possibility 
of dissociation, induced by Mab, of the [^ 5^ I]-OC-BGT labelled 
AChR complex. Such antibodies are extremely rare and must 
possess one or both of the following properties :- a higher 
affinity for the o£- BGT binding site than 0C-BGT itself 
(unlikely since OC-BGT binds in an almost irreversible fashion) 
or have the ability to interact with a site near to the 0C.-BGT 
binding site in such a way as to induce a conformational change 
in the AChR such that the affinity of the OC-BGT site for OC-BGT 
is reduced. None of the antibodies studied here possessed this 
property. Mehraban et al., (1984) has described a Mab which is
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capable of inducing the dissociation of labelled
AChR complex and IgG or serum from certain myasthenic patients 
have also shared this characteristic (Barkas & Simpson, 1982).
The Mab Ell proved to be somewhat anomalous in that it had low 
but detectable titres as assayed by RIA, ELISA and 
haemagglutination methods. This antibody also bound with high 
affinity to the [*^51 -Bgy labelled AChR complex. One would 
expect that a Mab directed at a region near, or at the 06-BGT 
binding site would show much lower precipitation of AChR 
saturated with [125 I3~0£“BGT. This would appear to hold true in 
the RIA for this Mab. However, Mab C7 does not share these 
properties showing relatively high titres in all the assays 
used. The finding that Mabs behave differently under different 
assay conditions is not unusual (Lukas 1984) and, indeed, some 
Mabs have shown reduced affinity for AChR immobilised on 
poly-(vinyl chloride) microtitre wells (Watters and Maelicke, 
1983; Lukas, 1984) relative to their affinity for detergent 
solubilised antigen in the immunoprecipitation assay. Overall, 
the present findings indicate that the Mabs C7 and Ell do not 
bind to the same antigenic determinant on the AChR. It may be 
worthwhile pursuing the study of the Mab Ell using ammonium 
sulphate cuts of culture supernatant, ascitic fluid or purified 
antibody to study the effects of higher concentrations on the 
inhibition of 0C--B6T binding to AChR by this Mab.
Competition, by cholinergic ligands, of Mab binding to AChR was 
studied by using the ELISA method. This provided an alternative
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procedure to the commonly used precipitation assay with labelled 
toxin-receptor complexes (James et al., 1980; Whiting et al., 
1985) and had been previously used by Watters and Maelicke 
(1983). The use of this kind of approach is, however, 
complicated by the affinities of the antibodies studied. Here, 
all the Mabs used had higher affinities (range ^  nM) for the 
AChR than the cholinergic ligands used to compete (Table 31 , 
page 191 ) leading to a situation where the higher antibody 
affinity binding could obscure the interaction of the 
cholinergic ligand with the AChR, hence reducing the chances of 
detecting anti-cholinergic ligand site directed Mabs.
Nevertheless, d-tubocurarine and BZQ partially competed with Mab 
C7 for binding to immobilised AChR. This finding and the 
ability of the Mab to inhibit Od-BGT binding confirms the 
finding that this Mab recognises a site near to but not directly 
at the cholinergic binding site. Partial inhibition of binding 
of Mabs by cholinergic ligands has been reported by several 
groups (Gomez et al., 1979; James et al 1980 and Watters and 
Maelicke, 1983). Mabs have also been reported that are only 
inhibited by (V-BGT (Gomez et al., 1979, James et al., 1980).
The cholinergic ligands used here are smaller than &1-BGT and 
hence inhibition by steric hindrance is not a major factor. 
Further investigations, using a wider range of cholinergic 
agents and making use of RIA methods may provide more 
information on the Mab C7.
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The binding of Mab E8 to AChR was partially affected only by the 
nicotinic antagonist BZQ. One possible explanation of this is 
that the antibody binds to a determinant affected by 
conformational changes induced in AChR by the binding of the 
antagonist. Maelicke et al., (1986) have proposed overlapping 
sub-sites for cholinergic ligands an the basis of studies using 
Mabs. Indeed a Mab has been produced that can differentiate 
between d-tubocurarine and carbamylcholine binding sites 
(Mihovilovic and Richman, 1984). This provides further evidence 
that Mabs may provide insights into the mechanisms of receptors 
that are not accessible with other ligands.
Table 31
Dissociation constants of cholinergic ligands for AChR
Liaand Kd
Carbamy1c ho1ine 4.5 x 10'5M
d-tubocurarine 8 x 10"* M
BZQ data unavailable from the 
literature
OC- bungarotoxin 2 x 10-<tM













30 Homology matrix for the human, calf and
T. californica acetylcholine receptor subunits
(Taken from Kubo et al., 1985)
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SECTION D
PREPARATION AND CHARACTERISATION OF LYMPHOCYTES 
WITH RESPECT TO CHOLINERGIC BINDING SITES
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fETHODS
1. Isolation and characterisation of leucocyte populations 
and preparation of membrane fractions
1.1 Separation of PBL and granulocytes.
1.2 Lysis of erythrocytes.
1.3 Preparation of mouse thymocyte cell suspensions.
1.4 Giemsa staining for the examination of leucocyte
populations.
1.5 Preparation of membrane fractions and detergent extracts 
of human PBL.
1.6 Preparation of P2 membrane fraction from rat brain.
2. Radioligand binding assays
2.1 [^25i]-p£_B0T bindings assays.
2.1.1 Filtration assay
2.1.2 Cen tri fugation assay
2.2 [3H]-QNB binding assays
2.3 [3H](-)-nicotine binding assays.
2.4 Bind ing k inetics.
2.5 Inhibition studies using test drugs and anti-(AChR)
monoclonal and polyclonal antibodies.
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1. Isolation and characterisation of leucocyte populations and 
preparation of membrane fractions for radioligand binding 
assays
Human PBL and granulocytes were prepared for use in radioligand 
binding assays.
1.1 Separation of human PBL and granulocytes 
PBL were separated from freshly-drawn heparinsed (10 IU/ml) 
venous blood (20-40m1), leucocyte enriched buffy coat and 
leucopheresis samples by density gradient centrifugation using a 
method described by Boyum (1968). Buffy coat samples (50ml) 
were obtained from healthy donors and supplied by the Blood 
Transfusion Service. These samples were routinely 10-2Oh old 
before being processed. Two leucopheresis samples from two MG 
patients were also processed. Buffy coat and leucopheresis 
samples were subjected to Dextran sedimentation prior to the 
density gradient centrifugation step in order to reduce the 
quantity of contaminating erythrocytes.
The buffy coat/leucopheresis sample was mixed with PBS 
containing Z/. (w/v) Dextran (molecular weight 20,000-75,000, 
16ml), and left to stand (l-2h, 37°C), until most of the 
erythrocytes had sedimented to the bottom leaving a white, 
turbid supernatant. This leucocyte rich fraction was removed, 
washed with PBS (200g, 10 min) and then resuspended in PBS 
(25ml). The suspension (5ml) was layered carefully onto 
Ficol1-Hypaque density gradients (4ml) and centrifuged (400g,
o
30min, 23 C). Heparinised venous blood samples were routinely 
diluted with an equal volume of PBS containing heparin (10
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IU/ml) before being layered onto the separation medium. The 
mononuclear cells were recovered carefully from the 
Ficol1/plasma interface using a siliconised pasteur pipette, 
washed twice by centrifugation (200g, 10 min, 23°C), in PBS and 
finally resuspended in PBS (10-20ml).
Granulocytes were prepared by carefully harvesting the pelleted 
cells from the Ficol1-Hypaque centrifugation step. The cells 
were washed with PBS, centrifuged (200g, 5 min) and the 
contaminating red cells were removed by lysis with ammonium 
chloride (Methods, Section D1.2).
The viability of isolated PBL and granulocytes was estimated by 
Trypan dye exclusion (Methods, Section B4.1) and was routinely 
>90*/.. Erythrocyte contamination of the fractions was assessed 
by the difference in cell count between samples treated with 
Methylene blue (0.017. (w/v) in 17. (v/v) acetic acid) and Trypan 
Blue. When the erythrocyte contamination was greater than 27. 
the red cells were removed by ammonium chloride lysis.
1.2 Lysis of Erythrocytes
Two different buffers were used for lysing human and non-human 
erythrocytes using essentially the same procedure.
Contaminating human erythrocytes (0.1ml packed cell volume) were 
mixed with lysis buffer (0.9ml, lOmM potassium bicarbonate 
containing 0.155M ammonium chloride and O.lmM EDTA) and 
incubated at room temperature for 5 min. The cells were then 
washed twice by resuspension in culture medium and
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centrifugation (300g, 5 min). This procedure was repeated if 
the red cell contamination was still greater than Z/.. For lysis 
of mouse erythrocytes, the cells were treated in the same way 
but the lysis buffer comprised 17mM Tris-HCl pH7.2 containing
0.144M ammonium chloride.
1.3 Preparation of mouse thymocyte cell suspensions
The thymus glands of 6 week-old CFLP mice were removed taking 
care to avoid any surrounding tissue. A suspension of 
thymocytes was prepared by gentle squeezing of the thymus with 
broad flat edged forceps into BSS comprising of 0.14M NaCl,
5.4mM KCL, 0.8rrt1 MgS04. 7H20., l.Orrt'l CaC12. 2H20., 0.4mM KH2P04 
and 1.4mM Na2HP04, pH7.2. A single cell suspension was obtained 
by passage of the resulting cells through a fine wire mesh. 
Contaminating erythrocytes were removed by lysis as described in 
the Methods, Section D1.2 and the cell viability, as assessed 
by Trypan dye exclusion, was >98*/.. The yield of thymocytes from
a
each thymus gland was 1.80 + 0.47 x 10 (mean t S.E., n=30).
1.4 Giemsa staining for the examination of leucocyte 
population
A nuclear stain, Giemsa, was used to study the morphological 
characteristics of fixed smears of human PBL.
Human PBL were prepared by density gradient centrifugation 
(Methods, Section Dl.l) and were suspended in neat NRS and 
smeared onto clean microscope slides. NRS was used to protect 
the cells from damage during smearing. The slides were allowed 
to air dry, fixed in methanol (90/i v/v) for 2 min and then
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washed extensively with distilled water.
The fixed cell smears were immersed in Giemsa buffer (23mM 
Na2hF04 containing 8.5mM citric acid, pH 5.7) for 5 min. The 
slides were stained for 15 min with freshly diluted Giemsa stain 
(diluted 1:5 with the above buffer), rinsed with the same 
buffer, air dried, and examined under the microscope.
1.5 Preparation of membrane fractions and detergent extracts of 
human PBL
For the preparation of PBL membranes, isolated PBL (00 x 10b 
cells) were lysed by hypo-osmotic shock using H20 (20mls). An 
equal volume of 0.64M sucrose was then added and the cells were 
homogenised in a glass homogeniser with a motor— driven Teflon 
pestle (10 strokes, 1500r.p.m.). The homengenate was
o
centrifuged (700g, 10 min, 4 C) and the supernatant was removed
O
and recentrifuged (42,000g, lh, 4 C ; Beckman ultracentrifuge). 
The resulting pellet, or P2 lymphocyte membrane fraction was
o
resuspended in 0.32M sucrose (5ml) at 4 C.
Detergent extracts of human PBL were prepared by stirring human
Is __
PBL (40 x 10 /2ml) over ice for 30 min in BSS containing 
additionally 0.57. (v/v) Triton X-100. The extract was then
O
centrifuged (42,000g, lh, 4 C , Beckman ultracentrifuge)and the 
supernatant retained.
The PBL detergent extract and membrane fractions were 
subsequently used for [*H] (-)- nicotine binding assays.
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1.6 Preparation of P2 membrane fraction from rat brain.
The method used was essentially the same as that described by 
Whyte et al., (1985) and outlined in Figure 31 ( page190).
Frozen rat brains from male Wistar rats (bodyweight 200g) were 
kindly provided by my colleagues. The brains had been quickly 
removed, chilled and stored at -20°C until required. All 
solutions contained ImM EDTA, ImM PMSF and 0.02*/. (w/v) sodium 
azide.
Frozen brains (20g) were added to chilled 0.32M sucrose, pH 7.2
o
(100ml) and left at 4 C for 30 min to thaw. The brain tissue 
was homogenised 0.32M sucrose (10 vol), using 2 x 6  strokes at 
100 r.p.m. in a Teflon homogeniser. The resulting homogenate
o
was centrifuged (lOOOg, 10 min, 4 C , MSE6L) and the supernatant 
(SI) decanted and retained on ice. The pellet was resuspended 
using a glass rod in 0.32M sucrose, pH 7.2 (5 vol) and 
centrifuged as before. The supernatant (S2) was removed, 
combined with the supernatant SI and centrifuged (17,000g, 30
o
min, 4 C ; MSE6L). The resulting pellet, P2 , was resuspended 
to 2ml/g wet weight of original tissue in cold 50mM potassium 
phosphate buffer, pH 7.4 and filtered through a double thickness 
of muslin to remove any unresuspended material. The P2
o
suspension was stored at 4 C for up to one week.
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Figure 31 General scheme of Rat brain P2 membrane preparation
20g Frozen rat brain
1. Homogenisation in 0.32M 
sue rose, pH 7.2.




Homogenisation in 0.32M 
sucrose pH 7.2.
Centrifugation (lOOOg, 




1. Centrifuge (17,000g, 
30 min, 4°C).
PELLET (P2)
1. Resuspend in 50mM potassium 
phosphate, pH 7.4.
2. Filter through muslin.
RAT BRAIN P2 SUSPENSION
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2. Radioliaand Binding Assays
Three cholinergic ligands were used in radioligand binding 
assays [125 i]-oc-BGT, [3H]-QNB and [3H] (-)-nicotine. A 
summary of the ligand binding assays used is given in Table33 .
2.1 C^ID-od-BGT binding assays.
The basic procedure for [125I]-oC-BGT binding was the same for 
all tissue sources, Cell suspensions (1-50 x 10 cells) or P2 
rat membrane (0.5-2.0mg protein) were incubated with increasing
125concentrations of [ I]-06-BGT (0-20nM), (specific activity 770
o
Ci/mmol) for 60 min at 22 C, in the presence and absence of 2.5 
-s
x 10 M ot~BGT. The method of separation of free and bound 
radiolabel was either by centrifugation (P2 membrane and cells) 
or filtration (cells only). Sections D2.1.1 and D2.1.2 give 
the different protocols for each method. All determinations 
were made in triplicate.
2.1.1 Filtration assay
125Cell suspensions (500yul) were incubated with [ I]-oc-BGT (as 
above) in a total volume of 540yul. The buffer used throughout 
was BSS (see Methods, Section D1.3). The mixture was filtered 
through pre-wetted DEAE-61 cellulose filters, GFB filters 
presoaked in BSS containing Z/. (w/v) BSA or GFB filters 
presoaked in PEI (see Methods, Section A2.1) on a Millipore 




The method described is similar to that described by Rapier et 
al., (1985). Assays were carried out in Eppendorf tubes which 
had been coated with PBS containing 17. (w/v) casein for lh and 
washed twice with PBS prior to use. Cell suspensions or P2 
membrane (500|jl1) were incubated in a final assay volume of 
540jjJi. The buffer used for P2 membranes was 500mM potassium 
phosphate buffer containing ImM EDTA, 0.5mM PMSF, 0.0Z/C (w/v) 
sodium azide, pH 7.4 and for cell suspensions, BSS. Bound 
radioligand was separated by centrifugation (1 min, high speed, 
MSE microfuge) and the tissues were washed three times (total 
volume 4.5ml) with ice cold buffer; which was PBS and BSS for 
P2 membranes and cells respectively. The pellets were then 
counted for radioactivity.
2.2 [3H]-0NB binding assays.
The binding of C3H]-QNB to mouse thymocytes, human PBL and 
erythrocytes was carried out by using a similar protocol to that 
described in Section 02.1.1. The differences are given here.
For saturation studies, the lymphocyte suspensions were
«> » 
incubated (lh, 22 C) with increasing concentrations of [3H]-QNB
(5-200nM, specific activity 46Ci/mmol) in the presence and
absence of 10 aM atropine. The specific binding of [5H]-QNB was
defined as the amount of [3H]-QNB bound in the absence of
competing ligand minus the amount bound in the presence of
atropine. Competition studies were usually carried out at 20nM
C3HD-QNB.
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2.3 [3H] (-)-Nicotine binding assays.
The binding of [3H](-)-nicotine to rat brain P2 membranes, 
mouse thymocytes and human PBL Mas performed by a method 
described by Rapier et al., (1985).
Lymphocytes (240yj.l, 0.5-2 x 1 0 cells, or lymphocyte membranes) 
or P2 membranes (240 p i , 0.5-2.Omg protein/ml) were incubated in 
a final volume of 300yul with [3H](-)-nicotine (usually 5-100nM,
o
specific activity 60-85 Ci/mmol) for 30 min at 22 C and lh at
o
4 C in the presence and absence of ImM nicotine (-) ditartrate. 
After incubation, samples were diluted with wash buffer (see 
below) (2ml at 4°C) and filtered under vacuum on GFC filters (P2 
membranes) or GFB filters (lymphocytes) presoaked in water 
containing 0.037. (v/v) PEI (Methods, Section A2.1b) for lh prior 
to use. The filters were washed twice with wash buffer or 
distilled water (total volume 4ml). The procedure was carried 
out quickly (^30s) from dilution to last rinse. The filters 
were transferred to scintillation vials and Optiphase
O
scintillation fluid added (5ml), left overnight at 4 C and 
counted for tritium. Counting efficiency was 367..
For rat brain P2 membranes, incubation and washing buffer was 
Hepes buffer (20nM Hepes-4-(2-hydroxyethy1)-1-piperazine-ethane 
sulphonic acid, 118mM NaCl, 4.8mM KC1, 1.2mM MgS04. 7H20,
2.5mM CaC12, pH adjusted to 10.5 with 10M NaOH). For 
lymphocyte studies the incubation and washing buffer was BSS.
2.4 Binding kinetics.
The time course for nicotine binding was determined by
202
3
incubating a fixed concentration of [ H3—(—) nicotine (20nM) and 
<0
human PBL (1 x 10 cells) for varying amounts of time (0-60 
o
min), at 23 C. Incubations were terminated at successive times 
by filtration as described in the previous section.
The time course for nicotine dissociation was followed by first 
incubating [3H] (-)-nicotine (20nM) and human PBL (1 x 10* cells)
o
until equilibrium was achieved, (60 min at 23 C). This 
incubation was followed by the addition of excess of unlabelled 
nicotine (-) ditartrate (lOmM), and rapid filtration at 
successive times (0-10 min). For each time point in all the 
kinetic studies, total binding and non-specific binding were 
determined in triplicate.
2.5 Competition studies using test drugs and anti-(AChR) 
monoclonal and polyclonal antibodies.
Competition assays using test drugs were conducted by
preincubating the tissue sample (rat brain P2 membrane or human
PBL) with varying concentrations of test drug (30^ 11) for 5 min
before the addition of radioligand. Inhibition assays
involving the use of 2-methyl piperidine and pyrrolidine were
carried out by using si1iconised glass tubes.
Similarly, rat brain P2 membranes or human PBL were 
preincubated with either polyclonal anti-(AChR) antisera T , FI 
or F2 (30yj.1) (see Results, Section C.l) or anti-(AChR) Mab 
ascites fluid (20jj.1) (see Results, Section C2.1) for 15 min 
prior to the addition of [3H] (-)-nicotine. Rabbit anti-(BSA) 
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1. Isolation and characterisation of leucocyte populations
The aim of the work described in this chapter was to investigate 
the presence of cholinergic binding sites on lymphocyte 
fractions. Suspensions of various cells were prepared and used 
in radioligand binding assays. The P2 membrane fraction of rat 
brain was used as a well characterised tissue source for 
establishing methodology and for comparative studies.
1.1 Separation of human PBL and granulocytes
PBL were isolated from whole heparinsed blood, leucopheresis and 
buffy coat samples by Ficoll-Hypaque density centrifugation as 
described in the Methods Section Dl.
The yield of PBL from freshly drawn blood from six normal 
healthy volunteers was 21.2t 1.0 x 10 fe cells per 20ml blood 
sample (mean - S.E.). The yield of lymphocytes from buffy coat 
samples (50 ml) was 2.38 t 0.76 x 108 cells (meant S.E.; n =
15). Leucopheresis samples were obtained from two patients with
£
MG and the yield of PBL obtained from 50ml samples was 6.25 x 10
and 3.3 x 108 cells. Patient 1 and patient 2 had anti-(AChR)
-b -S
titres of 0.28 x 10 M and 9.0 x 10 M respectively.
Granulocytes were prepared from buffy coat blood samples only 
(Methods, Section Dl) giving yields of 1.02 - 0.54 x 107 cells 
(mean ± S.E.; n = 3).
1.2 Giemsa staining of human PBL and granulocytes
The PBL and granulocyte populations obtained from one buffy coat 
sample were examined by using Giemsa stain on fixed cell smears.
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granulocy tes ly mphocyte
Human PBL and granulocytes were stained using Giemsa 
stain (Melhods D 1 4) and classified according to the 
morphology o f the ir nuclei .
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Cells were classified according to the morphology of their 
nuclei. Examples of the different cell types are shown in 
Figures 32 (page207) Cell counts were obtained by choosing
six non-overlapping fields of view and expressing the number of 
cell types observed as a 7. of the total number of cell counted. 
The results are shown in the Table 32 below. The preparation 
of PBL was relatively pure with approximately 157. contamination 
with other cell types. The granulocyte preparation, similarly, 
had little contamination from lymphocytes and monocytes.
Table 32 Characterisation of Cell populations isolated bv
Ficoll-Hvpaoue Density centrifuoation
Ficol1-Hypaque Granulocytes Lymphocytes Monocytes
Fraction
Top Fraction 2.27. 857. 127.
Bottom Fraction 967. 27. 0.37.
2. Cholinergic bindina sites on leucocyte and membrane 
fractions
2.1 Binding of C I]-0t~BGT to lymphocyte preparations
12SSpecific binding of C I]- 0t-B6T to mouse thymocytes and human
PBL from healthy donors and MB patients was assessed as the
1?^difference in the binding of C I]-CC“BGT in the presence and 
absence of 10“b M unlabelled oC-Bol. The separation of free 
from bound radioactivity was carried out by using filter assays 
and centrifugation assays (Methods, Section D2.1). A number of 




DEAE-fiIters were used routinely in the assay of purified AChR 
(Methods, Section A2.2) and this method was used in initial
125experiments to detect [I]-cc-BGT binding to lymphocyte 
preparations.
Initial experiments were carried out by using BSS (Methods.,
D1.3) as assay and washing buffer and it became apparent that 
binding of free [^^I]~0£_BGT to DEAE filters represented a 
significant source of error, especially at higher concentrations 
of C^^I]-o£-BGT (see Figure33 , page 209). Such errors may be 
important when trying to detect an unknown but probably small 
population of binding sites.
Several experiments were carried out to reduce the
125non-specific binding of ['*-JI]-0£-BGT to filters by soaking 
filters in solutions of 27. (w/v) BSA, IV. (w/v) casein and 0.17. 
(w/v) poly-L-lysine. The inclusion of 27. (w/v) BSA in the 
washing buffer and presoaking filters in this buffer was 
effective in reducing non-specific binding to DEAE filters (see 
Figure 33 , page209 )• In later experiments (n = 3) PEI-treated 
GFB filters were used, as described by Bruns et al., (1983). 
This method further reduced non-specific binding to 0.67. of the 
total counts added (see Figure 33 » page209 )■
125The apparent kd values from equilibrium studies of [ I]-06
-BGT binding to purified AChR are in the order of 2 x 1 0 M 
(Lukasiewicz et al., 1978) hence [^25 ij- ^ - bgt binding to 
lymphocyte preparations was studied over a concentration range
209



















[125I ]-oc-BGT (n MJ
Increasing concentrations of £2Sl]-06-BGT were filtered through 
DEAE-81 filters presoaked and washed with B.S.S. (->-) and B.S.S. 
containing 2% (w/v) BSA (-•-) or GFB filters soaked with PEI (-O-). 
The radioactivity retained by the filters was expressed as a % of the 
total radioactivity applied to the filter.
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of 0-25nM. In three experiments this range was extended to 60nM 
in order to detect any lower affinity binding sites. No
125specific binding of [ I]-o£-BGT to lymphocytes was detected 
using any of the modifications described. Table 33 ( page 211 
Section D2) gives a summary of the approaches used.
The effects of varying the number of cells used for each 
determination was also investigated at a fixed concentration of
125C I]-0C_BGT, usually 20nM. There was an obvious limitation in 
the number of cells that could be used, especially for 
determinations made in triplicate and especially for human 
lymphocytes where the number of lymphocytes obtained was 2 x 
108 per sample (see Results, Section Dl). The usual cell number 
used per assay was increased from 2 x 10 cells to 10 x 10 
cells. However, no specific binding was observed at this higher 
cell number which incidently led to slow filtration because of 
clogging of the filters. An alternative assay method, that of 
centrifugation was accordingly investigated.
2.1.2 Centrifugation assay
125The binding of [ I ]-(%-BGT to rat brain P2 membranes by 
centrifugation is a well established method in the laboratory 
(see Wonnacott et al., 1986) and the binding has been well 
characterised (see Schmidt et al., 1980). This tissue source 
was therefore used initially to establish the efficacy of the 
centrifugation assay in my hands.
2.1.2a [ ^ id-^-bgt binding to rat brain P2 membranes
125The binding of C ^ I3-&-BGT binding to rat brain P2 membrane
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The human PBL samples were from normal controls and patients with MG.
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was saturable (Figure 34 a, page213 ) with linear non-specific 
binding (r2, = 0.98). Sc ate hard analysis (Figure34 b, page2l3 ) 
gave an apparent Kd of 2.3 nM and Bmax 8 8 fmols/mg protein (rz 
= 0.98). The Hill plot (Figure34 c, page2l3 ) gave a Hill 
coefficient Nh = 1.06 indicating a single class of binding 
sites.
2.1.2b [^^I]HXr-BGT binding to mouse thymocytes 
Cell numbers greater than those used for filtration could 
be used in centrifugation assays and in experiments using mouse 
thymocytes the cell number used per assay tube was increased to
to u
20 x 10 and in one experiment to 50 x 10 . The non-specific
IOC
binding of C l ] - & - B G T  to lymphocytes represented approximately 
0.097. of the total counts added and this constitutes a 6 and 50 
fold improvement on the GFB/PEI and DEAE/BSA assays respectively 
(see Table 34 , page 213). High speed centrifugation tended to 
clump the cells making them difficult to wash. Hence, 
centrifugation at low speed for"v 30s was used. The addition of 
27. (v/v) FCS to the washing buffer also helped in resuspending 
the cells during the wash steps.
125The binding of [ I]-oC-BBT to mouse thymocytes was still 
however, found to be variable and in only one experiment out of 
five was saturable binding observed (Figure 35 , page 215). This
(o
experiment used 50 x 10 cells per assay tube. One fmole of 
[125i]-oe-BGT bound corresponded to approximately 1300 cpm. 
Non-specific binding was linear and Scatehard analysis 



















Bmax 3.4 fmols/ 10 cells (r = 0.87), equivalent to 2000sites 
per cell, assuming all cells have specific oC -toxin binding 
sites. The Hill plot gave a Hill coefficient Nh = 1.09 (r* =
0.93).
Table 34 Comparison of Non-specific binding and reproducibility 
[1251]-#-BGT binding assays in the presence of tissue
Non-specific binding as a 
Assay Procedure________ 7. of Total counts added
DEAE Assay 4.7 ± 0.4367.
GFB/PEI 0.61 t 0.0737.
Cen tri fugation 0.088 ± 0.0097.
Experiments were carried out by using the same number of 
thymocytes (10 x 10v’ ) and are the mean - S.E. of 10 
determinations at 16nM [^^ I ]-o£-BGT.
2.1.2c [ ^ I ] - 06-BGT binding to human PBL
Because of the limited number of human PBLs available from each
blood sample, it was impossible to use cell densities as high as
those in Results, Section D2.1.2b. Hence, PBL were used at 15 x 
£
10 cells per assay tube. If binding sites were present at the 
same density as shown in one experiment with mouse thymocytes 
(Results, Section D2.1.2b) one would expect specific counts of
125approximately 4000. However, no specific binding of [I]-£t-BGT 
was observed to normal PBL (n = 9) or PBL from two myasthenic 
patients using these conditions.
1?^Because of the poor reproducibility of VZ"J I]-cd”B6T binding to
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mouse thymocytes and apparent lack of specific [1 251 ]-pC-BGT 
binding sites on human lymphocytes, these binding studies were 
discontinued. In order to verify the binding methods used, the 
binding of [3H]-QNB to lymphocyte populations was examined, as 
this system has been well documented in the literature for the 
detection of mAChR (Gordon et al., 1978; Lopker et al., 1980; 
Strom et al., 1981; Zalcman et al., 1981; Atweh et al., 1984; 
Adem et al., 19863,13).
a
The binding of [ H]-QNB to lymphocyte preparations was carried
out as described in the Methods, Section D2.2.
2.2 Binding of [3H]-QNB to lymphocytes
The binding of [3H]-QNB was assessed over the concentration 
range 0-200nM. Specific binding was determined as the 
difference between [5H]-QNB binding in the absence and presence 
of the antagonist, atropine sulphate. The non-specific binding 
of C3H]-GNB to GFB/PEI filters was <17. of the total radio­
activity added in the absence of tissue using 6m1 wash volumes.
2.2.1 [3H]-QNB binding to mouse thymocytes
The specific binding of C^HJ-GNB to mouse thymocytes was
saturable, with linear non-specific binding (Figure 36 a, 
page217"). Scatchard analysis of the data (Figure 3 6 b, 
page 217) gave an apparent Kd of 39nM and Bmax 314 fmols/10b
5
cells, which is approximately equivalent to 2 x 10 sites/cell. 
The Hill coefficient Nh = 1.04 (ra = 0.94) indicated a single 
class of binding sites (Figure 36 c, page 21?).
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2.2.2 [?H]--QNB binding to mouse erythrocytes
The contamination of the thymocyte cell suspension by 
erythrocytes in this experiment was 5’/.. Human erythrocytes are 
known to possess specific [ H]-QNB binding (Aronstam et al., 
197V). To control for possible binding to murine erythrocytes, 
red cells were prepared (from blood collected by cardiac 
puncture) and incubated with [3H]-QNB under conditions identical 
to those used for the thymocyte population.
Specific l^HD-QNB binding sites were detectable on mouse 
erythrocytes (Figure 3? a, page 219 ), however, the observed 
binding affinity was much lower than that for thymocytes, with 
Scatchard analysis (Figured b , page 219 ) giving a Kd of
lo
approxim ately 250nM and a Bmax value of 3.9 fmols/10 cells, 
(equivalent to 2300 binding sites/cell, rx = 0.B2). Hence a 57. 
erythrocyte contamination contributed <0.2 fmols [SH]-QNB 
binding and was thus considered insignificant.
2.2.3 Binding of [3H]-0NB to human PBL
2.2.3a Relationship of radioligand binding and cell number 
The binding of [3H]-QNB (40nM) to normal human PBL was shown to
lo
be linear over the range 0-1 x 10 cells/assay tube
(Figure 38 ). Subsequent binding assays were carried out using
1 x 10* cells.
2.2.3b Saturation curves and Scatchard analysis 
The binding of [3H]-QNB to human PBL was highly reproducible 
over the concentration range 5-200nM. A typical binding curve 
is shown in Figure 39 (page 2 21 ). Scatchard analysis of the
219



































Results of triplicate determination of specific 
C 3 Hl-QNB binding at 40nM.
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data from experiments using isolated PBL from three different 
blood samples is shown in Figure 39 . Curvilinear Scatchard
plots were obtained for the three samples studied, suggesting 
either cooperativty or heterogeneity of binding sites. Further 
analysis of the data using a computer program ANOVA gave a high
to
affinity binding site with a Kd of 69nM and Bmax of 510 fmols/10 
cells and a low affinity site of Kd 233nM and 1750 fmols/10** 
cells (F = 138.8 at 4 and 15 Degrees Freedom).
2.2.3c Inhibition of [3H]-QNB binding to human PBL by atropine
An inhibition curve of [-^HU-QNB binding to human PBL by varying
concentrations of atropine is shown in Figure 40 . The
data were analysed to yield the Hill plot (Figure 41 ) to
derive the IC50 value (concentration of drug that inhibits
-5
specific binding by 507.) of 2.5 x 10 M.
2.2.4 Binding of [3H]-QNB to human erythrocytes 
Erythrocytes were prepared from buffy coat samples depleted 
of white cells by centrifugation and aspiration of the 
supernatant. Contamination of the erythrocytes by white blood 
cells, as estimated by the method described in Section Dl.l was 
0.57..
There was no specific binding of [3H]-QNB over the concentration 
range 0-200nM.
2.3 C^H] (-)- nicotine binding studies
It has been shown that not all nAChRs bind I]-oc-BGT (see 
Introduction, Section 3.6). In these instances the radioligand
223








Varying concentrations of atropine were preincubated with 
8 x 10s human PBL, followed by incubation with C5, hI-QNB 
(200nM). Each point is the mean of triplicate determinations,
Figure 41 Linear transformation of above data to yield the 
HILL PLOT
3
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P represents the percentage bound at each concentration of atropine.
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3
C H] (-)- nicotine has proved a useful and specific probe for 
detecting the non oc-BGT binding subclasses of nAChRs. Hence, 
C3H](-)“ nicotine was used as an alternative probe for nicotinic 
cholinergic receptors on lymphocyte preparations.
The binding of [3H] (-)- nicotine to lymphocyte populations was 
initially studied by using mouse thymocytes because they were 
easier to obtain in large numbers than human PBL.
2.3.1 [3H] (-)- nicotine binding to mouse thymocytes
The first experiments carried out determined the binding of [aH]
(-)- nicotine to increasing numbers of mouse thymocytes. The
-3
specific binding in the presence of lOli nicotine (-) ditartrate
IO
was found to be linear over the range 0-1.5 x 10 cells 
(Figured2a ) and subsequently 1 x 1 0 cells were used for a 
saturation binding study (Figure 4 3 ).
The binding of [3H] (-)- nicotine to mouse thymocytes was 
studied over the concentration range O-lOOnM (Figure 43 ).
Linear non-specific was observed. Binding was not saturable at 
lOOnM, however it was not possible to use higher concentrations 
of the radioligand because of its high cost. However, Scatchard 
analysis of the binding data shown in Figure 43 a yielded a 
straight line (ra =0.84) giving a Kd of approximately 136nM
lo
and a Bmax value of 56 fmoles/10 cells (34000 binding 
sites/cell) (Figure 43 b)» The Hill coefficient Nh = 1.04
indicated a single class of binding sites (r2 = 0.96) (Figure
43 c).
2 2 5
Figure 42 Specific L"3 h!-(-)-nicotine binding to lymphocyte 








Cell no x 10
The results are the mean of triplicate determinations of 
specific L 3 Hj-(-)-nicotine binding at lOnM.
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Following this success, no further studies using mouse
3
thymocytes were carried out and attention was focused on [ H]
(-)- nicotine binding to human PBL.
2.3.2 [3H] (-)- nicotine to human PBL
2.3.2a Linearity of binding with cell number
The binding of [^H] (-)- nicotine (lOnM) to normal human PBL was 
linear over the range 0 - 1  x 1 0 cells/assay (Figure42b). All 
subsequent binding assays were carried out using 0.5 - 1.0 x 10 
celIs.
2.3.2b Saturation curves and Scatehard analysis
Saturable specific binding of C^H] (-)- nicotine to isolated
human PBL was found (Figure 44 )• These data are representative 
of results obtained in 5 experiments using PBL from different 
donors. Table 35 summarises the data obtained. The mean Kd
, , , <D
was 59 Z lOnM (mean i S.E.) and Bmax values of 287 Z 00 fmols/10
cells (mean t S.E.).
PBL isolated from 1eucopheresis samples from two MG patients 
(see Results, Section Dl) were also used in [3H] (-)- nicotine 
experiments.
The binding of [3H] (-) nicotine to both myasthenic PBL samples 
was saturable. Figure45 a gives the saturation curve obtained 
when PBL from patient 1 was studied. Scatchard analysis of the 
data (Figure 45 b) gave a Kd of 79nM and Bmax value of 92 
fmols/lO*0 cells (rz = 0.88). Analysis of the data from patient 
2 gave a Kd of 65nM and Bmax value of 75 fmols/10*0 cells
228
Figure 44 L 3h]-(-)- nicotine binding to human PBL
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Table 35 Summary of the Binding Data of [ ^ H] (-)-nicotine to intact human PBL
Source of Kd Bmax ^ correlation ^ Hill coefficient
Lymphocytes nM fmols/10 cells coefficient r N h
Normal blood a28 67 0.99 0.92
II ft 44 157 0.96 0.95
II II 80 225 0.85 0.96
II II 94 555 0.72 0.90
II II 53 435 0.97 0.91
Leucopheresis sample 
Myasthenic patient 1 79 92 0 . 8 8 0.96
Leucopheresis sample 
Myasthenic patient 2 65 75 0.84 0.94
Mean - SE of all data 63 -  8.0 229 -  67 0.89 -  0.03 0.93 - 0.01
Data were obtained by using Scatchard analysis.
aThe saturation curve and Scatchard plot is shown in Figure 4 4  (paga228)*
229
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(r2, = 0.84). The Hill coefficients were 0.96 and 0.94 
respectively (Figure 45 c)
%
The binding of [ H] (-)- nicotine to normal human PBL was 
further examined by the determination of the association and 
dissociation constants.
2.3.2c Determination of the association rate constant fora
C H] (-)- nicotine binding to human PBL
o
The association rate (K + 1) was determined at 23 G, by 
incubating the assay mixture, human PBL and [3HJ (-)- nicotine 
for increasing times before filtration (see Methods, Section 
D2.4). The half-time (t 1/2) for association was approximately 
1.25min and the binding reached equilibrium within approximately
30min (Figure46a )•
The data were subjected to pseudo first-order treatment which 
takes into consideration the contribution of 1igand-receptor 
dissociation to the eventual reaching of a steady state of 
equilibrium (Beq) (see Bennett, 1978).
The bound concentration of [ H] (-)- nicotine (Bt) at any prior 
time is related to the equilibrium concentration (Beq) by the 
following equation :
Kobt
Hence, the slope of the plot Ln [Beq/Beq-Bt] versus time gives 
the experimentally observed apparent rate constant (Kobs) (see 


















Figure 463 Time course of association of Hj(-)-nicotine 
with human PBL
INCUBATION TIME (min)






Kobs = 0-4 66 
r2 = 0 977
Kobs is represented by the initial slope, determined graphically by 
least squares linear regression.
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Kobs is related to the association (K + 1) and dissociation 
(K - 1) rate constants and free ligand concentration CL] as 
follows:
K + 1 = Kobs - K -1 EQUATION 1
CL]
Hence, estimation of K + 1 requires knowledge of the 
dissociation rate constant (K -1). This was determined as 
described in the next section.
2.3.2d Determination of the dissocation rate constant or 
[3H] (-)- nicotine binding to human PBL
The rate of dissociation was determined by incubating human PBL
with [3H] (-)- nicotine at 23 C for 60min (ie: to equilibrium)
followed by the addition of excess unlabelled (-)- nicotine as
described in Methods, Section D2.4. The amount of [3H] (-)-
nicotine bound was determined at various times thereafter
(Figure 4? a).
If B = Bo at t = 0 then
Ln B = -K -l.t
Bo
Hence a plot of Ln [B/Bo] vs time has a slope of - K -1 (see 
Figure 47 b) estimated by linear regression analysis.
The t 1/2 for dissociation was approximately 2 min and the 
dissociation curve reached a plateau within 6 min. The 
dissociation rate constant (K-l) was determined graphically to
-i °
be 0.35min at 23 C and the association constant (K + 1) as
-a — I
calculated from equation (1) was 5.B x 10 nM min
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The dissociation of C3 h1 (-) -nicotine was determined as described 
Methods, Section D 2.4
Each point is the mean of 4 determinations.
in






The dissociation constant K-l is represented by the negative slope, 
determined by least-squares linear regression.
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The Kd determined by the ratio K-l/K+1 was 60nM, in agreement 
with the mean Kd determined by equilibrium studies from five PBL
samples examined (see Results, D2.3.2).
2.3.3 C3H] (-)- nicotine binding to human granulocytes
The binding of [3H] (-)- nicotine to another population of human
leucocytes, namely granulocytes was also investigated.
The binding of [3H] (-)- nicotine to two preparations of 
granulocytes was saturable. Figure 48 a shows a representative 
binding curve. Scatchard analysis (Figure 48b) of the data from 
the two binding curves gave a mean Kd of 40nM and Bmax values of 
750 fmoles/lO1* cells, indicating approximately 450,000 binding 
sites per cell. Hill coefficients for the two binding curves 
were 1.04 and 0.98(FigiirG 48c).
Granulocytes were also found to be a minor contaminant
(representing approximately 27.) of PBL population (see Table 32)
Hence a Z/. contamination by granulocytes would contribute
lo z
approximately 15 fmols/10 cells of [ H] (-)- nicotine binding 
sites to the estimation of [3H] (-)- nicotine binding sites on 
human PBL.
2.3.4 [3H] (-)- nicotine binding to human erythrocytes
No specific binding of [3H] (-)- nicotine to human erythrocytes 
was observed over the concentration range 0-60nM.
2.4 Competition Studies
The binding of CaH] (-)- nicotine binding to human leucocytes 
was further characterised with respect to stereoselectivity and
236








































The ability of anti -(nAChR) monoclonal and polyclonal 
antibodies (described in Results, Section D2.4.3) to inhibit 
C*H] (-)- nicotine binding to human PBL was also investigated.
2.4.1 Stereoselectivity of C^H] (-)- nicotine binding 
Two different tartrate salts (Nicotine hydrogen ( + ) tartrate and 
Nicotine (-) ditartrate) of (-) and (+) nicotine were compared 
for inhibition of [ H] (-)- nicotine binding to human PBL 
(Figure 49b ).
IC50 values (concentration of drug that inhibits specific
binding by 507.) were derived from linear transformations of dose
-5
response curves (see insert Figure49C ) were 5.0 x 10 M for
-14.
(+)-nicotine and 1 x 10 M for (-)-nicotine. Hence the 
inhibition by ( + ) and (-)-nicotine showed little 
stereoselectivity.
Assuming the Kd to be approximately 60nM (see Results, Section 
D2.3.2) the Ki values can be derived from IC50 values by the 
following equation (Cheng and Prusoff, 1973):
Ki = IC50 where [L] is the concentration
1 + [L] of radioligand used in the
Kd displacement study
-s
Hence the Ki values for (-) and (+) are 7.5 x 10 M and 3 x 
10 5M respectively.
3
In a comparative study the inhibition of [ H] (-)-nicotine 
binding to rat brain P2 membranes by nicotine (-) ditartrate was
238
Figure 493 Inhibition of[?h] (-)-nicotine binding to rat brain 
P2 membranes
Diluted rat brain P2 membrane was preincubated for 
5 min with concentrations of nicotine indicated on 
the abscissa before addition of 40nM|^H] (-)-nicotine. 
Assays were carried out as described in Methods. Section
p 2.3
Non-specific binding, determined in the presence of 
10 3 M (-) nicotine was subtracted from all values, 
binding in the presence of test concentrations of 
drug was calculated as a percentage of the total 
specific binding to the preparation. Data points 
are the means of triplicate determination of one 
experiment.
-0- (-)-nicotine ditartrate.
Figure 49b Stereospecif icity of inhibition of H*] (-)-nicotine
to human PBL bv nicotine
The conditions used were exactly the same as above 
except that human PBL were used and 30nM C5h1(-)-nicotine 
was used.
Data points are the means of triplicate determinations and 
the curves are representative of three experiments on 
different PBL preparations.
—  (-)-nicotine ditartrate;
—*0“" nicotine hydrogen ( + ) tartrate.
Figure 49C Linear transformation of the dose response curves shown
in Figure a and b where P represents the percentage bound 
























examined (Figure493 ). A much lower range of nicotine 
concentrations were used than for the displacement studies 
above. Linear transformation of the displacement curve binding 
data gave an IC50 value of 1 x 10'* M. [3H] (-)- nicotine 
binding to rat brain P2 membranes is well characterised in the 
laboratory and assuming a Kd value of 50nM (see Wonnacott, 
1986), the Ki value calculated as above was 37nM.
2.4.2 Pharmacological specificity of [3H] (-) nicotine 
binding to human PBL
The pharmacological specificty of [3H] (-)- nicotine binding to
human PBL was studied by examining the inhibition of specific
[3H] (-)- nicotine binding by various drugs (Figure50; Table 36
and 37 ) •
Three cholinergic drugs were effective in displacing [3H] (-)- 
nicotine binding, the nicotinic antagonists d-tubocurarine, 
dihydro-p-erthyroidine and atropine, a muscarinic antagonist. 
The IC50 values were estimated by using a linear transformation 
of the data, as described in Figure 50 , page241 , and are 
summarised in Table36 .
Other well established nicotinic agonists, acetylcholine 
carbachoi and Df“PP and the antagonists, DC -BGT, hexamethonium 
and decamethonium (see Introduction 2.2, page 4 ) failed to 
inhibit [3H] (-)- nicotine binding to human PBL (Table 37- ). 
Initial experiments using acetylcholine used physostigmine 
(10 M) as anticholinesterase agent, however this drug alone 


















Figure 50 Competition of cholinergic ligands for 
L 3 H](-)-nicotine binding.
Log [displacing ligand]M
The conditions used were exactly the same as described for 
Figure 49 • Data points are the mean of triplicate
determinations and are representative of three experiments 
carried out on different human PBL samples.
-Q- d-tubocurarine, H§- atropine,
-£> dihydro-p-erythroidine.
Stock dihydro-p -erythroidine was prepared in ethanol.
Controls using ethanol alone had no effect on C3h](-)-nicotine 
binding.
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producing 50’/. inhibition). An alternative anticholinesterase 
agent BW 284C51 which had no effect on [3H] (-)- nicotine 
binding to human PBL was used in subsequent experiments.
The inhibition profile of [3H](-)~ nicotine binding to human 
granulocytes was similar to that for human PBL.
Table 36 Inhibition of [3H] (-)- nicotine bindina to human PBL 
using cholinergic ligands
_________ Ligand____________________ IC50_____________
nicotine (-) ditartrate 1.0 x 10 ^ M
nicotine hydrogen
(+) tartrate 5.0 x 10-5 M
d-tubocurarine 2.5 x 10'** M
atropine 8.0 x 10'5 M
di hydro -j3- ethyroidine 5.0 x 10's M
Table 37” Cholinergic ligands which showed no inhibition of 








^ determined in the presence of the acetylcholinesterase 
BW 284C51 (lO^g/ml); b DMPP 1-1-dimethyl-4-phenyl 
piperazinium iodide was used at lO'^M; C 0C~BGT was 
used at 10*Vl. All other ligands were used at 10~3M.
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2.4.3 Inhibition studies using anti-(AChR) monoclonal and 
polyclonal antibodies
The polyclonal and monoclonal antibodies described in Section C
3
were examined for their ability to inhibit [ H] (-)- nicotine 
binding to rat brain P2 membranes and human PBL (see Methods, 
Section D2.5). None of the antibodies inhibited [3H] (-)- 
nicotine binding when compared to the control values using 
irrelevant antibodies. All the antibodies inhibited [3H] (-)- 
nicotine binding by approximately 107..
2.5 Effect of heat on binding of [ H] (-)- nicotine to human
PBL
Several other studies were carried out to investigate the 
anomolies of [3H] (-)- nicotine binding to human PBL. These 
anomalies are : lack of correlation between IC50 values and
observed Kd, lack of stereoselectivity and the lack of 
significant inhibition of [3H] (-)- nicotine binding by 
classical nicotinic agents.
2.5.1 Heat inactivation of [3H] (-)- nicotine binding to 
human PBL
The binding of [3H] (-)- nicotine (20nM) to human PBL was
sensitive to heat treatment, with 367. of the specific binding,
O o
observed at 22 C, remaining after incubating the cells at 60 C 
for 5min. The specific binding was totatyobliterated after heat 
treatment for 5 min at 100 C. Table 38 summarises the 
results.
2.5.2 Effect of incubation temperatures on [3H] (-)- 
nicotine binding
a
The binding of [ H] (-)- nicotine to human PBL was compared at
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6 o
4 C and 22 C. Human PBL from the same donor were either
o o
pre-cooled on ice to 4 C or left at room temperature (22 C).
Incubation with [3H] (-)- nicotine (40iM) for 30 min was carried
out at these temperatures. Table 39 gives the results. There
o
was no difference between the specific binding observed at 4 C 
and 22 C.
Table 38 Heat inactivation of [3H] (-)- nicotine binding to 
human PBL
Temp. Total binding non-specific specific
_______________ c.p.m._______________ c .p.m.______________ c . p.m.
22°C 2221 ± 29 1351 ± 00 870
60°C 1669 ± 20 1358 ± 100 311
100°C 1661 ± 50 1530 ± 8 0  12
Non-specific binding was carried out in the presence of 103 M(-) 
nicotine. 1.2 x 1 0 cells were used for each assay tube.
Results are expressed in c.p.m.
Table 39 Comparison of incubation temperature on [ H] (-)- 





Total non-specific specific total non-specific specific
binding c.p.m. C • pafDt binding c.p.m. c.p.m.
c.p.m.
5426 ± 129 2038 ± 139 3338 5321 ± 141 1851 ±40 3470
Non-specific binding was carried out in the presence of 10 M(-)
nicotine. 1.8 x 10 * cells were used per assay tube and 
determinations are the mean ± S.E. of triplicates. Results are 
expressed as c.p.m.
245
2.6 Binding of [3H] (-)-nicotine to subcellular fractions of 
human PBL
The binding of [^H] (-)- nicotine to lymphocyte membranes and 
detergent extracts of lymphocytes was determined in the 
following studies.
a
2.6.1 [ H] (-)- nicotine binding to detergent extract of
lymphocytes
A detergent extract of human PBL was assayed for [3H] (-)- 
nicotine binding sites (Methods, Section D1.5). Detergent 
extracts prepared from two PBL samples showed no specific
3
binding of [ H] (-)- nicotine. The presence of detergent at 
0.1% (v/v) had no effect on the binding of [3H] (-)- nicotine to 
rat brain P2 membranes (see Table40 page248 ).
Human PBL or rat brain P2 membranes were incubated with [3H]
(-)- nicotine in assay buffer (Methods, Section D2.3) or assay 
buffer containing additionally 0.17. (v/v) Triton X-100 or 0.017. 
(v/v) Triton X-100. The presence of detergent had little effect 
on the specific binding of [3H] (-)- nicotine to rat brain P2 
membranes, but reduced the binding of [3H] (-)- nicotine to 
human PBL to approximately 227. of the binding found in buffer. 
Table 40 summarises the results. In a parallel experiment, 
human PBL were incubated with buffer and 0.1% (v/v) Triton X-100 
alone and samples (30ymL) were stained with Trypan Blue 
(Methods, Section Dl.l) and examined under the light microscope. 
The PBL remained intact in buffer but only approximately 157. of 
the cells were intact from the PBL/detergent sample.
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3
2.6.2 C H] (-)- nicotine binding to lysed lymphocytes 
One PBL preparation in buffer was repeatedly frozen in liquid N2 
and thawed at room temperature in order to determine [3H] (-)- 
nicotine binding to lysed lymphocytes. However, this procedure 
was unsuccessful because the lysed cells produced a solid mass 
which was difficult to disrupt. Alternative methods of 
determining [3H] (-)- nicotine binding to lymphocyte membranes 
were thus investigated.
Lymphocyte membranes were prepared from human PBL using 
hypo-osmotic shock, followed by homogenisation and 
centrifugation (see Methods, Section D1.5). Lymphocyte 
membranes and intact lymphocytes from the same donor were used 
in [3H] (-)- nicotine binding experiments. Lymphocyte 
membranes, equivalent to 4 x 10 cells were used for each 
determination whilst assays using intact lymphocytes employed 1 
x 10*° cells.
No specific binding of LSH] (-)- nicotine (40nM) was observed to 
three preparations of lymphocyte membranes although specific 
binding of [ H] (-)- nicotine was found as described above 
(Results, Section D2.3.2) in parallel experiments using intact 
lymphocytes.
In an alternative approach intact lymphocytes were incubated
3
with C H] (-)- nicotine and then lysed on the filter using a 
water wash step. Parallel experiments used buffer washes only 
(see Methods, Section D2.3).
24?
An initial experiment, using rat brain P2 membranes in the 
radioligand binding assay was carried out to investigate the 
effects of a water wash on [3H] (-)- nicotine binding. Table 40 
summarises the results. A water wash did not alter the binding 
of C H] (-)- nicotine to rat brain P2 membranes. However, the 
specific binding of [3H] (-)- nicotine to human PBL was 
apparently abolished. When the binding of [3H] (-)- nicotine to 
human PBL was systematically studied, over a range of 
concentrations of radioligand, specific binding to human PBL was 
observed but was abolished by washing with water.
The study of [3H] -QNB binding to human PBL (Results, Section 
D2.2) had also used intact lymphocytes. To examine whether cell 
lysis affected the binding of [3H]-QNB (30nM), parallel 
experiments were set up, as above, using buffer wash and water 
wash steps (see Table 40 ). Specific binding to PBL was still 
detectable after lysis but was reduced to 217. of that found 
using intact lymphocytes.
0
Table 40 Effect of Lysis by Hyposmotic shock or treatment with detergent on [ H ] (-)-nicotine
binding to lymphocyte and Rat brain P2 membranes














Buffer +0.1% (v/v) Triton X-100 1246




Buffer +0.1% (v/v) Triton X-100 176
Buffer + 0.01% (v/v) 182
Buffer Wash 6001
Water Wash 1279
3 3H] (-)-nicotine was used at lOnM and [ H QNB at 30nM.
Rat brain P2 membranes were used at 1.2mg/ml 
f* Human PBL used at 2.0 x 10^ cells/assay
..............  1.2 x 10 cells/assay
The filtration assays employed water as a washing agent 
(lysed lymphocytes) and buffer as a washing agent (Intact 
lymphocytes). (see Methods, Secti onD2.3).
249
DISCUSSION
Despite the detection, by using iodinated c£-BGT, of AChR - 
bearing myoid and epithelial cells in the thymuses from human 
and animal sources (see Introduction, Section 4) there is little 
information concerning binding of OC-BGJ to thymic cells. In
175the present study, saturable specific binding of V*--* I]-0£-BGT
was observed in only one of several preparations of CFLP
thymocytes. Analysis of the binding suggested a single binding
site with an affinity (Kd = 6.3nM, Results, Section D2.1.2b)
similar to that of nAChRs from skeletal muscle and electric
organ, suggesting a similar receptor type. In contrast, a
previous study, using Triton X-100 extracts of rabbit thymus,
found two [^25 i]_££_]307 binding components with respective Kd's,
O.llnM and 2nM (Ueno et al., 1900). Uhfortunately it is not
possible to compare the receptor content of the thymuses
concerned, because of the different approaches. However, the
contents are small; in this work the mouse thymus contained 
ii
approximately 10 [ I]-/£-BGT binding sites, equivalent to
approximately 400fmoIs AChR whereas Ueno et al, (1900) reported 
0.6pmol((-toxin binding sites/mg protein using thymic
extracts.
One disadvantage of using whole thymic cell populations or 
thymic extracts is that it is impossible to determine which cell
125type or types are binding [ I]-06~BGT. The thymus contains a
heterogeneous population of cells; T cells at different stages 
of maturation, B cells, follicular dendritic and interdigitating
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cells, in addition to myoid and epithelial cells. There are 
reports of immunoreactivity of anti-AChR antibodies with mouse 
thymocytes (Fuchs et al., 1980; Horvat et al., 1983; Riviera 
et al., 1987). However, not all thymocytes appear to bind 
anti-(AChR) antibody, some 38-807. of the population being 
positive. Similar results have been reported for human 
thymocytes (Horvat et al., 1983; Pizzighella et al., 1983b; 
Riviera et al., 1987). The reasons for the inconsistency of 
[I25i]-0C-BGT binding to CFLP mouse thymocytes used in this 
study are unclear, as the cell suspensions and assays were 
apparently carried out under identical conditions. Fuchs et 
al., (1980) were unable to demonstrate any significant toxin 
binding activity an thymocytes or in thymic extracts, although 
immuno-reactivity with anti-AChR antibodies was found.
Antibody-reactive AChR thymic components have been found both in 
mice genetically susceptible to EAMB and those which are not 
(see Fuchs et al., 1980). Similarly, AChR has been found to be 
present in both control and MG thymus (Pizzighella et al., 1983b’ 
Matsumoto et al., 1986; Kirchner et al., 1987; helms et al., 
1988). This suggests that the presence of AChR in the thymus is 
not a pathological feature of EAMG or MG.
Although some functional nAChRs do not bind OC-BGT (see 
Introduction, Section 3.6), 06-BGT has been shown to alter the 
functional response of nAChR on lymphocyte and monocyte 
populations isolated from normal blood. Thus, 0£-BGT, at a 
concentration of 10nM, was shown to abrogate the enhancing
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effects of ACh on the production of complement factor C2 by 
monocytes (Whaley et al., 1981). In the present study, PBL 
fractions were not depleted of monocytes, which represented 1Z/. 
of the total leucocyte population used in binding assays 
(Results, Table 32 )- In other studies, lOnM 06-BGT was able to 
inhibit lymphocyte-mediated cytotoxicity induced by O.lnM 
carbamylcholine (Strom et al., 1974), while Richman and 
co-workers (1979; 1981) found that 0£-BGT, albeit at a much
higher concentration (lOjjtM), was able to reverse the 
suppressive effect of nanomolar concentrations of 
carbamylcholine on PBL proliferation. Together, these studies 
indicate that 0£-BGT can interact with the nAChR on human 
lymphocytes and monocytes and it appears paradoxical that 
specific [I]-od~BGT binding sites were not found on normal 
lymphocytes in this study. However, the number of sites may be 
very small so as to be undetectable in binding studies. Morrell 
(1979, 1981) was similarly unable to detect OC -BGT-binding, 
although such sites were apparently present on lymphocytes of 
untreated MG patients and patients who do not respond to steroid 
therapy. The MG-specific receptor might represent a 
structurally different type that binds OC-BGT. These findings 
imply a novel role of steroid in controlling the expression of 
the protein. It would be interesting to use the lymphocytes 
from these two groups in the functional assays described by 
Richman and co-workers (1979; 1981) and Mizuno et al., (1982a)
to see if they behave differently.
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The situation is complicated by the finding that a functional 
nAChR may reside on a particular T cell subset (Richman et al., 
1981; Mizuno et al., 1982b; Menard and Rola-Pleszczynski,
1983) and that this may be of the suppressor type (Richman et 
al., 1981; Mizuno et al., 1982b; Menard and Rola-Pleszczynski, 
1983). This subset clearly would represent a small proportion 
of the total lymphocyte population and detection of DC -BGT 
binding sites on such a population would be difficult. Hence 
fractionation of lymphocyte populations prior to their use in 
binding assays may be more enlightening.
The evidence for the presence of AChR in the thymus, 
demonstrated either by iodinated 0<L-BGT or by immunoreactivity 
with anti-AChR antibodies, is now overwhelming. However, the 
exact situation is not known and needs to be clarified. It is 
possible that the GC-BGT binding components are neither 
functional nor typical AChRs; such components are known to 
exist in the brain (see Introduction, Section 3.6). Further­
more, a variety of cell types exhibit both -BBT binding and
anti-AChR antibody cross-reactivity and it is not clear whether 
these properties belong to the same protein entity. Double 
labelling techniques, using, for example, rhodamine labelled OC 
-BGT and fluorescein-conjugated second antibody to detect 
anti-AChR antibodies along with well characterised fractionated 
thymic cell populations may help resolve this question.
The function, if any, of thymic AChR is not known. Pizzighella 
and co-workers (1982) have suggested that the receptor is
253
involved with cell proliferation, as an anti-AChR binding site 
directed Mab was able to reverse the inhibition produced by the 
effects of succinylcholine on the spontaneous uptake of [3H]- 
thymidine by mouse thymocytes. The data also suggested a link 
between the receptor and cAMP production. This second messenger 
is normally associated with hormone receptor systems and has not 
previously been linked to AChRs. Of interest here, is the
finding that thymopoietin, a polypeptide hormone of the thymus,
can bind to and compete with, the oc-BGT binding site of AChR 
prepared from T.califomica (Venkatasubramanian et al., 1986).
Whether thymopoietin is the native ligand of thymic AChR is not 
known. However, this peptide hormone is able to induce the 
differentiation of prothrombocytes to thymocytes and to regulate 
the functions of T lymphocyte (Venkatasubramanian et al., 1986), 
systems which most likely function through cell surface 
receptors.
The presence of mAChRs on lymphocytes has been described by many 
authors, using both binding and functional assays (see Table 41 , 
page 255, Richman and Amason, 1979, 1981; Strom et al., 1981). 
In the present work mAChRs were detected on murine erythrocytes 
and thymocytes and this appears to be the only report of 
[ 3 H]-QNB binding to these murine cell types. It is,
therefore, difficult to make a direct comparison of the results
obtained. However, some observations can be made with respect 
to the findings of other workers. A single high affinity 
binding site for [3H]-QNB on thymocytes was observed in this 
work (Results, Section D2.2.1) and this is similar to the
2 5 4
findings of Gordon et al., (1978) using mouse spleen cells 
(Table 41 > page255 )• It would appear, however, that the 
muscarinic receptors are present at a one thousand fold lower 
density on spleen cells than on thymocytes. The majority of 
other workers have also shown that T cells possess more mAChRs 
than B cells (Shapiro and Strom, 1980; Strom et al., 1981) and 
that stimulation by the mitogen PHA, specific for T cells, can 
cause an increase in [^HH-QNB binding (Szelen^/i et al., 1987). 
However, Atweh et al., (1984) found higher binding to B cell 
preparations than to T cells. Moreover, they detected two 
[ H]-QNB binding sites on mouse spleenocytes of much lower 
affinity than that found in the present study or in that of 
Gordon et al., (1978). One of the sites reported is of a 
similar Kd to that observed for [^Hj-GNB binding to mouse 
erythrocytes found in this work and although erythrocyte 
contamination of the spleen cell preparation was reported to be 
low, a binding site on the red cells may have been detected. The 
low affinity binding sites observed by Atweh et al., (1984) also 
showed mixed muscarinic and nicotinic pharmacology, a property 
shared with the high affinity site reported to be present on 
human erythrocytes by Aronstram and co-workers (1977). The 
significance of muscarinic cholinergic receptors on erythrocytes 
is unclear. In the present study, [3H]-QNB binding sites were 
detected on mouse erythrocytes but not on human erythrocytes. 
This latter finding is in contrast to the high affinity site (Kd 
InM) found by Aronstram et al., (1977) on human erythrocyte 
ghosts. However, it is likely that such a high affinity site
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Table 41 Binding of C H3-QNB to Leucocyte Populations






Bmax (sites/cell) Reference 
52 x 10 




Gordon et al., 
1978

























Lopker et al., 
1980
Q HumanI cells
















All studies were carried out using whole cells unless otherwise 
stated.
N.D. not determined in publication, 
a using T cells activated by Concanovalin A
b no binding observed over the range 0-200nM C^HD-QNB
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would not have been detected in this present study because of 
the concentration range of [3H]-QNB employed. Similarly, a low 
affinity site found in this work would not have been detected in 
Aronstram's study.
Investigation of [3H]-QNB binding sites on human PBLs in the 
present study gave a curvilinear Scatchard plot suggesting 
either the presence of multiple binding sites or co-operativity. 
The data, however, were consistent with a two site model by 
computer analysis and although, in inhibition studies, atropine 
failed to distinguish between the two sites, Hill plot analysis 
suggested a lack of co-operativity (Results, Section D2.2.3). 
Further studies examining association and dissociation rates 
would help to provide further support for the presence of two 
populations of receptors. Positive co-operativity has 
previously been demonstrated in QNB binding studies to human 
phagocytes (Lopker et al., 1980).
The high affinity [3H]-QNB binding site, Kd = 69nM, observed on 
human lymphocytes in this work corresponded closely to that 
observed by Zalcman et al., (1981) although the low affinity 
site was not observed by these workers. Other workers have 
similarly found high affinity [3H]-QNB binding sites, not only 
on lymphocytes but also on human granulocytes and monocytes 
(Table 41 )• The presence of two mAChRs which are functionally 
active at different carbamylcholine concentrations has been 
described by Richman and Amason (1979) in in vitro lymphocyte 
proliferation studies. The receptors appear to be active at
25?
O.lnM and l^ JlM carbamylcholine concentrations. Although these 
concentrations do not correspond to the binding affinities found 
here, this may be due to the approaches used and the differences 
in the affinity of the receptor for various cholinergic ligands. 
Electrophysiological experiments, using murine T lymphocytes 
have also shown that a wide range of concentrations of ACh and 
carbamylcholine can produce changes in membrane potential, 
effects abrogated only by the muscarinic antagonist atropine and 
not by nicotinic agents. Maximum responses were observed using 
lOnM ACh and InM carbamylcholine although higher concentrations 
of ACh and carbamylcholine were also effective.
Muscarinic cholinergic stimulation of lymphocytes appears to 
result in an increase in cGMP levels (Szelenyi et al., 1987) and 
this increase has ben shown to be directly involved in other 
muscarinic lymphocyte responses; augmentation of mitogen- 
induced DNA synthesis and cytotoxicity. Changes in Ca24* 
concentration are also implicated in these responses and indeed 
carbamylcholine binding to mAChRs on lymphocytes appears to open 
voltage insensitive calcium channels, accounting for the 
changes in membrane potential observed by Shapiro and Strom 
(1980). It would therefore appear that the mAChR on lymphocytes 
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IC50 values (M) of [3H]-QNB displacement bv 
atropine in lymphocyte studies
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The IC50 value obtained in this study for the displacement of 
[3H]-QNB binding by atropine compared well with those obtained 
by the majority of other workers (see Table 42 )* although 
strict comparison is difficult because of the different assay 
protocols used. However, it is evident that the muscarinic 
binding sites on lymphocytes have a much lower affinity for 
atropine and [3H]-QNB than muscarinic binding sites found in 
brain (Marks & Collins, 1982, Table 42 )• mAChRs, in general, 
are functionally diverse and it is now emerging that there are 
distinct subtypes of mAChRs. The collective data (Table 42 ) 
suggest also multiple types of mAChRs with different affinities 
for [3H]-QNB, and the possibility exists that the binding sites 
are not homeogenously distributed and that they may be present 
on different lymphocyte populations.
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The majority of workers have used intact lymphocytes in [3H]-QNB 
binding studies (Table 41 )• Intact cells were used in this 
work as the preparation was simple and quick. However, later 
studies using hypertonically lysed lymphocytes gave four times 
less C^H]-QNB binding than the parallel study using whole cells 
(Results Section D2.6). Two other groups have also reported 
similar results; Adem et al., (l986b) reported a seven fold 
reduction, whilst Atweh et al., (1984) showed a five fold 
reduction of ONB binding to membrane fractions compared with 
whole cells. In the present work, the binding of [3H]-QNB to 
whole lymphocytes was found to be saturable and displaceable. 
Nevertheless the findings overall would suggest that an uptake 
of ^Hj-QNB by the intact cells could have occurred, in addition 
to ligand binding to the membrane. Gossuin et al., (1984) has 
described trapping of ligands within neuroblastoma cells.
The results found in this present study obviously indicate a 
change in Bmax values following cell lysis; whether a 
concomittant change in kd also occurred was not investigated.
Two groups have demonstrated slight reduced but not 
significantly different kd values using membrane fractions 
rather than whole cells (Lopker et al., 1980; Adem et al., 
1986b see Table41 ) and also changes in IC50 values (Adem et 
al., 1986b Table42 ). As two [^H]-QNB binding sites with high 
and low affinity were demonstrated on intact human lymphocytes 
in this work, the effect of lysis on the presence of these sites 
remains to be investigated.
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[ H]-nicotine provided an alternative probe for nAChR on human 
lymphocytes. The initial characterisation of [3H](-)-nicotine 
binding to human PBL by Scatchard & Hill plot analysis was 
encouraging and indicated that neither positive nor negative 
cooperativity or multiple sites were present (Results, Table 35)- 
Additionally, the binding observed gave kd values compatible 
with the concentrations quoted in functional studies by Richman 
et al., (1981; InM) and Mizuno et al., (1982a; 5-50nM).
However, it was only by further analysis of this binding by 
inhibition studies and finally using lymphocyte membranes 
instead of intact cells (Results, Section D2.6) that the 
'binding' of [^H]-nicotine appeared to represent accumulation of 
trapped ligand within the cells.
The evidence leading to this conclusion, comparison of these 
findings with those of other workers and the consequences of 
nicotine accumulation within the cells will be discussed here.
Two other groups have used [^H]-nicotine in the study of binding 
sites on human lymphocytes (Davies et al., 1982; Adem et al., 
19863)and leucocyte fractions (Davies et al., 1982) and the 
results are compared in Table 43 • The 'binding' observed in 
the present study gave similar kd values to those found by 
Davies et al., (1982), but the Bmax value obtained here was ten 
fold higher than that quoted by Davies et al., (1982) and more 
closely resembled the Bmax value for human monocytes (see 
Table43)- The monocytes fraction represented approximately 1Z/. 
of a typical lymphocyte preparation (Results, Table 32 ) and
261
Table 43 Binding of [ H]-nicotine to leucocyte populations
Stereoisomer of 




















63 130 x 103 Thesis
Davies et
3 0 + 5  1 8 + 4X 103 al., 1982
36+ 28 87+ 61xl03
38 ±10 74 ± 50x101
This
40 450 x 103 Thesis
Hoss et
168 + 2.9 65+17x103 al., 1986
7.7+ 1.6 48 x 103
Adem et
6 - al., 19860
Human Lymphocyte This
Membranes - NO BINDING OBSERVED Thesis
Murine This
Thymocytes - 136 3.4 x 10^ Thesis
amean of all binding data see Results, Table 35
N.G. not quoted in publication
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this may account for part of the difference in Bmax values 
obtained. In the studies by Davies and co-workers (1982), 
binding of [3H]-nicotine was carried out by using whole cells; 
binding to leucocyte membrane fractions was not examined. Both 
the present study and the work of Davies et al., (1982) contrast 
with the results of Adem et al., (1986) where non-saturable
o
binding was observed over the range 5-60nM [ H]-nicotine using 
intact lymphocytes whereas using lymphocyte membrane fractions a 
high affinity site was demonstrated. In the present work, no 
binding to membrane preparations was detected.
Several other properties of the 'receptor' system studied in 
this work differed from those described previously by other 
groups. Firstly, the 'binding' observed here showed little 
stereoselectivity, with the (+) enantiomer being only slightly 
more potent than the (-) isomer. These findings are in sharp 
contrast to those with the nAChR of brain, which is known to be 
stereoselective for the naturally occurring (-) isomer; (+) 
nicotine being generally 80 times weaker in competition studies 
(see Wonnacott, 1986). This leads to a 2 fold difference in kd 
between racemic mixture and [3H3(-)-nicotine. Similar 
differences in kd values, when using optically pure and racemic 
radioligand mixtures, have been obtained by Hoss et al., (1986) 
studying the nicotine receptor on granulocytes. However, in 
this case, the receptor appears to be selective for the (+) 
isomer of nicotine (Hoss et al., 1986; see Table 43 , page261.
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The present study also demonstrated a discrepancy of 
approximately four orders of magnitude between the observed kd 
for [3H](-)-nicotine binding to intact lymphocytes and the Ki 
value obtained for inhibition by (-) nicotine.
Parallel experiments, using rat brain P2 membrane, gave good 
correlation (Results, Section D2.4.1). It has been shown that, 
for the accurate determination of Ki values, it is important 
that the concentration of receptor sites should not exceed 107. 
of the kd for the labelled ligand (Jacobs et al., 1975). These 
conditions were met in this study, where the observed kd was 
60nM and the range of concentration of 'sites' was approximately
0.5-0.9nM. Other workers have shown good correlation between 
IC50 values and kd values (see Table42 and44 ) using intact 
neutrophil (Davies et al., 1982) and granulocyte populations 
(Hoss et al., 1986) and human lymphocytes membranes (Adem et 
al., 19863).
The pharmacological profile of the 'binding' site on human
lymphocytes obtained by inhibition studies demonstrated non-
cholinergic properties, in that classical nicotinic agonists
failed to compete for [3H] (-)-nicotine binding (Results, Section
D2.4.2). Similar non-choiinergic properties of a nicotine
binding site have also been described by Davies et al., (1982)
on human phagocytic leucocytes and by Hoss et al., (1986) on
human granulocytes. Nicotinic antagonists, in general, are
known to be weak inhibitors of [3H](-)-nicotine binding to
-5
central nAChRs and IC50 values of greater than 5 x 10 M have
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Table 44 1C50 values for nicotine inhibition
Nicotine Stereoisomer of 
Cel Is Isomer C^H]-nicotine used IC50 Reference
Human _ ^  This
Lymphocytes - - 1 x 10 Thesis
Human _5 This
Lymphocytes + - 5 x 10 Thesis
Human
Neutrophils - + 8-0 x 10 Davies et
+ - 2.8 x 10'* al., 1982
Human
Granulocytes - + 5.2 x 10"’<* Hoss et
+ + 5 x 10“* al., 1986
Human
Lymphocytes Adem et
Membranes N.G. N.G. 2 x l O  al., 19863
N.G. Not quoted in publication
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been reported for d-tubocararine and the muscarinic antagonist
atropine and both these drugs showed weak but similar inhibition
of [ H](-)-nicotine 'binding' to human lymphocytes (Results,
Table 36 )- Adem et al., (19863) have also demonstrated
inhibition of C^H]-nicotine binding to human lymphocyte
-4-
membranes by atropine (IC50 3 x 10 M) and d-tubocurarine (IC50 
— to
2 x 10 M). However, a full pharmacological profile, including
nicotinic agonists was not quoted. A third nicotinic antagonist 
dihydro-^-erythroidine, known to be a potent competitor for the 
central nAChR, also gave weak inhibition. However, all the 
drugs that inhibited showed similar IC50 values, indicating a 
non-discrimatory receptor site.
It would appear from these studies that a pyrrolidine ring 
structure was critical for inhibition; this structure being 
common to nicotine, atropine and dihydro-p -erythroidine. This 
was further suggested by the lack of inhibition by
2-methylpiperdine but inhibition by pyrrolidine and proline 
(Results, Section D2.4.2). For structures see Appendix 1. 
Nicotine, at the pH of the assay system, would exist in a 
monoprotonated form and the presence of the basic N atom may 
also be an important consideration, since d-tubocurarine does 
not contain the pyrrolidine ring structure but is diprotanated.
a
The observed Kd values obtained for F'H](-)-nicotine 'binding' 
to human lymphocytes was verified by the study of association 
(K + ) and K - 1) dissociation constants (Results, Section 
D2.3).
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Neither of the groups discussed above have used this method to 
verify the Kd values observed, so a comparison is not possible. 
Kinetic parameters have, however, been analysed for brain nAChRs 
(Marks and Collins, 1982). Association rates are mainly 
dependent on the rate of diffusion of the radioligand to the 
receptor site and the kinetics of [ H](-)-nicotine binding to 
lymphocytes could be described as a single first-order process. 
The dissociation rate is obviously affected by temperature and 
it is thus difficult to compare values for K-l at temperatures 
different to the one used in this work. However, the 
dissociation rate observed in the present work (K - 1 = 0.35
-I
min ) was similar to that quoted by Marks and Collins, (1982;
. -I
K - 1 = 0.282 3 0.048min ) for mouse brain nAChR. Human
neutrophils also appear to display apparent first order off rate 
kinetics with a tl/2 of approximately 20min, (Davies et al.,
-i
1982), corresponding to a k - 1 = 0.034min ) using the equation
k - 1 = 0.693/tl/2 (see Bennett, 1978), but this was carried out 
o
at 4 C.
There are, however, differences in the dissociation curves; in 
the study of Marks and Collins (1982) less than 107. of the 
radiolabel was remaining after 10 min whereas in this present 
study approximately 457. of the ligand remained over the same 
time period at the same temperature. Similar results were 
obtained by Maslinski et al., (1980) using [ H]-acetylcholine as 




If the observed 'binding' of [ H](-)-nicotine represents the 
influx of [ H3(-)-nicotine into the lymphocytes, how can one 
account for the saturation curves, dissociation, association 
kinetics and inhibition curves? Firstly, if all the tests are 
carried out in the presence of the same cold competing ligand 
which has the same properties as the radioligand then specific 
binding is observed in-the same way as binding to membrane 
receptors except that uptake is measured. Hence the parameters 
being measured were Km and Vmax for the influx of 
r^H](-)-nicotine. The association rate represents the time 
necessary for the influx of [3H](-)-nicotine into the cells, 
whereas the dissociation rate probably represents the 
equilibration of cold nicotine outside and labelled nicotine 
inside; hence full dissociation was not observed, and was only 
observed to a maximum of approximately 50*/. (Results, Section 
D2.3.2d). The initial dissociation rate observed would hence 
represent the rate of flux of cold and labelled nicotine.
Inhibition curves would be observed because as the concentration 
of competing cold nicotine was reduced, more radiolabelled 
nicotine would enter. Similarly, other molecules which have 
properties in common with nicotine would behave in the same 
manner.
The pharmacological profile of this 'site' on human lymphocytes 
was similar to that described by Davies et al., (1982) on human 
phagocytic leucocytes in that both showed non-choiinergic 
properties and specificity for the pyrrolidine ring structure.
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The same properties were also observed for human granulocytes in 
the present study, a system directly comparable to that 
described by Hoss et al., (1986). In the latter study and in 
the work presented here, the binding of [ H](-)-nicotine to 
granulocyte membranes was not studied. These studies would help 
confirm that true binding of radioligand was being observed and 
not uptake as demonstrated in the present study using intact 
human lymphocytes.
The final experiments, using lysed lymphocytes, did indeed 
indicate that the 'binding' of [ H](-)-nicotine to human 
lymphocytes was uptake of radioligand. The process, however, 
appeared not to be an active process as it was not affected by 
low temperature (Results, Table39 ). This could have been 
further verified by the use of sodium azide. Interestingly 
there was no binding to human erythrocytes which could control 
for the lymphocytes acting as membrane sacs. However, whether 
this uptake is unique to lymphocytes is unclear. Heat 
inactivation studies can provide information on the physical 
state and environment of ligand binding sites and in this study 
binding or uptake was found to be highly thermolabile, a finding 
not surprising as denaturation of the lymphocyte membrane and 
reduction of cell volume with higher temperatures would reduce 
uptake.
Nicotine is a hydrophobic molecule and would readily seek the 
membrane environment. However, it would appear from these 
results that the ligand penetrates the membrane readily.
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Nicotine has previously been shown to affect cell membranes and 
electron-spin resonance studies have demonstrated that 
(-)-nicotine can produce perturbation of granulocyte membranes 
at micromolar concentrations (Gala et al., 1984). Nicotine also 
causes aggregation of human blood platelets (Merle and 
Schievelbein, 1965), and here nicotine was thought to enhance 
the permeability of the platelet membrane by changing its 
charge. Nicotine has also been shown to be a chemotactic agent 
for neutrophils and enhances neutrophil responsiveness to 
chemotactic peptides by a process which is thought to affect 
membrane fluidity (Totti et al., 1984).
The uptake of nicotine by lymphocytes also has consequences for 
the smoking habit as nicotine is known to reach plasma 
concentrations of 3Q-300nM in cigarette smokers; levels at 
which, according to results shown here, nicotine uptake would 
occur. Two groups have studied the suppressive effects of 
nicotine in lymphocyte responses to the mitogen PHA (Neher,
1974; Menard and Rola-Pleszcznski, 1983). In the latter study, 
effects were observed as nM concentrations, and could be blocked 
by the addition of myasthenic serum. In this study no
O
inhibition of [ H](-)-nicotine uptake was observed using 
polyclonal or monoclonal anti-(AChR) antibodies. The effect of 
nicotine appears to be primarily an DNA synthesis and not on the 
process of lymphocyte stimulation or cell survival, (Neher,
1974). Hence, it would appear that smoking can adversely 
affect the immune response.
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Cross-reactivitv studies using Solid Phase 
Radioimmunoassay and ELISA techniques
The cross-reactivity of anti-(AChR) antibodies with human PBL 
was studied using Solid Phase Radioimmunoassay and ELISA 
techniques. These methods required the preparation of fixed PBL 
coated plates.
1.1 Preparation of fixed PBL coated plates
The preparation of fixed PBL coated plates provided the common 
target material for the Solid Phase RIA procedure and ELISA 
technique and will thus be described first.
PBLs were prepared as described in Methods, Section Dl.
The cells were washed twice with PBS containing 27 (w/v) BSA and
o
0.00Z/. (w/v) sodium azide by centrifugation (200g, 10 min, 23 C)
and were finally resuspended in the same buffer to 2 x 10
cells/ml. Samples (100yjll) of this cell suspension were added
to each well of microtitre plates which had previously been 
©
incubated (lh, 23 C) with Concanavalin A (Con A) solution
(lmg/ml, 100yjLl/well) and washed twice with PBS. Following 
o
incubation (2h, 37 C) of the cell suspension with the Con A 
coated plates, 100jxl of (v/v) 0.05"/. glutaraldehyde in PBS (100
o
yu.1) was added and the plates were left for 15 min at 23 C.
After this period the plates were washed three times with PBS
o
and incubated (30 min, 23 C) with 0.1M glycine containing 0.17. 
(w/v) BSA. The wash step was repeated and culture medium 
containing 107 (v/v) FCS (IOOju.1) was added to each well andro
incubated (lh, 37 C). The plates were then either stored at
2?2
O
-20 C or used immediately.
1.2 Solid Phase Radioimmunoassay
The technique involved the use of iodinated Protein A to detect 
the binding of anti-(AChR) antisera to fixed PBL coated plates.
1.2.1 Iodination of Staohv1ococcus aureus Protein A
125Protein A Mas labelled with [ I] by the chloramine T method 
(Hunter, 1967) as modified by Urbaniak et al., (1973). 
Preparation of the Protein A prior to iodination was carried out 
as described by Hudson & Hay (1976). Protein A (0.57. (w/v) in 
200JJJ distilled water) was added to 0.12M carbonate-bicarbonate 
buffer, pH 9.0 (BOOyuJ.) and a solution of dioxane containing
lOmg/ml hydroxyphenol succinimide (10 ul). The mixture was
o *
incubated (25 min, 23 C, with occasional mixing), and then
o
dialysed against PBS (2L, 16h, 4 C). Protein A, so treated, was 
iodinated by the same method used for the iodination of OC-BGT 
(Methods, Section Al.l).
1.2.2 Determination of the biological activity of
[125 13-Protein A
125The biological activity of [ 13 Protein A can be assessed by
its ability to bind IgG. However, Protein A does not form a 
precipitable immune complex and it is necessary to immobilise 
the IgG onto a solid support such as nitrocellulose paper or 
Sepharose beads. These methods were used to assess the
195biological activity of the C*--'13-Protein A preparations.
Human IgG (2mg/ml) was spotted (lyj-l volume) onto nitrocellulose 
paper circles, which had been equilibrated in the dilution
2?3
buffer 50mM Tris-HCl buffer, pH 7.4 containing 200mM NaCI to
give the range of concentrations 10ng/ yjil, lOOig/yw.1, lyjig/yull
and 2^JLg/yuU. BSA at the same concentrations was used also to
spot the nitrocellulose paper in order to determine non-specific
binding. All dilutions were made in the dilution buffer. The
o
paper circles dotted with immunoglobulin were dried at 37 C for
10 min and then incubated with a range of dilutions of
[125i]-Protein A (1/10, 1/50, 1/100 in dilution buffer, lOOyml).
o
Following incubation (2h, 37 C), with occasional mixing, the 
paper circles were washed extensively with the dilution buffer, 
dried and then counted for radioactivity.
The second method used rabbit-IgG conjugated to Sepharose beads.
Increasing amounts of rabbit IgG conjugated to ACA-22 beads
(200 ul; 1 jxl of beads corresponding to 575ng of rabbit IgG)
°were incubated for 90 min at 37 C with C 13 Protein A 
(O.lnmol, 100ljlI). The beads were then washed with PBS (2 x
'  o
3ml) by centrifugation (high speed, 4 C, 5 min; Beckmann 
microfuge) and the radioactivity bound to the beads was 
determined. Non-specific binding of ^25 j]-protein A was 
determined by using non-IgG conjugated ACA-22 beads.
1.2.3 Solid Phase Radioimmunoassay protocol
The fixed PBL-coated plates (Section Dl.l) were washed twice
with PBS before the addition and incubation of diluted serum or
©
antiserum (lOOyuil/well; 2h, 37 C). The antisera used were
rabbit anti-(Torpedo AChR) (designated T), two rabbit 
anti-(fetal calf AChR) antisera (designated FI & F2), rabbit
2?4
anti-human IgG, rabbit anti-BSA and W3S. All dilutions of the
sera were made in wash buffer (PBS containing 2% w/v) BSA and
0.002% (w/v) sodium azide). Tests were made in triplicate for
each dilution and some wells were incubated with wash buffer
only to assess background values. After incubation, the plates
were washed three times with wash buffer and I] Protein A
o
(lOOyjLl/well) was added and left for 90 min at 4 C. The plates 
were then washed six times with wash buffer and the individual 
wells were cut up and counted for radioactivity.
1.3 ELISA using fixed PBL coated plates
The method is exactly the same as that used for the Solid Phase
RIA except that the binding of antisera to the fixed PBL was
detected by the means of an enzyme-labelled second antibody
(alkaline phosphatase conjugated goat anti-rabbit IgG; lOOyxl/
well, diluted 1/1000 in PBS containing 2% (w/v) BSA). After
o
incubation (90 min, 23 C) the plates were extensively washed 
with the above buffer and substrate solution (100ynl; lmg/ml 
p-nitrophenylphosphate in 0.1M glycine buffer pH 10.4 containing 
additionally ImM MgClZand ImM ZnClZ) was added. The absorbance 
at 405nm was read after 30 min using a Titretek ELISA reader.
2. ImmunopreciDitation of iodinated PBL membranes bv 
anti-(AChR) antisera and Mabs
Human PBL were iodinated using a lactoperoxidase-catalysed 
reaction and the iodinated membranes solubilised and used in 
immunoprecipitation assays with anti-(AChR) antisera and Mabs.
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2.1 Lactoperoxidase-catalysed iodination of lymphocyte plasma 
membranes
Normal PBL (viability >957.) were isolated as described in
Methods, Section D1 and were washed 3 times by
centrifugation (200g, 10 min) using PBS to remove extracellular
protein. PBL (5 - 10 x 10^celIs) were then finally resuspended
o
in PBS (150^x1) and placed in a water bath at 30 C.
Lactoperoxidase solution (0.25mg/ml/PBS, lOjxl) was then added, 
followed by the addition of PBS (20jud) and Na C^^I] (lOyxl, 
lmCi). The lactoperoxidase-catalysed iodination reaction was
started by the addition of H202 ( 0.037. (v/v)/ PBS, lOyxl),
followed immediately by vigourous mixing. The reaction mixture
o
was then incubated (4 min, 30 C) before the addition of H202
(0.037. (v/v) in PBS, 10^x1). The incubation step and the
addition of H202 was repeated once more, before the reaction was
o
terminated by adding PBS (5ml, 4 C). The reaction mixture was
o
centrifuged (200g, 10 min, 4 C) and the resulting supernatant
was collected. The lymphocyte pellet was washed with PBS (5ml, 
e
4 C), centrifuged as before, and again the supernatant was 
collected. Samples ( 5 jjl1) of the two resulting supernatants were
125kept for counting in order to estimate free [ I]. The
o
lymphocyte pellet was resuspended in PBS (1ml, 4 C) and a sample 
(5jj.l) was taken for counting to assess the radioactivity 
associated with the lymphocyte membrane.
1252.2 Solubilisation of C I]-lymphocytes
175The C I]~lymphocytes were solubilised by using the detergent
o
Nonidet-P40 (NP-40). All manipulations were carried out at 4 C.
2?6
The iodinated lymphocyte suspension was again centrifuged (200g, 
o
10 min, 4 C) and to the pellet was added 0.057. (w/v) NP-40 in
lOmM Tris/NaCl buffer pH 7.2 containing the protease inhibitors,
lOmM EDTA, 20mM iodoacetamide and ImM PMEF. The solubilisation
step was carried out for a total of 30 min with vigorous mixing
every 10 min. The mixture was then centrifuged (high speed, 5 
o
min, 4 C, Beckman bench centrifuge) and the supernatant was 
removed and tested for trichloroacetic acid (TCA) insoluble 
radioactivity.
2.3 Trichoroacetic acid precipitation
Prior to TCA precipitation, the extract was diluted (1/100) in 
PBS containing 57. BSA (w/v). Samples (100 jXl) of the diluted 
extract were added to 107. (w/v) TCA solution (100yU) and left 
to incubate for 90 min at room temperature. The solutions were 
then filtered through GFC filters and the filters were washed (2 
x 5ml) with 57 (w/v) TCA. The filters were then dried and 
counted for radioactivity.
The percentage incorporation of radioactivity into protein was 
then calculated as follows
7 incorporation = cpm filter after TCA precipitation x 100 
cpm of 1.00jx 1 (1/100 labelled membranes)
2.4 Immunoprecipitation assay
This assay used Eppendorf tubes which had been incubated (24h, 
o
37 C) with 17. (v/v) normal serum in PBS from the same species as 
the origin of the second immunoprecipitating antibody. The 
tubes were then washed 3 times with PBS.
2??
The iodinated lymphocyte membrane extract was diluted (1/5-1/10) 
in NP-40 washing buffer comprising 0.05’/. (w/v) M3-40, 0.05 M 
Tris-HCl buffer, pH 7.2 containing 0.15M NaCl, 5mM EDTA, 17.
(w/v) casein, lOmM KI and 0.027 (w/v) sodium azide and incubated
o S
(overnight, 4 C) in 100 J^Ll volumes (representing 5 x 10
iodinated PBL) in a final volume (500yjJ) with control or test
antibody.
Cross reactivity studies were carried out by using Mab culture 
supernatants (200^jl1) from Bll, C7, Cll, E8 and Ell. Here,
MIS (10jxl) was added as a carrier protein. Ascites fluid 
(10^1) from Mabs Bll, C7, Cll, E8 and Ell were also used, with 
anti-neurofilament and anti-BSA ascites fluid and MIS as 
controls. The cross reactivity of rabbit anti-(AChR) antisera 
(5^ jl1) FI, F2 & T was also studied using anti-BSA and 
anti-(human FatyJL ) as controls.
Immunoprecipitates were formed after the addition of appropriate
second antibody (goat anti-mouse IgG, 70^11; goat anti-rabbit
o
IgG, 135yuQ) and an incubation period of 2h at 37 C. The
immunoprecipitates were collected by centrifugation, washed
three times with ice-cold washing buffer (3 x 1ml, high speed, 2 
o
min, 4 C, Beckman microfuge) and then counted for radioactivity. 
All determinations were made in triplicate.
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RESULTS
1. Solid Phase Radioimmunoassay
1.1 Iodination and biological activity of Protein A
1.2 Cross-reactivity studies using polyclonal anti-(AChR) 
antisera
2. Cross-reactivitv of anti-AChR antisera by ELISA
3. Immunoprecipitation studies
3.1 Iodination of lymphocyte membranes and extract preparation
1253.2 Immunoprecipitation of [ I]-PBL membrane extract by 
anti-(AChR) antibodies
279
This section examines the cross-reactivity of both polyclonal 
anti-(AChR) antisera, Tl, FI and F2 (see Sections B and C) and 
the Mabs C7, Ell, Bll, Cll and E8 with human PBL.
The studies using polyclonal antisera were carried out before 
the availability of the Mab probes and cross-reactivity was 
assessed by Solid Phase RIA using iodinated Protein A and ELISA 
using enzyme conjugated second antibody as detecting signals.
1. Solid Phase Radioimmunoassay
This method used fixed human PBL (Methods, Section El.l) as 
targets for rabbit-anti-(AChR) antisera and control rabbit 
sera.
lot:
[  ^ I]—protein A was used to detect any binding of the rabbit 
serum samples to the PBL.
1.1 Iodination and biological activity of Protein A
125The elution profile of Protein A from the G25 Sephadex
column (Methods, Section El.2.1) was similar to that shown for 
the iodination of O0-BGT as shown in FigureS(Results Section 
A1.1). Three iodinations of Protein A were carried out and each
125gave 93-947. incorporation of [ I] (see Table45 )• However, 
retention of biological activity after treatment with the 
oxidising agent chloramine T, used during the iodination process
125was a problem. The first preparation of [ 13 Protein A proved
to have a low biological activity (37.) (see Table45 )• The 
iodination protocol was, accordingly modified for the two
Table 45 Iodination of Protein A
Iodination Ratio Protein A (nmoles) Reaction time Specificity % incorporation Biological 
No. 126 I -Na(mCi) with Activity of *iSI Activity
Chloramine T Ci/mmol
1 0.475 nmoles/mCi 60 secs 1980 94% a3%
2 3.80 nmoles/mCi 30 secs 246 93% a>16%
3 4.75 nmoles/mCi 30 secs 198 94% ^69%
a The biological activity of the preparations was assessed using immobilised human IgG on 
nitrocellulose paper (Methods, Section E 1.2.2)
b The biological activity was determined using Rabbit IgG conjugated to ACA-22 beads 
(Methods, Section E 1.2.2)
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following iodinations. These modifications involved reduction 
of the reaction time (60S - 30S) between the protein and
['■L-'I]-Na in the presence of chloramine T, and also increasing
125the Protein A to [ IHJa ratio, from 0.475 nmoles/mCi to a 
maximum 4.75 nmoles/mCi. This resulted in a reduction of the 
specific activity of the preparations from 1900 Ci/mmol to 198 
Ci/mmol but increased the biological activity of the 
preparations (see next section).
125The biological activity of [ * I ]-protein A preparations 1 and 2 
was assessed by the binding of the diluted preparations to 
nitrocellulose circles dotted with known amounts of human IgG 
(Methods, Section El.2.2). Using this method, 13 Protein A 
from iodination 1 showed little binding to the human IgG 
(maximum 3/C of the total counts added using 2jjlq human IgG). 
Accordingly, this preparation was not used in the 
radioimmunoassay. However, preparation 2 had a much greater 
biological activity of greater than 16’/., using 2^tg human IgG 
(see Table 45 and Figure 51 a). It was, however, difficult to
accurately determine the biological activity of the iodinated 
preparations using this method; the binding of preparation 2 
was not saturating (Figure 51 a) and it was difficult to dot 
more immunoglobulin onto the circles. Because of this, an 
alternative assay method was used to determine the biological 
activity of preparation 3.
This method used rabbit IgG conjugated to ACA-22 beads and was 
advantageous because the amount of IgG used was simply a factor
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Figure 51 The Biological Activity of i] -Protein A
u—o
The biological activity of two £25 fj-protein A preparations,
(- - -, iodination 1; ------ iodination 2) were assessed by
incubating nitrocellulose circles dotted with varying amounts 
of human IgG with diluted [,2S i]-Protein A (-Q , 1/10; 1/50;











b. The biological activity of £25 f] -protein A (iodination 3) was 
assessed by incubating varying amounts of beads coated with 
rabbit IgG with diluted ['25IJ-protein A (1/50, equivalent to 
approximately 26,000 cpm) as described in Methods, SGCtiOH E 1.2.2
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of how many beads were used in the incubation step with
125[ I]-Protein A. This method gave a biological activity of 677.
4 or
for [ I]-Protein A preparation 2 (Figure 51 b).
1.2 Cross-reactivity studies using polyclonal anti-(AChR) 
antisera
1?^[ I ]-Protein A preparations 2 and 3 were used to detect the 
binding of anti-(AChR) antisera (T, FI and F2) to fixed 
monolayers of human PBL (Methods, Section El.2.3). Rabbit 
anti-(human IgG) antiserum provided a positive control, while 
NRS and rabbit anti-(BSA) antiserum were negative controls. The
125binding of [,L*'I]-Protein A to human PBL in the absence of sera 
was determined to control for binding to surface immunoglobulin 
on the PBL. Using PBL from four different individuals, this 
binding represented 0.52 i 0.17 (mean! S.E.) of the total 
radioactivity added.
The first cross-reactivity studies used serum samples at 
dilutions of 1/2 and 1/4 and the results are shown in Figures 
52a and b. The assay was reproducible; the errors between 
triplicates were small, being 0.1 - 2.57. of the specific cpm
bound. The binding of the antisera to human PBL was assessed by 
analysis of variance. The binding of antiserum FI to human PBL 
was not significantly different from that of NRS and rabbit 
anti-(BSA) sera, whereas the binding of antisera F2 and rabbit 
anti-(human IgG) gave significantly increased binding (p <0.01). 
The binding of the antiserum T was significantly different from 
the negative controls (p <0.01) in Figure 52 b only.
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Figure 52 Cross-reactivity of Rabbit anti-(AChR) antisera with 





































The cross-reactivity of the sera was determined at two dilutions 
(□,/£; E  , X) against fixed human PBL from two different individuals 
Binding was detected by [25 i] -Protein A (preparation 2; Figure a 
173264 cpm ) Figure b 140685 cpm was adde<$. Binding of f2SlJ-Protein A 
in the absence of sera was 1269 and 1490 cpm for figures a and b 
respectively).
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In titration curves (Figures 53 a and 53 b) the binding of 
antisera F2 and rabbit anti-(human IgG) was significantly 
different (p <0.01) from that of NRS and rabbit anti-(BSA) 
antisera at all the dilutions used.
The IgG concentrations of the antisera Tl, FI and F2 were 14.2, 
13.B and 12.B mg/ml respectively. The control sera NRS, rabbit 
anti-BSA and rabbit anti-(human IgG) contained 11.8, 13.1 and
12.4 mg/ml, respectively (determinations were carried out by a 
colleague).
2. Cross-reactivitv of anti-AChR antisera bv ELISA
The cross-reactivity of the anti-(AChR) antisera, FI. F2 and T 
with fixed human PBL from three different individuals was 
detected by an ELISA system as described in Methods, Section 
El.3. Errors for each determination made in triplicate 
represented 2.57. - 10V. of the optical density measured. For 
each PBL population studied antisera F2 gave higher binding than 
the other antisera and control sera, NRS and anti-(BSA) antisera 
(greater than three standard deviations of control binding; 
Figure 54 ).
3. Immunoprecipitation studies
125The extracellular surface of PBL was labelled with [ I] by a 
lactoperoxidase catalysed reaction (Methods, Section E2.1). The 
iodinated PBL were then solubilised by using detergent (Methods, 
Section E2.2) and then the ability of polyclonal and monoclonal
Figure 53 Cross-reactivity of Rabbit anti-(AChR) antisera F2 with 














Varying dilutions of NRS, (~0~); rabbit anti-(BSA), (-□-); 
rabbit anti-(human IgG), (-#-) and antisera F2 (-■-) were 
incubated with PBL from 2 different individuals (a and b). 
Binding was detected b y p 25 ij-protein A (preparation 3; 
figure a 133280 cpm; figure b 123180 cpm). Binding of 
[_aS Ijprotein A in the absence of sera was 720 and 1112 cpm 











Figure 5 4  Cross-reactivity of anti-AChR antiserum with 









ELISA wells coated with fixed human PBL from three different 
individuals; Figures a, b and c; were incubated with dilutions 
of NRS (-o-); rabbit anti-BSA, (-■-); antiserum FI (-X-); 
antiserum F2 (-#-); antiserum T (-□-). The plates were then 
incubated with alkaline phosphatase conjugated second antibody 
and developed as described in Methods, Section £ >.3.
Each point is the mean of a determination made in triplicate.
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anti-(AChR) antibodies to immunoprecipitate the iodinated 
membranes was assessed (Methods, Section E2.4).
3.1 Iodination of lymphocyte membranes and extract preparation 
Human PBL were iodinated by using a lactoperoxidase-catalysed 
reaction (Methods, Section E2.1). The lactoperoxidase enzyme 
cannot cross the plasma membrane of viable cells and only 
surface components are iodinated. Hence, only PBL preparations 
with high viability were used. The incorporation of C^^I] 
varied with each iodination (see Table 46 )> with 85-997. of
these counts present in the extract after solubilisation of the 
cell membranes. The incorporation of [!^I] into protein was 
determined by TCA precipitation (Methods, Section E2.3) and 
varied from 2-97. of the total radioacitivty of the extract.
1753.2 Immunoprecipitation of C I3“PBL membrane extract by 
anti-(AChR) antibodies
The ability of polyclonal and monoclonal anti-(AChR) antibodies
125to immunoprecipitate [ IJ-PBL membrane extracts was assessed 
(Methods, Section E2.4).
In experiments using polyclonal antisera only antisera F2 and 
rabbit anti-(human Fabym ) antisera gave binding significantly 
different from that of the controls (Table 47" )•
The initial experiments using Mabs used culture supernatants as 
the source of antibody. However, no differences between test 
and control supernatants were observed and it was decided to use 
ascites fluid, as this provided a much more concentrated form of
125antibody. In two experiments, using [ I]-PBL from two
Iodination
Number





% cpm Proportion of sample
extracted radioactivity bound
to protein
1 9.8 x 107 8% 95% 9%
2 6.5 x 107 5% 85% 2%
3 1 x 10® 25% 99% 8%
Tab! e 46 Summary from the Lactoperoxidase catalysed iodination of lymphocyte membranes
ro
QO
The values were determined as follows:- 'O
(a) cpm associated with cells as a % of the total cpm added
(b) cpm extracted as % of cpm associated with the cells
(c) TCA insoluble cpm as % of cpm of extract
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different individuals (preparations 1 and 3, Table 46 )» the 
Mabs C7, Bll and Ell gave binding significantly different 
(p<0.01) from that of the negative controls NMS, mouse 
anti-neuro filament and mouse anti-BSA (Figure 55 ).
i?c
Table lyj- ImmunopreciDitation of extract of human PBL
membranes by anti-(AChR) antisera
Serum Sample Binding (c.p.m.
Mean + S.E
Rabbit normal serum 5034 + 66
Rabbit anti-BSA 4909 + 101
Rabbit anti human FabyA ♦6107 + 203
Rabbit antisera FI 5374 + 32
Rabbit antisera F2 *6572 + 23
Rabbit antisera T 5420 + 24
1?5Rabbit serum samples were incubated with [ I]-PBL membranes 
(preparation 1. 006444 cpm total) followed by the addition of 
goat anti-(rabbit IgG) as described Methods, Section E2.4. 
Background counts were 5645 cpm. Results are the mean i S.E. 
of triplicate determinations. *Values significantly different 



















NMS C? E11 B11 C11 E8
The results shown are the mean from two immunoprecipitation 
experiments using [*l5l]-PBL preparations 1 and 3. Normal mouse 
serum (NMS), and the ascitic fluid anti-BSA and anti-nuclear 
filament were used as negative controls. Values significantly 
different from the control values were obtained with anti-(AChR) 
Mab ascitic fluid C7, Bll and Ell.
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DISQJ5SICN
Several groups have used polyclonal and monoclonal anti-(AChR) 
antibodies to investigate the presence of AChR epitopes on 
immune cells. However, the majority of these studies have used 
human (Horvat et al., 1983; Pizzighella et al., 1983; Kirchner 
et al., 1987) and mouse thymocytes (Fuchs et al., 1980; Horvat 
et al., 1983; Riviera et al., 1987) as target cells. The 
present study was primarily concerned with the presence of nAChR 
on human PBL which has been implicated by a number of studies 
(Table 48, page 292a).
Solid Phase Radioimmunoassay and ELISA techniques necessitated 
the use of immobilised PBL. Con A which binds to the surface 
glycoproteins of lymphocytes provided a reliable means of 
immobilising the cells onto mictotitre plates. Poly-l-lysine 
has also been successfully employed in Cell ELISA and this 
acts to increase the electrostatic attraction between the 
cells and the microtitre wells (Drover and Marshall, 1986). 
Fixation of the human PBL by a dilute solution of glutaraldehyde 
ensured no cell loss during the subsequent extensive washing and 
incubation procedures. However, because glutaraldehyde fixation 
has been shown to damage or destroy cell surface antigenic 
determinants, (Drover and Marshall, 1986), a dilute solution of 
glutaraldehyde and a short-fixation period were used, as 
recommended by Drover & Marshall, 1986 and references therein.
Iodinated Protein A provided a sensitive means of detecting 
cross-reactivity as Protein A readily reacts with all subclasses
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Table 48 Studies implicating the presence of nAChRs on human 
PBL
Functional Studies
Effect of nicotinic cholinergic 
ligands on PBL proliferation
Neher et al., 1974 
Strom et al., 1974 
Richman and Amason,1979 
Richman et al., 1981 
Menard and
Rola-Pleszcznski, 1983
Reversal by d-tubocurarine of the Mizuno et al., 1982a, b.
inhibitory effect of carbachol on 
E-rosette formation
Abrogating effect of OC -BGT on Whaley et al., 1981





Arimori et al., 1981 
Mischak and Dau, 1981
PC-BGT binding to PBL Morrell, 1979, 1981.
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of rabbit IgG (Richman et al., 1982). The conditions of the 
iodination reaction appeared to be crucial. Loss of activity in 
the first preparation may have resulted from chemical damage 
caused by the harsh oxidising conditions promoted by chloramine 
T.
Other workers have shown that limiting amounts of chloramine T 
relative to the protein concentration and a short reaction time 
are critical for the conservation of biological activity 
(Langone, 1980) and this was also observed in this study 
(Results, Table45 ). It appears that all four tyrosine 
residues of Protein A are necessary for maximum functional 
activity and that loss of Fc binding can result from the 
incorporation of more than one iodine atom per molecule 
(Langone, 1980). These factors could account for the low 
biological activity of preparation 1.
The use of beads coated with rabbit IgG proved to be a more 
precise indicator of the biological activity of the iodinated 
Protein A preparations than the immunodot method (Results, 
Section El. 1). The use of the former method was also more 
relevant to their subsequent use in detecting all human IgG 
subclasses (Richman et al., 1982). Hence, the use of this assay 
probably led to an underestimation of the biological activity of 
the first two iodinated Protein A preparations. Nevertheless, 
it was evident that the use of a modified iodination procedure 
for preparations 2 and 3 resulted in a concommitant increase in 
biological activity.
294
Both the Protein A and ELISA assays were reproducible and 
background noise, due to the binding of iodinated Protein A to 
Fc receptors on human PBL or cross-reactivity of conjugated 
second antibody with human PBL was negligible. Additionally 
there was no apparent problem with interference of the cell- 
coated plates with the measurement of optical density.
The immunoprecipitation studies provided another means of 
detecting cross-reacting epitopes on human PBL and was used as 
an alternative assay as the anti-(AChR) Mabs were of IgGl 
subclass; a mouse sub-class not detected by Protein A. A 
lactoperoxidase catalysed iodination of human PBL was chosen 
because it was the mildest iodination procedure available. It 
is a highly controlled procedure, dependent on the amount of 
peroxidase added and it labels only the external surfaces of 
lymphocytes provided that highly viable cells are used.
Only a small percentage of the total added [®25i] was associated 
with protein components (Results, Table 46 ). It is likely that 
the majority of the counts represent free [^ 25 j] with small 
amounts associated with glycolipid (see Johnstone and Thorpe., 
1982). These components were not thought to interfere with the 
use of solubilised iodinated PBL membrane in immunoprecipitation 
studies, but they could have been removed by gel filtration.
The choice of control sera in such cross-reactivity studies is 
important as the immunoglobulin concentration or spectrum of 
sera from animals which have been hyperimmunised against antigen 
is not the same as that found in normal serum. There is usually
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a significant increase in levels of IgG in immune sera. Hence, 
antisera raised against a non-AChR related antigen (anti-BSA) 
was used in the assays as an additional control and indeed 
slightly higher binding of anti-BSA antisera compared to NRS was 
observed in both solid phase RIA and ELISA assays (Results,
Table47 and FigureS2“54). For the same reasons, ascites fluid 
raised against antigens other than AChR were used in addition to 
(VMS as negative controls in immunoprecipitation experiments.
In Protein A, ELISA and immunoprecipitation assays antisera F2 
raised against fetal calf AChR consistently showed cross­
reactivity with human PBL and, interestingly, this antiserum 
showed the highest cross-reactivity with human muscle AChR 
compared with the other anti-AChR antisera tested (Results, 
Section Cl). Additionally, three Mabs raised against Torpedo 
AChR (Mabs C7, Ell and Bll) showed significantly increased 
reactivity compared to the other Mabs and controls in 
immunoprecipitation experiments. All these antibodies showed 
cross-reactivity with human muscle AChR (Results, Section Cl and 
2) although to different degrees. Direct and indirect evidence 
respectively indicated that Mab Bll and Mab C7 react with the 
OC -subunit of Torpedo AChR (Discussion, Section C) and Kirchner 
et al., (1987) have previously shown cross-reactivity of anti-PL 
-subunit Mabs with thymic AChR. However, in this present study 
two other oC -subunit reactive Mabs E8 and Cll failed to show 
reactivity with human PBL. Two of the cross-reacting Mabs, C7 
and Ell, also appear to bind near the cholinergic binding site 
of AChR and Pizzighella et al., (1982) have shown that d
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similar cholinergic site directed Mab can modify the function of 
an AChR present on mouse thymocytes. It is not known whether 
the thymic AChR component is related to a similar anti-AChR 
antibody binding protein on PBL. With respect to this, a study 
by Horvat et al., (1983) failed to show cross- reactivity of 
anti-(Torpedo AChR) antisera with human PBL, but could 
nevertheless, demonstrate cross-reactivity in the thymus, using 
immunofluorescence studies. Hence indicating that the cross- 
-reacting epitopes are not the same.
It is important to emphasise that these cross-reactivity studies 
do not confirm the presence of AChR epitopes on human PBL. The 
exact specificity of the binding to human PBL should be checked 
in order to rule out the possibility that antibodies of other 
non-AChR specificities could react with human PBL. Similarly, 
there could be components other than anti-AChR antibodies 
present in ascites fluid. Additionally, there appear to be 
differences in the adhesiveness of the different classes of 
immunoglobulin, with IgM being the most 'sticky' (Drover and 
Marshall, 1986).
Verification of true reactivity could be carried out by using 
purified antibodies F(ab)zfragments or by specific absorption of 
anti-(AChR) antibodies by AChR-Sepharose adsorbent and the use 
of absorbed and nan-absorbed antisera in parallel experiments. 
These studies were not carried out because of time 
considerations. Nevertheless, the methods used in this present 
work could be used to screen large libraries of anti-AChR
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antisera and Mabs for reactivity with human PBL. Cross-reacting 
antibodies detected by these initial screening methods could 
then be more rigorously studied. The antisera F2, and Mabs C7, 
Ell and Bll would be good candidates in this respect. The 
immunoprecipitation of iodinated PBL membranes by cross-reacting 
antibodies has an important advantage over the other screening 
assays, as cross-reacting components can be analysed electro- 
phoretically, hence giving useful information on the molecular 
weight of the cross-reacting protein. FACS analysis, as used by 
Fuchs et al., (1980) in the study of 'AChR like' antigens on 
mouse thymocytes would also be useful in these studies, however 
such expensive equipment is not always available.
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GENERAL DISCUSSION AND PERSPECTIVES
The evidence for the presence of nAChR on cells of the immune 
system has previously relied on information obtained from 
functional assays. However, definitive proof of the presence of 
this receptor on human PBL depends upon the correlation of 
functional activity with a structurally defined receptor 
protein. In this work two approaches were used to look for
12 SnAChRs on human PBL: radioligand binding assays using [ IJ-PC 
-BGT and ['H](-)- nicotine and cross-reactivity studies with 
anti-(AChR) antibodies.
This work was, however, unable to demonstrate the presence of 
nicotinic cholinergic binding sites on human PBL (Section D). 
This may be due to the receptors being present in extremely low 
numbers and/or the possibility that the receptors are present on 
a particular subset or subsets of lymphocytes which may 
represent only a small proportion of the total lymphocyte 
population. The use of larger numbers of lymphocytes in the 
assay procedure may have overcome this problem. Investigation 
of the presence of nAChRs on certain lymphocyte subsets could be 
studied by using fractionated lymphocyte populations in the 
radioligand binding assays. If successful this work could be 
extended to the separation of the cells bearing nAChRs by cell 
affinity chromatography an OC-toxin or nicotine derivatives 
attached to a solid support such as Sepharose 6B. However, 
these studies require a large source of lymphocytes and this is 
not always possible.
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The presence of PBL membrane proteins that cross-reacted with 
anti-AChR antibodies was indicated in the latter studies of this 
thesis (Section E) and as above the use of fractionation 
techniques and antibody affinity columns may be useful in the 
purification of the receptor protein. Using immunofluorescent 
studies it should also be possible to determine whether the 
anti-AChR cross-reacting epitopes and the cholinergic binding 
sites represent the same protein entity.
Finally, another approach would be to make use of cDNA probes 
specific for AChR subunits to probe the mRNA of human PBL in 
cross-hybridisation experiments. Such an approach would provide 
a relatively clear— cut answer to this controversial subject and 
would then provide a more, solid foundation for the study of 
functional and structural properties of this receptor.
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